osh-10q_20210331.htm

0001564590-21-026086.txt : 20210510 0001564590-21-026086.hdr.sgml : 20210510 20210510163127 ACCESSION NUMBER: 0001564590-21-026086 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210510 DATE AS OF CHANGE: 20210510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oak Street Health, Inc. CENTRAL INDEX KEY: 0001564406 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 843446686 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39427 FILM NUMBER: 21907720 BUSINESS ADDRESS: STREET 1: 30 W. MONROE ST., STE. 1200 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: 312-773-3374 MAIL ADDRESS: STREET 1: 30 W. MONROE ST., STE. 1200 CITY: CHICAGO STATE: IL ZIP: 60603 FORMER COMPANY: FORMER CONFORMED NAME: Oak Street Health, LLC DATE OF NAME CHANGE: 20121211 10-Q 1 osh-10q_20210331.htm 10-Q osh-10q_20210331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39427

Oak Street Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	84-3446686
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

30 W. Monroe Street Suite 1200 Chicago, Illinois 60603	60603
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (312) 733-9730

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

OSH

NYSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 4, 2021, the registrant had 240,790,848 shares of common stock, $0.001 par value per share, outstanding.

PART I.	FINANCIAL INFORMATION	5

Item 1.	Financial Statements	5

	Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020	6

	Consolidated Statements of Operations for the Three-Months Ended March 31, 2021 and 2020 (unaudited)	8

	Consolidated Statements of Changes in Redeemable Investor Units and Stockholders’ Equity/Members’ (Deficit) for the Three-Months Ended March 31, 2021 and 2020 (unaudited)	9

	Consolidated Statements of Cash Flows for the Three-Months Ended March 31, 2021 and 2020 (unaudited)	10

	Notes to Consolidated Financial Statements	11

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	41

Item 4.	Controls and Procedures	41

PART II.	OTHER INFORMATION	42

Item 1.	Legal Proceedings	42

Item 1A.	Risk Factors	42

Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	44

Item 3.	Defaults upon Senior Securities	44

Item 4.	Mine Safety Disclosures	44

Item 5.	Other Information	44

Item 6.	Exhibits	45

FORWARD-LOOKING STATEMENTS

Throughout this Quarterly Report on Form 10-Q, we make “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results or strategies and can often be identified by the use of terminology such as “may,” “will,” “estimate,” “intend,” “plan,” “continue,” “believe,” “expect,” “anticipate,” “target,” “should,” “could,” “potential,” “opportunity,” “goal” or similar terminology. The forward-looking statements contained in this Quarterly Report on Form 10-Q are generally set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” but may be found in other sections as well. These statements are based upon management’s current expectations, assumptions and estimates and are not guarantees of timing, future results or performance. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. Actual results may differ materially from those contemplated in these statements due to a variety of risks and uncertainties and other factors, including, among other things:

•

our history of net losses and our ability to achieve or maintain profitability in an environment of increasing expenses;

•

the impact of the Coronavirus disease 2019 (“COVID-19”) pandemic or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business, financial condition and results of operations;

•

the effect of our relatively limited operating history on investors’ ability to evaluate our current business and future prospects;

•

the viability of our growth strategy and our ability to realize expected results;

•

our ability to attract new patients;

•

the dependence of our revenues and operations on a limited number of key payors;

•

the risk of termination or non-renewal of the Medicare Advantage contracts held by the health plans with which we contract, or the termination or non-renewal of our contracts with those plans;

•

the impact on our business from changes in the payor mix of our patients and potential decreases in our reimbursement rates;

•

our ability to manage our growth effectively, execute our business plan, maintain high levels of service and patient satisfaction and adequately address competitive challenges;

•

our ability to compete in the healthcare industry;

•

our ability to timely enroll new physicians and other providers in governmental healthcare programs before we can receive reimbursement for their services;

•

the impact on our business of reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;

•

our dependence on reimbursements by third-party payors and payments by individuals;

•

our assumption under most of our agreements with health plans of some or all of the risk that the cost of providing services will exceed our compensation;

•

the impact on our business of renegotiation, non-renewal or termination of capitation agreements with health plans;

•

risks associated with estimating the amount of revenues and refund liabilities that we recognize under our risk agreements with health plans;

•

the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;

•

our ability to develop and maintain proper and effective internal control over financial reporting;

•

the impact on our business of disruptions in our disaster recovery systems or management continuity planning;

•

the potential adverse impact of legal proceedings and litigation;

•

the impact of reductions in the quality ratings of the health plans we serve;

•

the risk of our agreements with the physician equity holder of our practices being deemed invalid;

•

our ability to maintain and enhance our reputation and brand recognition;

•

our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;

•

our ability to obtain, maintain and enforce intellectual property protection for our technology;

•

the potential adverse impact of claims by third parties that we are infringing on or otherwise violating their intellectual property rights;

•

our ability to protect the confidentiality of our trade secrets, know-how and other internally developed information;

•

the impact of any restrictions on our use of or ability to license data or our failure to license data and integrate third-party technologies;

•

risks associated with our use of “open-source” software;

•

our dependence on our senior management team and other key employees;

•

the concentration of our primary care centers in Illinois, Michigan, Pennsylvania, Ohio, Texas and Indiana;

•

the impact on our business of an economic downturn;

•

our ability to attract and retain highly qualified personnel;

•

our management team’s limited experience managing a public company;

•

the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;

•

the impact of failures by our suppliers, material price increases on supplies, lack of reimbursement for drugs we purchase or limitations on our ability to access new technology or products;

•

our ability to maintain our corporate culture;

•

the impact of competition for physicians and nurses, shortages of qualified personnel and related increases in our labor costs;

•

our ability to attract and retain the services of key primary care physicians;

•

the risk that our submissions to health plans may contain inaccurate or unsupportable information regarding risk adjustment scores of members;

•

our ability to accurately estimate incurred but not reported medical expense;

•

the impact of negative publicity regarding the managed healthcare industry;

•

the impact of state and federal efforts to reduce Medicaid spending;

•

the impact on our centers of adverse weather conditions and other factors beyond our control;

•

factors related to our recent issuance of Convertible Senior Notes (as defined later within this Quarterly Report on Form-10-Q); and

•

other factors disclosed in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q and in similar sections in our other filings with the Securities and Exchange Commission (“SEC”).

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our other SEC filings and public communications. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

PART I

FINANCIAL INFORMATION

Item 1.

FINANCIAL STATEMENTS

OAK STREET HEALTH, INC.

CONSOLIDATED FINANCIAL STATEMENTS

For the quarterly period ended March 31, 2021

OAK STREET HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

($ in millions, except shares/units and per share data)

		March 31, 2021 (unaudited)			December 31, 2020
Assets
Current assets:
Cash	$		1,146.4	$		409.3
Restricted cash			10.4			10.4
Other patient service receivables, net (Humana comprised $0.1 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)			1.1			7.6
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)			293.6			248.9
Prepaid expenses			6.0			6.8
Other current assets			5.1			4.2
Total current assets			1,462.6			687.2

Long-term assets:
Property and equipment, net			84.1			78.8
Security deposits			1.4			1.3
Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)			112.6			-
Goodwill			11.4			9.6
Intangible assets, net			2.9			3.0
Other long-term assets			1.0			1.1

Total assets	$		1,676.0	$		781.0

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$		11.5	$		8.8
Accrued compensation and benefits			39.2			32.0
Liability for unpaid claims (Humana comprised $78.8 and $78.5 as of March 31, 2021 and December 31, 2020, respectively)			274.6			262.1
Other liabilities (Humana comprised $10.8 and $4.6 as of March 31, 2021 and December 31, 2020, respectively)			30.3			12.6
Total current liabilities			355.6			315.5

Long-term liabilities:
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)			118.3			-
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)			-			13.5
Other long-term liabilities (Humana comprised $22.5 and $20.1 as of March 31, 2021 and December 31, 2020, respectively)			26.0			28.8
Long-term debt			898.1			-

Total liabilities			1,398.0			357.8
Commitments and contingencies (See Notes 7 & 14)

Stockholders' equity:
Preferred Stock, par value $0.001; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020			-			-

		March 31, 2021 (unaudited)				December 31, 2020
Common stock, par value $0.001; 500,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 240,784,438 and 240,756,714 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively			0.2				0.2
Additional paid-in capital (Humana comprised $50.0 and $50.0 as of March 31, 2021 and December 31, 2020, respectively)			891.7				971.8
Accumulated deficit			(619.2	)			(555.8	)
Total stockholders' equity allocated to Oak Street Health, Inc.			272.7				416.2
Non-controlling interests			5.3				7.0
Total stockholders' equity			278.0				423.2

Total liabilities and stockholders' equity	$		1,676.0		$		781.0

The accompanying notes are an integral part of these consolidated financial statements.

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

($ in millions, except shares/units and per share data)

		Three-Months Ended
		March 31, 2021				March 31, 2020
Revenues:
Capitated revenue (Humana comprised $121.4 and $96.5 for the three-months ended March 31, 2021 and 2020, respectively)	$		291.2		$		196.6
Other patient service revenue (Humana comprised $1.2 and $0.8 for the three-months ended March 31, 2021 and 2020, respectively)			5.5				5.2
Total revenues			296.7				201.8

Operating expenses:
Medical claims expense (Humana comprised $73.0 and $59.8 for the three-months ended March 31, 2021 and 2020, respectively)			199.7				132.3
Cost of care, excluding depreciation and amortization (Humana comprised $2.0 and $1.2 for the three-months ended March 31, 2021 and 2020, respectively)			60.3				43.8
Sales and marketing			24.1				11.9
Corporate, general and administrative expenses			73.1				24.3
Depreciation and amortization			3.3				2.5
Total operating expenses			360.5				214.8

Loss from operations			(63.8	)			(13.0	)

Other (expense)/ income:
Interest expense, net			(0.2	)			(2.5	)
Other			-				0.1
Total other (expense)/ income, net			(0.2	)			(2.4	)
Net loss			(64.0	)			(15.4	)

Net loss attributable to non-controlling interests			0.6				0.4
Net loss attributable to the Oak Street Health, Inc.	$		(63.4	)	$		(15.0	)

Undeclared and deemed dividends	$		-		$		(9.6	)
Net loss attributable to common stock/unitholders			(63.4	)			(24.6	)
Weighted average common stock outstanding - basic and diluted¹			220,736,845			N/A
Net loss per share – basic and diluted	$		(0.29	)		N/A

¹	Basic and diluted loss per share of common stock is applicable only for periods after the Company's IPO that was completed on August 10, 2020.

The accompanying notes are an integral part of these consolidated financial statements.

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN

REDEEMABLE INVESTOR UNITS AND STOCKHOLDERS’ EQUITY/MEMBERS’ (DEFICIT)

(Unaudited)

($ in millions, except shares/units and per share data)

	Three-Months Ended
	Redeemable Investor Units					Members’ Capital						Common Stock
	Shares Issued			Amount		Shares Issued				Amount		Shares Issued			Amount			Additional Paid-In Capital			Accumulated Deficit				Non-Controlling Interest				Total Equity/Deficit
Balances December 31, 2019		11,000,619	$		320.6		2,530,864		$		4.2		-	$		-	$		-	$		(354.4	)	$		5.3		$		(344.9	)
Issuance of series I, II and III investor units		1,471,623			224.4		-				-		-			-			-			-				-				-
Issuance of common units		-			-		265,500				-		-			-			-			-				-				-
Repurchases – profits interests		-			-		(5,531	)			-		-			-			-			-				-				-
Forfeitures – profits interests		-			-		(438	)			-		-			-			-			-				-				-
Unit-based compensation expense		-			-		-				1.8		-			-			-			-				-				1.8
Net loss		-			-		-				-		-			-			-			(15.0	)			(0.4	)			(15.4	)
Balances March 31, 2020		12,472,242	$		545.0		2,790,395		$		6.0		-	$		-	$		-	$		(369.4	)	$		4.9		$		(358.5	)

	Three-Months Ended
	Common Stock
	Shares Issued				Amount			Additional Paid-In Capital				Accumulated Deficit				Non-controlling Interest				Total Equity/Deficit
Balances December 31, 2020		240,756,714		$		0.2	$		971.8		$		(555.8	)	$		7.0		$		423.2
Purchase of capped calls		-				-			(123.6	)			-				-				(123.6	)
Issuance of common stock upon vesting of restricted stock units		17,864				-			-				-				-				-
Issuance of common stock upon exercise of options		53,307				-			1.2				-				-				1.2
Forfeitures		(43,447	)			-			(0.1	)			-				-				(0.1	)
Stock compensation expense		-				-			42.4				-				-				42.4
Payments to non-controlling interest		-				-			-				-				(1.1	)			(1.1	)
Net loss		-				-			-				(63.4	)			(0.6	)			(64.0	)
Balances March 31, 2021		240,784,438		$		0.2	$		891.7		$		(619.2	)	$		5.3		$		278.0

The accompanying notes are an integral part of these consolidated financial statements.

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

($ in millions)

		Three-Months Ended
		March 31, 2021				March 31, 2020
Cash flows from operating activities:
Net loss	$		(64.0	)	$		(15.4	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on debt and related issuance costs			0.2				0.4
Depreciation and amortization			3.3				2.5
Non-cash operating lease costs			3.5				-
Stock and unit-based compensation, net of forfeitures			42.3				1.8
Change in fair value of bifurcated derivative			-				(0.1	)
Change in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable			(38.2	)			(58.3	)
Prepaid expenses and other current assets			(1.0	)			3.7
Security deposits and other long-term assets			0.1				0.1
Accounts payable			1.7				(0.3	)
Accrued compensation and benefits			7.2				(13.0	)
Liability for unpaid claims			12.5				41.0
Operating lease liabilities			(3.0	)			-
Other current liabilities			4.3				0.2
Other long-term liabilities			2.3				0.4
Other			-				0.1
Net cash used in operating activities			(28.8	)			(36.9	)

Cash flows from investing activities:
Purchase of business			(1.0	)			-
Purchases of property and equipment			(7.8	)			(3.4	)
Net cash used in investing activities			(8.8	)			(3.4	)

Cash flows from financing activities:
Proceeds from borrowings on convertible senior notes, net			898.2				-
Purchase of capped calls			(123.6	)			-
Proceeds from issuance of redeemable investor units			-				224.4
Capital distributions to non-controlling interests			(1.1	)			-
Proceeds from exercise of options			1.2				-
Net cash provided by financing activities			774.7				224.4

Net change in cash, cash equivalents and restricted cash			737.1				184.1
Cash, cash equivalents and restricted cash, beginning of period			419.7				42.3
Cash, cash equivalents and restricted cash, end of period	$		1,156.8		$		226.4
Supplemental disclosures
Cash paid for interest			-				2.0
Unpaid debt offering costs in accounts payable and accrued liabilities			0.3				-
Additions to construction in process funded through accounts payable			0.6				0.1

The accompanying notes are an integral part of these consolidated financial statements.

OAK STREET HEALTH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

Description of Business

Oak Street Health, Inc. (collectively with its consolidated subsidiaries is referred to as “Oak Street Health,” “OSH,” “we,” “us,” “our,” or the “Company”) was formed as a Delaware corporation on October 22, 2019 for the purpose of completing a public offering and related reorganization transactions (collectively referred to as the “IPO”) in order to carry on the business of Oak Street Health, LLC (“OSH LLC”) and its affiliates. As the managing member of OSH LLC, Oak Street Health, Inc. operates and controls all of the business affairs of OSH LLC and its affiliates.

The Company operates primary care centers serving Medicare beneficiaries. The Company, through its centers and management services organization, combines an innovative care model with superior patient experience. The Company invests resources into primary care to prevent unnecessary acute events and manage chronic illnesses. The Company engages Medicare eligible patients through the use of an innovative community outreach approach. Once patients are engaged, the Company integrates population health analytics, social support services and primary care into the care model to drive improved outcomes. The Company contracts with health plans to generate medical costs savings and realize a return on its investment in primary care. As of March 31, 2021, the Company operated 86 centers.

Initial Public Offering and Reorganization Transactions

On August 10, 2020, we completed our IPO in which we issued and sold 17,968,750 shares of common stock, par value $0.001 per share, at an offering price of $21.00 per share. The share amount included the exercise in full of the underwriters’ options to purchase 2,343,750 additional shares of common stock. We received net proceeds of $351.2 million, after deducting underwriting discounts and commissions of $22.6 million and deferred offering costs of $3.5 million. Deferred, direct offering costs were capitalized and recorded against proceeds from the offering and consisted of fees and expenses incurred in connection with the sale of our common stock in the IPO, including the legal, accounting, printing and other offering related costs.

In conjunction with the IPO, OSH LLC completed a series of transactions that resulted in Oak Street Health, Inc. becoming the ultimate parent company of OSH LLC and subsidiaries. Additionally, immediately prior to the closing of the IPO, unitholders of OSH LLC exchanged their membership interests for common stock in Oak Street Health, Inc. as part of the related IPO reorganization transactions. All 15,928,876 units of our then outstanding redeemable investor units (preferred stock including their respective undeclared and deemed dividends) and members’ capital (former founders’ units and incentive units/profits interests) plus 1,924 of options to purchase incentive units were converted into 200,286,312 shares of common stock of the Company and 22,612,472 shares of restricted common stock subject to service-based vesting (“RSA”) of the Company.

Basis of Presentation and Consolidation

The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2020 in the Company’s Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-months ended March 31, 2021, including the impact of COVID-19, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.

The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation.

is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.

Upon completion of our IPO, OSH’s sole material asset is its interest in OSH LLC and its affiliates. In accordance with the master structuring agreement dated August 10, 2020, by and among OSH and the other signatories party thereto (the “Master Structuring Agreement”), we have all management powers over the business and affairs of OSH LLC and to conduct, direct and exercise full control over the activities of OSH LLC. Due to our power to control the activities most directly affecting the results of OSH LLC, we are considered the primary beneficiary of the VIE. Accordingly, following the effective date of the IPO, we consolidate the financial results of OSH LLC and its affiliates and the financial statements for the periods prior to the IPO have been adjusted to combine the previously separate entities for presentation purposes.

Oak Street Health MSO LLC (“MSO”), a wholly owned subsidiary of OSH LLC, was formed in 2013 to provide a wide range of management services to the Physician Groups (as defined below). Activities include but are not limited to operational support of the centers, marketing, information technology infrastructure and the sourcing and managing of health plan contracts. Oak Street Health Physicians Group PC, OSH-IN Physicians Group PC, OSH-MI Physicians Group PC, OSH-OH Physicians Group LLC, OSH-PA Physicians Group PC, OSH-RI Physicians Group PC, Oak Street Health of Texas, PLLC, Griffin Myers Medical PC, Oak Street Health Physicians Group of South Carolina LLC, Oak Street Health Physicians Group of Louisiana LLC and Oak Street Health Physicians Group of Mississippi LLC (collectively, the “Physician Groups”) employ healthcare providers to deliver primary care services to the Medicare covered population of Illinois, Indiana, Louisiana, Michigan, Mississippi, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas and New York. These entities are consolidated as each are considered variable interest entities where the Company has a controlling financial interest (see Note 15).

In addition, Oak Street Health is the majority interest owner in three joint ventures: OSH-PCJ Joliet, LLC, OSH-RI, LLC and OSH-ESC Joint Venture, LLC, which are consolidated in the Company’s financial statements. In March 2021, distributions were made from OSH-PCJ Joliet, LLC to Oak Street Health MSO, LLC (50.1% ownership) and Primary Care Physicians of Joliet (49.9% ownership) totaling $1.1 million to each owner.

Emerging Growth Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have elected to avail ourselves of this extended transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.

COVID-19

The COVID-19 pandemic did not have a material impact on our results of operations, cash flows and financial position for the three-months ended March 31, 2021. Over 98% of our total revenues are recurring, consisting of fixed monthly per-patient-per-month capitation payments we receive from Medicare Advantage plans.

On March 27, 2020, the United States President signed into law the Coronavirus Aid, Relief and Economic Securities Act (“CARES Act”) which provides economic assistance to a wide array of industries, including healthcare. Thus far, the Company has taken the following actions related to this legislation:

•

Provider Relief Funds. The U.S. Department of Health and Human Services (“HHS”) distributed grants to healthcare providers to offset the impacts of COVID-19 pandemic related expenses and lost revenues through the Public Health and Social Services Emergency Fund. Grants received are subject to the terms and conditions of the program, including that such funds may only be used to prevent, prepare for and respond to COVID-19 and will reimburse only for health care related expenses, general and administrative expenses or lost revenues that are attributable to the COVID-19 pandemic as defined by the HHS. Payments from this fund are not loans and, therefore, they are not subject to repayment. We recognize grant payments as income when there is reasonable assurance that we have complied with conditions associated with the grant. Our estimates could change materially in the future based on the government’s evolving compliance guidance. During the three-months ended March 31, 2021 and 2020, the Company received $2.6 million and $0.0 million, respectively, related to these grants and recognized $1.9 million and $0.0 million, respectively, as income to offset

COVID-19 pandemic related expenses incurred in the cost of care, excluding depreciation and amortization. The remaining HHS grants of $1.6 million have been recorded in other current liabilities as they must be utilized or given back to HHS by June 30, 2021.

•

Medicare Accelerated and Advanced Payment Program. The Centers for Medicare & Medicaid Services (“CMS”) expanded its Accelerated and Advance Payment Program which allows participants to receive expedited payments during periods of national emergencies. Under the program, we received an interest-free advancement of 100% of our Medicare payment amount for a three-month period. Repayment will begin one year from the date the payments were received and will be paid back against future fee-for-service claims. Beginning at one year from the date the payment was issued and continuing for eleven months, payments will be recouped at a rate of 25%. After the eleven months end, payments will be recouped at a rate of 50% for another six months, after which any remaining balance will become due. During 2020, the Company received approximately $1.5 million in CMS advance payments, which were recorded in other current liabilities and will be paid back against future fee-for-service claims.

•

Payroll Tax Deferral. Under the CARES Act, the Company elected to defer payment on its portion of Social Security taxes, on an interest free basis, incurred from March 27, 2020 to December 31, 2020. One-half of such deferral amount will become due on each of December 31, 2021 and December 31, 2022. The total deferred payroll taxes were $7.0 million, $3.5 million was classified as a short-term liability and $3.5 million was classified as a long-term liability at March 31, 2021.

•

Temporary Suspension of Medicare Sequestration. The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare fee-for-service claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments. All Medicare rate payments and settlements have incurred this mandatory reduction and it will continue to remain in place through at least 2023, unless Congress takes further action. In response to COVID-19, the CARES Act temporarily suspended the automatic 2.0% reduction of Medicare claim reimbursements for the period of May 1, 2020 through December 31, 2021, which immaterially increased both revenues and medical expenses for the three-months ended March 31, 2021.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company described its significant accounting policies in Note 2 of the Notes to Consolidated Financial Statements for the year ended December 31, 2020 included in its Form 10-K. During the three-months ended March 31, 2021, there were no significant changes to those accounting policies, other than the adoption of ASC 842 (as defined below), Accounting Standards Update (“ASU”) 2020-06 and those policies impacted by the new accounting pronouncements adopted during the period and further described below as well as in the “Recently Adopted Accounting Pronouncements” section.

Leases

The Company leases offices, operating facilities, vehicles and IT equipment, which are accounted for as operating leases. These leases have remaining lease terms of up to 30 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company determines if an arrangement is a lease at inception and evaluates the lease classification (i.e., operating lease or financing lease) at that time. Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the term of the lease.

Operating leases are included in operating lease right-of-use assets, operating lease liabilities, current portion (recorded within other current liabilities) and long-term operating lease liabilities on the Company’s consolidated balance sheets. Operating lease right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company has no financing leases.

The Company uses its incremental borrowing rate on the commencement date for determining the present value of lease payments. The Company considers the likelihood of exercising options to extend or terminate the lease when determining the lease term.

The Company has lease agreements with lease and non-lease components. The Company has elected the practical expedient to account for the lease and non-lease components as a single lease component for all leases.

Convertible Debt

The Company evaluates all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. In accounting for the issuance of the 0% Convertible Senior Notes

due 2026 issued in March 2021 (the “Convertible Senior Notes”), the Company recorded a long-term debt liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the debt issuance and offering costs on the Company’s consolidated balance sheets. The conversion feature is not required to be accounted for separately as an embedded derivative. The Company will amortize debt issuance and offering costs over the term of the Convertible Senior Notes as interest expense utilizing the effective interest method on the Company’s consolidated statements of operations.

Capped Call Transactions

In connection with the issuance of the Convertible Senior Notes, the Company entered into capped call transactions. The capped call transactions are expected generally to reduce the potential dilution to the holders of the Company’s common stock upon any conversion of the Convertible Senior Notes. The capped call transactions are purchased call options on the issuer’s stock that settle by reference to the Company’s stock with no forced cash payment. The terms of the capped call transactions allow the purchased call options to be classified as an equity instrument and will not be subsequently remeasured as long as the conditions for equity classification continue to be met. The Company recorded the cash used to purchase the capped call transactions as a reduction to additional paid-in capital within the Company’s consolidated statements of changes in redeemable investor units and stockholders’ equity/members’ (deficit).

Net Income (Loss) Per Share

The diluted net income (loss) per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the if-converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, restricted stock awards and contingently issuable shares under our Convertible Senior Notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.

Recently Adopted Accounting Pronouncements

In 2016, the FASB issued guidance on leases, Accounting Standards Updates 2016-02, Leases (“ASU 2016-02), with amendments issued in 2018 and 2019 (collectively, “ASC 842”). ASC 842 requires lessees to recognize assets and liabilities related to lease arrangements on the balance sheet; leases are to be recorded as a lease liability (on a discounted basis) with a corresponding right-of-use (“ROU”) asset. Leases will be classified as finance or operating, with the classification affecting the pattern and classification of expense recognition over the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. This guidance also expands the required quantitative and qualitative disclosures for leasing arrangements and gives rise to other changes impacting certain aspects of lessee and lessor accounting. The two permitted transition methods under the guidance are the modified retrospective transition approach, which requires application of the guidance for all comparative periods, and the cumulative effect adjustment approach, which requires prospective application the adoption date.

We adopted ASC 842 as of January 1, 2021 on a prospective basis, did not adjust the comparative reporting periods and applied the lessee package of practical expedients. The package of practical expedients included that the Company was not required to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Also, as part of the adoption, the Company elected to not recognize short-term leases (those with lease terms less than a year) on the consolidated balance sheets, not separate lease and non-lease components and did not use hindsight to determine lease term. The most significant impact was the recognition of ROU assets and lease liabilities for our operating leases. The ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease at lease commencement date. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its consolidated balance sheets, however it did not have a material impact on the consolidated statements of operations or cash flows for the three- months ended March 31, 2021. The Company recognized ROU assets and lease liabilities for operating leases of $108.1 million and $126.8 million, respectively, upon adoption as of January 1, 2021. The difference between the lease liability and right-of-use asset mainly related to the reversal of existing deferred rent balances.

The Company utilized a comprehensive approach to assess the impact of this guidance on the consolidated financial statements and related disclosures, including the increase in assets and liabilities on the consolidated balance sheets and the impact on the current lease portfolio.

See Note 7 in this Quarterly Report for our lease accounting policy and the quarterly impact of our adoption of ASC 842.

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity. Among other changes, ASU 2020-06 removes the

liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share and updates the disclosure requirements in ASC 470-20, making them easier to understand for financial statement preparers and improving the decision-usefulness and relevance of the information for financial statement users. This ASU was early adopted on January 1, 2021 and applied to the Company’s 0% Convertible Senior Notes due 2026 issued in March 2021 (Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s Convertible Senior Notes). The Company had no other debt arrangements to apply this guidance to.

In December 2019, the FASB issued ASU 2019-12, “Income Taxes Topic 740-Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of ASC 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures.

In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures.

Recent Accounting Pronouncements Not Yet Adopted

In October 2018, the FASB issued ASU 2018-17, Consolidation – Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810) (“ASU 2018-17”). ASU 2018-17 eliminates the requirement that entities consider indirect interests held through related parties under common control in their entirety when assessing whether a decision-making fee is a variable interest. Instead, the reporting entity will consider such indirect interests on a proportionate basis. ASU 2018-17 is effective for a private company for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. All entities are required to apply the adjustments in ASU 2018-17 retrospectively with a cumulative-effect adjustment to retained earnings at the beginning of the earliest period presented. Early adoption is permitted. The Company is currently evaluating the impact ASU 2018-17 will have on its consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for us beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

NOTE 3. REVENUE RECOGNITION

Both our capitated and fee-for-service revenue generally relate to contracts with patients in which our performance obligation is to provide healthcare services to the patients. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type.

Capitated Revenue and Accounts Receivable

Capitated revenue consists primarily of capitated fees for medical services provided by us under capitated arrangements directly made with various Medicare Advantage managed care payors. The Company receives a fixed fee per patient under what is typically known as a “risk contract.” Risk contracting, or full risk capitation, refers to a model in which the Company receives from the third-party payor a fixed payment per patient per month (“PPPM” payment) for a defined patient population, and the Company is then responsible for providing healthcare services required by that patient population. The Company is responsible for incurring or paying for the cost of healthcare services required by that patient population in addition to those provided by the Company. Fees are recorded gross in revenues because the Company is acting as a principal in arranging for, providing and controlling the managed healthcare services provided to the managed care payors’ eligible enrolled members. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

The Company’s payor contracts generally have a term of one year or longer, but the contracts between the enrolled members (our customers) and the payor are one calendar year or less. In general, the Company considers all contracts with customers (enrolled members) as a single performance obligation to stand ready to provide managed healthcare services. The Company identified that contracts with customers for capitation arrangements have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company stands ready to fulfill its obligation to enrolled members.

Our revenues are based upon the estimated PPPM amounts we expect to be entitled to receive from Medicare Advantage managed care payors. The PPPM rates are determined as a percent of the premium the Medicare Advantage plan receives from CMS for our at-risk members. Those premiums are determined via a competitive bidding process with CMS and are based upon the cost of care in a local market and the average utilization of services by the patients enrolled. Medicare pays capitation using a “risk adjustment model,” which compensates providers based on the health status (acuity) of each individual patient. Payors with higher acuity patients receive more, and those with lower acuity patients receive less. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after the final data is compiled. As premiums are adjusted via this risk adjustment model, our PPPM payments will change in unison with how our payor partners’ premiums change with CMS. The Company determined the transaction price for these contracts is variable as it primarily includes PPPM fees which can fluctuate throughout the contract based on the acuity of each individual enrollee. Our capitated accounts receivable includes $32.2 million and $23.5 million as of March 31, 2021 and 2020, respectively, for acuity-related adjustments that are estimated to be received in subsequent periods. In certain contracts, PPPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. There were no PPPM adjustments related to performance incentives/penalties for quality-related metrics for the three-months ended March 31, 2021 and 2020. The capitated revenues are recognized based on the estimated PPPM transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of projected acuity adjustments and performance incentives/penalties because the Company is able to reasonably estimate the ultimate PPPM payment of these contracts. We recognize revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. Subsequent changes in PPPM fees and the amount of revenue to be recognized by the Company are reflected through subsequent period adjustments to properly recognize the ultimate capitation amount and do not result in a significant reversal of revenue when the uncertainty is resolved in subsequent periods. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

Certain third-party payor contracts include a Medicare Part D payment related to pharmacy claims, which is subject to risk sharing through accepted risk corridor provisions. Under certain agreements the fund risk allocation is established where the Company, as the contracted provider, receives only a portion of the risk and the associated surplus or deficit. The Company estimates and recognizes an adjustment to Part D capitated revenues related to these risk corridor provisions, based upon pharmacy claims experience to date, as if the annual risk contract were to terminate at the end of the reporting period. Medicare Part D comprised 2% of capitated revenues for the three-months ended March 31, 2021 and 2020, and 3% and 4% of medical claims expense for the three-months ended March 31, 2021 and 2020, respectively.

The Company had agreements in place with the payors listed below and payor sources of capitated revenue for each period presented were as follows:

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Humana		42	%		49	%
Wellcare/Meridian		18	%		14	%
Cigna-HealthSpring		10	%		11	%
Other		30	%		26	%

Other Patient Service Revenue

Other patient service revenue is comprised of ancillary fees earned under contracts with certain managed care organizations for the provision of certain care coordination services and care management services and is also comprised of fee-for-service revenue. The composition of other patient service revenue for each period was as follows ($ in millions):

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Care coordination and care management	$		3.9	$		4.1
Fee for service			1.6			1.1
Total other patient service revenue	$		5.5	$		5.2

The Company has entered into multi-year agreements with Humana and its affiliates to provide services at certain centers to members covered by Humana. The agreements contain an administrative payment from Humana in exchange for the Company providing certain care coordination services during the term of the contract (“Care Coordination Payment”). The Care Coordination Payments are recognized in other patient service revenue ratably over the length of the terms stated in the contracts and are refundable to Humana on a pro-rata basis if the Company ceases to provide services at the centers within the length of the term specified in the contracts. We have identified a single performance obligation to stand ready to provide care coordination services to patients, which constitutes a series of distinct service increments. As of March 31, 2021 and December 31, 2020, the Company’s contract liabilities related to these payments totaled $18.2 million and $16.6 million, respectively. The short-term portion is recorded in other liabilities and the long-term portion is included in other long-term liabilities in the accompanying consolidated balance sheets.

Care management services are provided to enrolled members of certain contracted managed care organizations regardless of whether those members are Oak Street Health patients. Similar to the other care management services provided to the Company’s centers, the Company provides delegated services and other administrative services to plans in order to assist with the management of its Medicare population, therefore, we have identified a single performance obligation to stand ready to provide care management services, which constitutes a series of distinct service increments.

Fee-for-service revenue is primarily derived from healthcare services rendered to patients. The services provided by the Company have no fixed duration and can be terminated by the patient or the Company at any time, therefore each treatment is its own standalone contract. Services ordered by a healthcare provider during an office visit are not separately identifiable, and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligation is completed on the date of service. Fee-for-service revenue is recognized in the period in which services are provided at estimated net realizable amounts from patients, third-party payors and others. The fee-for-service revenue by payor source for each period presented were as follows:

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Medicare		38	%		46	%
Humana		11	%		8	%
Other		51	%		46	%

Other patient service accounts receivable consists primarily of amounts due from Medicare and Medicare Advantage plans for fee-for-service patients. Receivables from commercial or government payors are recorded at a net amount determined by the original charge for the service provided, less contractual discounts provided to the payor. Receivables due directly from patients are recorded at the original charge for the service provided less amounts covered by third-party payors and an allowance for financial assistance.

The Company has a financial assistance policy in which patients will be assessed for financial hardship and other criteria that are used to make a good-faith determination of financial need, in which case the Company will waive or reduce a Medicare beneficiary’s obligation to pay copay, coinsurance or deductible amounts owed for the provision of medical services. The majority of our fee-for-service patients qualify for financial assistance. The total amount of patient revenues that were waived per the Company’s financial assistance policy were $1.2 million and $1.5 million for the three-months ended March 31, 2021 and 2020, respectively. The Company’s cost to provide care in regard to the services for which the patient’s financial obligation was waived was estimated to be $3.5 million and $2.5 million for the three-months ended March 31, 2021 and 2020, respectively using a cost-to-charge ratio estimate. The Company invests heavily in primary care to prevent unnecessary acute events and manage chronic illnesses, and the cost incurred exceeds the amount that the Company would have realized under fee-for-service payment arrangements. The Company is willing to accept this deficit as many fee-for-service patients become Medicare Advantage patients under capitated arrangements.

Remaining Performance Obligations

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to continue receiving services at our facilities.

Note 4. Fair Value of Financial Instruments

The carrying amounts of financial instruments including cash, accounts receivable, accounts payable, accrued liabilities and short-term borrowings approximate fair value due to the short maturity of these instruments.

The Company's Convertible Senior Notes are classified within Level 2 of the fair value hierarchy as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of March 31, 2021, the fair value of the Convertible Senior Notes was $918.3 million compared to their carrying value of $898.1 million, which is net of unamortized debt issuance and offering costs.

NOTE 5. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of March 31, 2021 and December 31, 2020 ($ in millions):

		March 31, 2021				December 31, 2020
Leasehold improvements	$		67.5		$		63.6
Furniture and fixtures			5.1				4.9
Computer equipment			20.6				17.8
Internal use software			7.7				6.1
Office equipment			9.9				9.7
Construction in process			4.0				4.2
Total, at cost			114.8				106.3
Less accumulated depreciation			(30.7	)			(27.5	)
Property and equipment, net	$		84.1		$		78.8

The Company recorded depreciation expense of $3.2 million and $2.4 million for the three-months ended March 31, 2021 and 2020, respectively.

The Company expensed $0.3 million and $0.1 million of capitalized development costs for the three-months ended March 31, 2021 and 2020, respectively. Capitalized external software costs include the actual costs to purchase software licenses from vendors. Costs incurred to maintain existing software are expensed as incurred.

NOTE 6. GOODWILL AND INTANGIBLE ASSETS

On January 22, 2021, Oak Street Health entered into an agreement to purchase the assets of a medical practice for $1.8 million base purchase price which was accounted for under the acquisition method of accounting pursuant to ASC 805.

Goodwill, which represents the excess of cost over the fair value of net assets acquired, amounted to $11.4 million and $9.6 million at March 31, 2021 and December 31, 2020, respectively.

Intangible assets with a finite useful life continue to be amortized over its useful lives. Net intangible assets amounted to $2.9 million and $3.0 million at March 31, 2021 and December 31, 2020, respectively. The Company recorded amortization expense of $0.1 million for the three-months ended March 31, 2021 and 2020.

NOTE 7. LEASES

ASC 842 Disclosures

Operating lease and variable lease costs are included in cost of care, excluding depreciation and amortization and corporate, general and administrative expenses in the consolidated statements of operations. Variable lease costs are the portion of lease payments that are not fixed over the lease term. Variable lease costs include real estate payments that are adjusted periodically for inflation or other variables as well as payments for taxes, insurance, maintenance and other expenses. Also included in variable lease costs are license fees paid to Humana (see Note 16). We expense variable lease costs as incurred. The Company elected to combine lease and non-lease components as a single lease component and not include short-term leases, defined as leases with an initial term of twelve months or less, in its consolidated balance sheets. The Company’s short-term leases were immaterial. The components of lease expense for the Company’s operating leases were as follows for the three-months ended March 31, 2021 ($ in millions):

		March 31, 2021
Operating lease cost	$		4.5
Variable lease cost			4.9
Total lease cost	$		9.4

The Company entered into operating leases that resulted in $7.6 million of right-of-use assets in exchange for operating lease obligations for the three-months ended March 31, 2021.

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	March 31, 2021
Weighted-average remaining lease term (in years)		10.6
Weighted-average discount rate		4.07	%

The table below presents the future minimum lease payments under the noncancelable operating leases as of March 31, 2021 ($ in millions):

2021	$	13.7
2022		17.7
2023		16.3
2024		14.7
2025		13.9
2026		13.7
Thereafter		75.4
Total lease payments	$	165.4
Less: imputed interest		(34.0	)
Total operating lease liabilities	$	131.4
Reported as:
Operating lease liabilities, current (1)		13.1
Operating lease liabilities, noncurrent		118.3
Total operating lease liabilities	$	131.4

(1) Included in other liabilities on the consolidated balance sheet

ASC 840 Disclosures

Prior to adoption of ASC 842, the Company accounted for its lease arrangements under ASC 840, Leases, with no ROU assets or lease liabilities being reflected on the consolidated balance sheets. Therefore, the Company recognized $4.6 million (including $0.9 million of Humana license fee expense) of rent expense for the three-months ended March 31, 2020 included in costs of care and corporate, general and administrative expenses in the consolidated statements of operations. Additionally, the Company recorded $13.5 million at December 31, 2020 of deferred rent that was classified as a long-term liability in the consolidated balance sheets.

NOTE 8. OTHER CURRENT AND LONG-TERM LIABILITIES

Accrued compensation and benefits consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Accrued paid time off	$		6.1	$		5.0
Accrued bonus and commission			20.9			19.1
Employee stock purchase plan contributions			1.4			-
Accrued payroll and taxes			5.7			1.8
CARES Act deferred payroll taxes			3.5			3.5
Other			1.6			2.6
	$		39.2	$		32.0

Other current liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee	$		2.7	$		0.6
Operating lease liabilities			13.1			-
Contract liabilities, current			4.4			4.3
Accrual for goods or services received, not invoiced			4.5			3.6
CARES Act Medicare advances & Provider Relief Funds			3.1			2.3
Other current liabilities			2.5			1.8
	$		30.3	$		12.6

Other long-term liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee, net of current	$		8.4	$		7.3
Contract liabilities, net of current			14.1			12.8
Lease incentive obligation, net of current			-			5.1
CARES Act deferred payroll taxes			3.5			3.5
Other long-term liabilities			0.0			0.1
	$		26.0	$		28.8

NOTE 9. LIABILITY FOR UNPAID CLAIMS

Medical claims expense and the liability for unpaid claims include estimates of the Company’s obligations for medical care services that have been rendered by third parties on behalf of insured consumers for which the Company is contractually obligated to pay (through the Company’s full risk capitation arrangements), but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported, which includes estimates for claims that have not been received or fully processed, using a process that is consistently applied, centrally controlled and automated. This process includes utilizing actuarial models when a sufficient amount of medical claims history is available from the third-party healthcare service providers. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, medical care utilization and other medical cost trends, membership volume and demographics, the introduction of new technologies, and benefit plan changes. In developing its unpaid claims liability estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent three-months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PPPM medical costs incurred in prior months for which more complete claims data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period that have been adjudicated by the Company at the date of estimation). For the months prior to the most recent three-months, the Company applies completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months.

The Company purchases provider excess insurance to protect against significant, catastrophic claims expenses incurred on behalf of its patients. The total amount of provider excess insurance premium was $0.9 million and $0.8 million, and total reimbursements were $0.4 million and $0.3 million for the three-months ended March 31, 2021 and 2020, respectively. The provider excess insurance premiums less reimbursements are reported in medical claims expense in the consolidated statements of operations. Provider excess recoverables due are reported in other current assets in the consolidated balance sheets. As of March 31, 2021, the Company’s provider excess insurance deductible was $0.3 million per member and covered up to a maximum of $5.0 million per member per calendar year.

Activity within liabilities for unpaid claims was as follows for the three-months ended March 31, 2021 and 2020 ($ in millions):

		March 31, 2021				March 31, 2020
Balance, beginning of period	$		262.1		$		170.6
Incurred health care costs:
Current year			192.3				131.4
Prior years			6.6				-
Total claims incurred	$		198.9		$		131.4
Claims paid:
Current year			(20.6	)			(59.7	)
Prior years			(165.5	)			(30.5	)
Total claims paid	$		(186.1	)	$		(90.2	)
Adjustments to other claims-related liabilities			(0.3	)			(0.2	)
Balance, end of period	$		274.6		$		211.6

We assess the profitability of our managed care capitation arrangement to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a premium deficiency reserve is recognized. No premium deficiency reserves were recorded as of March 31, 2021 and December 31, 2020.

NOTE 10. LONG-TERM DEBT

Convertible Senior Notes

On March 16, 2021, the Company issued, at par value, $920.0 million aggregate principal amount of 0% Convertible Senior Notes in a private offering exempt from registration under the Securities Act of 1933, including $120.0 million in aggregate principal amount pursuant to the option we granted to the initial purchasers to purchase additional convertible senior notes, which was exercised in full in March 2021 (collectively, the “Convertible Senior Notes”). Total proceeds received by the Company from the sale of the Convertible Senior Notes, net of debt issuance and offering costs of $22.1 million, were $897.9 million. The Company used $123.6 million of the net proceeds to pay for the cost of the capped call transactions (see discussion on capped call transactions further below).

The Convertible Senior Notes are governed by an indenture (“Indenture”), dated as of March 16, 2021, between the Company and U.S. Bank National Association, as trustee. Under the Indenture, the Convertible Senior Notes are general senior, unsecured obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted. The Convertible Senior Notes are equal in right of payment with the Company’s future senior, unsecured indebtedness and structurally subordinated to all indebtedness and liabilities of the Company’s subsidiaries. The Convertible Senior Notes will not bear regular interest, and the principal amount of the Convertible Senior Notes will not accrete. We will pay special interest, if any, at a rate per annum not exceeding 0.50% of the principal amount of the notes outstanding as the sole remedy at our election relating to the failure to comply with our reporting requirements with the Securities and Exchange Commission and certain other obligations under the Indenture for the first 365 days after the occurrence of such an event of default.

The Convertible Senior Notes are convertible, subject to certain conditions described below, into shares of our common stock at an initial conversion rate of 12.6328 shares per $1,000 principal amount of the Convertible Senior Notes, which represents an initial conversion price of approximately $79.16 per share, subject to adjustments upon occurrence of certain events set forth in the Indenture. Certain events described in the Indenture that occur prior to the maturity date or if the Company delivers a notice of redemption may increase the conversion rate for holders who elect to convert their Convertible Senior Notes in connection with such events should they occur. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination thereof at our election. If the Company elects cash or combination settlement, the Company will pay an amount equal to the sum of the daily conversion values for each trading day in a 40 trading-day observation period. The maximum number of shares issuable should there be an increase in the conversion rate is 16,561,656 shares of the Company’s common stock.

The Convertible Senior Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 15, 2025, only under the following circumstances:

•

during any calendar quarter ending after June 30, 2021, if our closing stock price is greater than or equal to 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) of the last 30 consecutive trading days of the immediately preceding calendar quarter;

•

during the five business day period after any 10 consecutive trading day period in which the trading price (as defined in the Indenture) is less than 98% of the product of the closing price of our common stock and the conversion rate for the Notes on each such trading day;

•

if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and

•

upon the occurrence of specified corporate events as set forth in the Indenture.

On or after December 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Convertible Senior Notes may convert all or any portion of their Convertible Senior Notes at any time, regardless of the circumstances applicable to conversions prior to December 15, 2025.

We may not redeem the Convertible Senior Notes prior to March 20, 2024. On or after March 20, 2024, the Convertible Senior Notes are redeemable for cash, in whole or in part (subject to minimum redemption amounts), at our option at any time, and from time to time, if the last reported sale price of the common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Convertible Senior Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. If the Company redeems less than all the outstanding Convertible Senior Notes, at least $150 million aggregate principal amount of Convertible Senior Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the Convertible Senior Notes.

If the Company undergoes a fundamental change (as defined in the Indenture), holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Convertible Senior Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date.

The Indenture includes customary covenants and events of default after which the Convertible Senior Notes may be declared immediately due and payable.

In accounting for the issuance of the Convertible Senior Notes, we performed an assessment of all of the embedded features of the debt instrument to determine if any will impact the initial measurement of the liability. The Company concluded that the embedded features are not required to be accounted for separately as embedded derivatives, and therefore the Convertible Senior Notes were accounted for in their entirety as a liability equal to the proceeds received from issuance net of debt issuance and offering costs. The Company will amortize debt issuance and offering costs over the term of the Convertible Senior Notes as additional non-cash interest expense utilizing the effective interest method.

Capped Call Transactions

In connection with the pricing of the Convertible Senior Notes, the Company entered into convertible note hedge transactions (the “capped call transactions”) with six initial purchasers or their respective affiliates and other financial institutions (the “option counterparties”) of $123.6 million concurrent to mitigate the impact of potential economic dilution to our common stock upon conversion of the Convertible Senior Notes and have an initial strike price of approximately $79.16 per share, which corresponds to the initial conversion price of the Convertible Senior Notes. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of Convertible Senior Notes, with such reduction and/or offset subject to a cap initially equal to $138.8750 per share.

The capped call transactions will expire on March 12, 2026. The capped call transactions are separate transactions and are not part of the terms of the Convertible Senior Notes. The shares related to the capped call transactions are excluded from the calculation of diluted earnings per share as they are anti-dilutive.

The capped call transactions cover, subject to anti-dilution adjustments, approximately 11,622,176 million shares of the Company’s common stock, par value $0.001. The capped call transactions are subject to either adjustment or termination upon the occurrence of specified extraordinary and disruption events affecting the Company.

The capped call transactions are purchased call options on our own stock that settle by reference to our own stock with no forced cash payment; therefore, the transactions are classified as an equity instrument and recorded within stockholders’ equity. These transactions are not accounted for as derivatives. The Company recorded the capped call transactions as a reduction to additional paid-in capital and will not be remeasured as long as the conditions for equity classification continue to met.

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the Consolidated Balance Sheet as of March 31, 2021 ($ in millions):

	March 31, 2021
Liability component:
Principal		920.0
Less: debt issuance costs, net of amortization		21.9
Net carrying amount		898.1

Equity component recorded at issuance:
Capped call transactions		123.6

The following table sets forth the debt issuance and offering costs recognized in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three-months ended March 31, 2021 ($ in millions):

	March 31, 2021
Debt issuance costs		22.1
Amortization of debt issuance costs		0.2
Debt issuance costs, net of amortization		21.9

Effective interest rate of the liability component		0.49	%

NOTE 11. INCOME TAX

The most significant impact to the Company’s effective tax rate is related to the tax treatment of certain equity compensation. However, the Company continues to be in a net operating loss and deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to zero. The Company’s effective tax rate for the three-months ended March 31, 2021 and 2020 was 0.0%.

NOTE 12. STOCKHOLDERS’ EQUITY

Common Stock

In connection with the IPO, we increased our authorized shares from 1,000 to 500,000,000 shares of our common stock, par value of $0.001. Additionally, upon completion of our IPO in August 2020, we sold 17,968,750 shares of common stock at an offering price of $21.00 per share, including 2,343,750 shares of common stock issued pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Redeemable Investor Units, Profits Interests and Incentive Units

All shares of redeemable investor units outstanding at the time of the IPO, totaling 12,472,242 units and undeclared and deemed dividends of $103.6 million, were converted into 184,787,783 shares of common stock and their carrying value, totaling $545.0 million was reclassified into stockholders’ equity on our condensed consolidated balance sheets in conjunction with the completed IPO. No shares of redeemable convertible preferred stock were issued or outstanding as of March 31, 2021 or December 31, 2020.

Additionally, all shares of profits interests then outstanding, totaling 3,456,634 units were converted into 38,111,001 shares of common stock, 22,612,472 of which were considered RSAs at the time of conversion. The carrying value of $7.0 million was reclassified

into common stock and additional paid in capital on our consolidated balance sheet. No profits interests or incentive units were issued or outstanding as of March 31, 2021 or December 31, 2020.

Preferred Stock

Also, in connection with our IPO, we authorized the issuance of 50,000,000 shares of our preferred stock, par value $0.001. There was no preferred stock outstanding as of March 31, 2021.

NOTE 13. STOCK AND UNIT-BASED COMPENSATION

2020 Omnibus Incentive Plan

On August 5, 2020, the Company’s Board of Directors adopted the 2020 Omnibus Incentive Plan (the “2020 Plan,”). Under the 2020 Plan, employees, consultants and directors of our company and our affiliates that perform services for us are eligible to receive awards. The 2020 Plan provides for the grant of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights, RSAs, performance awards, other share-based awards (including restricted stock units (“RSUs”)) and other cash-based awards. The maximum number of shares available for issuance under the 2020 Plan may not exceed 48,138,967 shares (subject to annual increases as approved by the Board of Directors).

Stock Options Activity

Stock options granted by the Company generally vest over four years with 25% of the option shares vesting each year. Options generally expire ten years from the date of the grant.

The following is a summary of stock option activity transactions as of and for the three-months ended March 31, 2021 ($ in millions):

	Number of Options				Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)			Aggregate Intrinsic Value

Outstanding, December 31, 2020		14,958,969		$		21.01		9.60	$		600.6
Granted		305,505				59.63
Exercised		(53,307	)			21.00
Cancelled		(25,582	)			21.07
Outstanding, March 31, 2021		15,185,585		$		21.79		9.36	$		494.9

Options exercisable as of March 31, 2021		2,375,304		$		21.00		9.35	$		79.0

The aggregate intrinsic value of options exercised in the three-months ended March 31, 2021 and 2020 was $1.8 million and $0.0 million, respectively. Aggregate intrinsic value represents the difference between the exercise price of the option and the closing price of the Company’s common stock on the date of exercise. The fair value of options granted for the three-months ended March 31, 2021 and 2020 was $8.8 million and $0.0 million, respectively.

RSA Activity

The RSAs were granted as part of the pre-IPO conversion (see Note 12). The following is a summary of RSA transactions as of and for the three-months ended March 31, 2021:

	Unvested Shares				Grant Date Fair Value

Unvested, December 31, 2020		21,599,118		$		11.77
Granted		-				-
Vested		(1,701,267	)			1.50
Canceled and forfeited		(43,447	)			14.05
Unvested, March 31, 2021		19,854,404		$		12.65

RSU Activity

RSUs granted generally vest over four years. RSUs are accounted for as equity using the fair value method, which requires measurement and recognition of compensation expense for all awards granted to our employees, directors and consultants based upon the grant-date fair value. The following is a summary of RSU transactions as of and for the three-months ended March 31, 2021:

	Unvested Shares				Grant Date Fair Value
Unvested, December 31, 2020		216,804		$		32.21
Granted		182,272		$		59.63
Vested		(17,864	)			50.46
Canceled and forfeited		(6,130	)			21.52
Unvested, March 31, 2021		375,082		$		44.84

Employee Stock Purchase Plan

On August 5, 2020, the Board of Directors adopted, and the OSH LLC’s and OSH MH LLC’s majority unitholders approved, the 2020 Employee Stock Purchase Plan (the “ESPP”) for the issuance of up to a total of 2,386,875 shares of common stock. In addition, the number of shares available for issuance under the ESPP will be increased annually on January 1 of each calendar year beginning in 2021 and ending in and including 2030, by an amount equal to the lesser of (A) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by our Board of Directors, subject to an increase each January. In no event will more than 30,000,000 shares of our common stock will be available for issuance under the ESPP. Each offering period will be approximately six months in duration commencing on January and July 1 of each year and terminating on June 30 or December 31. The ESPP allows participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the grant date or purchase date.

As of March 31, 2021, no shares of common stock have been purchased under our ESPP.

Stock and Unit-Based Compensation Expense

The Company recognized $0.0 million and $1.8 million in unit-based compensation expense related to the profits interests for the three-months ended March 31, 2021 and 2020, respectively. The Company recorded $1.8 million in corporate, general and administrative expenses. The Company recognized $42.3 million and $0.0 million related to RSAs, options and RSUs for the three-months ended March 31, 2021 and 2020, respectively. The Company recorded $41.2 million in corporate, general and administrative expenses, $0.8 million in sales and marketing, and $0.3 million in cost of care.

As part of the pre-IPO equity conversion discussed in Note 12, the profits interests that were subject to vesting over a period of continuous employment or service and were unvested upon the conversion were converted into RSAs and options that vest over the remaining requisite service period from the original grant dates. The unvested profits interests that were subject to vesting upon the “Sponsor’s Exit” performance condition were converted into RSAs and options that cliff vest between two years post IPO and four years from the original grant dates. A Sponsor's Exit is defined to occur if either (1) a Sponsor sells down to one or more third parties their direct or indirect equity investment in OSH LLC to less than 20% of the units owned by such sponsor, or (2) a sale, transfer or other disposition of all or substantially all of the assets of OSH LLC to one or more third parties.

As a result of this conversion and modification of vesting terms from Sponsor’s Exit to service-based vesting at the IPO, the Company determined that RSAs and options should be accounted for as a Type III modification (the award was not probable to vest prior to the modification but it was probable of vesting under the modified condition). The stock compensation expense, net of forfeitures, recorded for these modifications was $29.3 million for the three-months ended March 31, 2021.

As of March 31, 2021, the Company had approximately $251.1 million in unrecognized compensation expense related to all non-vested awards (RSAs, options and RSUs) that will be recognized over the weighted-average period of 1.49 years.

Valuation of Stock Options

The grant date fair value of stock options that were granted post-IPO was estimated using a Black-Scholes option-pricing model with the following assumptions:

		March 31, 2021

Risk-free interest rate			0.79	%
Volatility			50.00	%
Expected term to expiration (years)			6.25
Expected dividend yield			0.00	%
Estimated fair value	$	28.69

The determination of fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company’s common stock as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgement to determine. The valuation assumptions were determined as follows:

Fair Value of Common Stock

The fair value of the Company’s common stock is determined by the closing price, on the date before the grant, of its common stock, which is traded on the NYSE.

Expected Term

We determine the expected term of awards using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method.

Expected Volatility

We use an average historical stock price volatility of a peer group of comparable publicly traded healthcare companies representative of our expected future stock price volatility, as we do not have sufficient trading history for our common stock. For purposes of identifying these peer companies, we consider the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measure historical volatility over a period equivalent to the expected term.

Risk-Free Interest Rate

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with maturities similar to the expected term of the award.

Expected Dividend Yield

We have not paid and do not anticipate paying any dividends in the foreseeable future. Accordingly, we estimate the dividend yield to be zero.

NOTE 14. COMMITMENTS – LITIGATION AND CONTINGENCIES

Contingencies

The Company is presently, and from time to time, subject to various claims and lawsuits arising in the normal course of business. In the opinion of management, the ultimate resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

Uncertainties

The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statues and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed.

Management believes that the Company is in compliance with fraud and abuse as well as other applicable government laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as regulatory actions unknown at this time.

NOTE 15. VARIABLE INTEREST ENTITIES

The Physician Groups (as defined in Note 1) were established to employ healthcare providers, contract with managed care payors, and to deliver healthcare services to patients in the markets that the Company serves.

The Company evaluated whether it has a variable interest in the Physician Groups, whether the Physician Groups are VIEs, and whether the Company has a controlling financial interest in the Physician Groups. The Company concluded that it has variable interests in the Physician Groups on the basis of its Administrative Service Agreement (“ASA”) which provides for reimbursement of costs and a management fee payable to the Company from the Physician Groups in exchange for providing management and administrative services which creates risks and a potential return to the Company. The Physician Group’s equity at risk, as defined by U.S. GAAP, is insufficient to finance its activities without additional support, and, therefore, the Physician Groups are considered VIEs.

In order to determine whether the Company has a controlling financial interest in the Physician Groups, and, thus, is the Physician’s primary beneficiary, the Company considered whether it has i) the power to direct the activities of Physician Groups that most significantly impact its economic performance and ii) the obligation to absorb losses of the Physician Groups that could potentially be significant to it or the right to receive benefits from Physician Groups that could potentially be significant to it. The Company concluded that the shareholders and employees of the Physician Groups are structured in a way that neither shareholder, employees nor their designees has the individual power to direct the activities of the Physician Groups that most significantly impact its economic performance. Under the ASA, MSO is responsible for providing management and administrative services related to the growth of the patient population of the Physician Groups, the management of that population’s healthcare needs, and the provision of required healthcare services to those patients. The Company has concluded that the success or failure of MSO in conducting these activities will most significantly impact the economic performance of the Physician Groups. In addition, the Company’s variable interests in the Physician Groups provide the Company with the right to receive benefits that could potentially be significant to it. The single member of the Physician Groups is a member and employee of OSH. As a result of this analysis, the Company concluded that it is the primary beneficiary of the Physician Groups and therefore consolidates the balance sheets, results of operations and cash flows of the Physician Groups. The Company performs a qualitative assessment of the Physician Groups on an ongoing basis to determine if it continues to be the primary beneficiary.

The table below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

March 31,

2021

December 31,

2020

Total assets

394.2

286.1

Total liabilities

337.7

332.1

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Total revenues	$		294.3	$		198.5
Medical claims expense			198.9			131.4
Cost of care			32.9			15.3
Total operating expenses	$		231.7	$		146.7

Physician Group revenues consist of amounts recognized for services provided to patients and includes capitated revenue and a portion of the Company’s other patient service revenue and exclude certain care management services. All capitation arrangements are executed at the Physician Group level.

Operating expenses consist primarily of medical claims expense, a majority of which are third-party medical claims expenses and administrative health plan fees and exclude fees to perform payor delegated activities and provider excess insurance costs. Cost of care, excluding depreciation and amortization primarily include provider salaries and benefits and other clinical operating costs which are reported in cost of care, excluding depreciation and amortization in the consolidated statements of operations. These amounts do not include intercompany revenues and costs, principally management fees between MSO and the Physician Groups, which are eliminated in consolidation.

of the Company have recourse to the assets owned by the Physician Groups. There are no liabilities for which creditors of the Physician Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physician Groups with respect to potential dividend payments.

NOTE 16. RELATED PARTIES

Humana

Revenues

Humana holds over 5% of our common stock and has entered into a Director Nomination Agreement with the Company. The Company has capitated managed care contracts with Humana. Total capitated revenues related to the Humana payor contracts were $121.4 million and $96.5 million for the three-months ended March 31, 2021 and 2020, respectively. Receivables from Humana represented $87.2 million and $65.7 million of the capitated accounts receivable balance at March 31, 2021 and December 31, 2020, respectively.

Within the Company’s other patient services revenue, revenues from Humana are included in both fee-for-service revenue and care coordination revenue. The Company had recognized $0.1 million in other patient service revenue in the three-months ended March 31, 2021 and 2020, related to the fee-for-service revenues. The Company had recognized $1.1 million and $0.7 million in other patient service revenue in the three-months ended March 31, 2021 and 2020, respectively, related to the Care Coordination arrangements. Receivables from Humana represented $0.1 million and $0.0 million of the other accounts receivable balance at March 31, 2021 and December 31, 2020, respectively, which is all related to fee-for-service arrangements. The unearned portion of the Care Coordination Payments was recorded as contract liabilities in both the short term and long-term other liabilities accounts. The liability related to Humana Care Coordination Payments represented $4.1 million and $2.6 million of the other current liabilities and $14.1 million and $5.0 million of the other long-term liabilities’ balances at March 31, 2021 and December 31, 2020, respectively.

Expenses

Total medical claims expenses related to the Humana payor contracts were $73.0 million and $59.8 million in the three-months ended March 31, 2021 and 2020, respectively. Unpaid claims related to Humana capitated contracts represented $78.8 million and $78.5 million of the liability for unpaid claims balance at March 31, 2021 and December 31, 2020, respectively.

The Humana Alliance Provision contains an arrangement for a license fee that is payable by the Company to Humana for the Company’s provision of health care services in certain centers owned or leased by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including rental payments, center maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements, and other expenses identified by Humana. The total license fees paid to Humana during the three-months ended March 31, 2021 and 2020 were $0.7 million and are included in cost of care expenses in the consolidated statement of operations. The liability was recorded in both the short term and long-term other liabilities accounts. The liability for the Humana license fee represented $2.7 million and $0.6 million of the other current liabilities and $8.4 million and $7.3 million of other long-term liabilities balance at March 31, 2021 and December 31, 2020, respectively.

The Company has entered into certain lease arrangements with Humana, which accounted for approximately $1.3 million and $0.5 million of the total operating lease rental payments within the cost of care line item for the three-months ended March 31, 2021 and 2020, respectively. The deferred rent liability related to Humana leases represented $0.0 million and $0.8 million at March 31, 2021 and December 31, 2020, respectively. The Company adopted ASC 842 as of January 1, 2020 and the ROU asset and liability related to Humana leases represented $40.6 million and $41.8 million at March 31, 2021, respectively.

Blue Cross Blue Shield of Rhode Island

Blue Cross Blue Shield of Rhode Island (“BCBSRI”) owns 49.9% of our joint venture, OSH-RI, LLC, and one of our Board members served as president and CEO of BCBSRI through the year ended December 31, 2020. Total capitated revenue associated with the BCBSRI payor contract was $2.3 million for the three-months ended March 31, 2020. Capitated receivables from BCBSRI represented $10.0 million of the capitated accounts receivable balance at December 31, 2020.

Total medical claims expenses related to the BCBSRI payor contract were $1.6 million for the three-months ended March 31, 2020. Unpaid claims related to these capitated contracts represented $11.1 million of the liability for unpaid claims balance at December 31, 2020.

Zing Health

capitated revenue associated with the Zing Health payor contract was $1.2 million and $0.6 million for the three-months ended March 31, 2021 and 2020, respectively. Capitated receivables from Zing Health represented $0.8 million and $0.2 million of the capitated accounts receivable balance at March 31, 2021 and December 31, 2020, respectively.

Total medical claims expenses related to the Zing Health payor contract was $1.0 million and $0.4 million for the three-months ended March 31, 2021 and 2020, respectively. Unpaid claims related to these capitated contracts represented $1.2 million and $0.7 million of the liability for unpaid claims balances at March 31, 2021 and December 31, 2020, respectively.

NOTE 17. SEGMENT FINANCIAL INFORMATION

The Company’s chief operating decision maker (“CODM”) regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company also identified its operating segments based on the responsibility of its CODM and where we operate. We report a single operating segment, which is to care for our patients’ needs. Although the Company derives its revenues from several different geographic regions, the Company neither allocates resources based on the operating results from the individual regions, nor manages each individual region as a separate business unit. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability. For the periods presented, all of the Company’s long-lived assets were located in the United States, and all revenues were earned in the United States.

NOTE 18. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per common share for the three-months ended March 31, 2021:

		Three-months ended March 31, 2021
Numerator:
Net loss	$		(64.0	)
Less: Net loss attributable to non-controlling interests			(0.6	)
Net loss attributable to OSH Inc. stockholders			(63.4	)
Denominator:
Weighted average common stock outstanding - basic and diluted			220,736,845
Net loss per share – basic and diluted	$		(0.29	)

The Company’s potentially dilutive securities, which included stock options, unvested RSUs, unvested RSAs and securities associated with our Convertible Senior Notes have been excluded from the computation of diluted net loss per share as the effect would reduce the net loss per share. Therefore, the weighted average number of common shares/units outstanding used to calculate both basic and diluted net loss per share was the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:

		Three-months ended March 31, 2021

Stock options			15,185,585
RSUs			375,082
RSAs			19,854,404
Convertible Senior Notes	*		11,622,176
			47,037,247

*The Company entered into capped call transactions to mitigate the impact of potential economic dilution to our common stock upon any conversion of our Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of the Convertible Senior Notes up to a cap price of $138.8750 per share. See Note 10 for further details on the capped call transactions.

iTEM 2. Management’s Discussion and Analysis of FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. This discussion should be read in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and the accompanying notes as well as “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2020 (File No. 001-39427). Unless the context otherwise indicates or requires, the terms “we”, “our,” “the Company” and “Oak Street Health” as used herein refer to Oak Street Health, Inc. and its consolidated subsidiaries, including Oak Street Health, LLC, which is Oak Street Health, Inc.’s predecessor for financial reporting purposes for periods presented prior to August 10, 2020.

The discussion contains forward-looking statements about the business, operations and financial performance of the Company based on our current expectations that involves risks, uncertainties and assumptions. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed above in “Forward-Looking Statements,” and Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q as well as those discussed under the “Risk Factors” section in our Annual Report on Form 10-K for the year ended December 31, 2020.

Business Overview

Oak Street Health, Inc. operates primary care centers within the United States serving Medicare beneficiaries. Since our founding in 2012, the Company’s mission has been to build a care delivery platform, built on a chassis of primary care, that directly addresses rising costs and poor outcomes, two of the most pressing challenges facing the United States healthcare industry. Our approach shifts the allocation of healthcare resource delivery from traditional acute and specialist care into an enhanced, patient-centered care delivery platform which meaningfully improves the quality of care and outcomes for high-risk populations. Our approach also disrupts the current state of care delivery for Medicare-eligible patients and aims to align the incentives of our patients, our providers and our payors with the goal of simultaneously improving health outcomes and care quality, lowering medical costs and improving the patient experience.

Oak Street Health was designed to provide and manage Medicare-eligible patients’ total healthcare through capitated, value-based payments. We created a new care platform because the then-existing primary care infrastructure was not built with the capacity to drive the significant improvements in cost and quality the current health system needs. We decided to focus on the Medicare market due to its size, growth tailwinds and largely clinically cohesive population. We designed our platform to take risk in managing patients’ health below an agreed-upon baseline cost because we believed there was a meaningful opportunity to produce system-wide cost savings by changing where and how patients’ healthcare is delivered. Our platform’s design has included investments in technology and patient-centered, community-based care delivery to create a different and we believe, better approach to addressing the needs of high risk Medicare-eligible patients.

As of March 31, 2021, the Company operated 86 centers in 20 markets across 13 states, which provided care for approximately 109,500 patients. We, together with our affiliated physician practice organizations, employed approximately 3,500 team members, including approximately 400 primary care providers. Our operations are organized and reported under one segment.

COVID-19 Update on our Business

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. The rapid spread of COVID-19 around the world and throughout the United States has altered the behavior of businesses and people, with significant negative effects on federal, state and local economies, the duration of which is unknown at this time. Various policies were implemented by federal, state and local governments in response to the COVID-19 pandemic that caused many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. While some of these restrictions have been eased across the U.S. and most states have lifted moratoriums on non-emergent procedures, some restrictions remain in place. The virus disproportionately impacts older adults, especially those with chronic illnesses, which describes many of our patients.

In response to the COVID-19 pandemic, we took the following actions to ensure the safety of our employees and their families and to address the physical, mental and social health of our patients:

•

Created a COVID-19 Response Team in March 2020 that is supported by team members from across our organization to ensure a coordinated response to the pandemic;

•

Temporarily closed all of our corporate offices and enabled our entire corporate work force to work remotely;

•

Implemented travel restrictions for non-essential business;

•

Transitioned much of our center-based care to be delivered by our providers virtually through newly developed telehealth capabilities, including video and telephone through June 2020 but have transitioned our business back to a more normal operating cadence as of July 2020, including seeing a larger proportion of our patients via in-center visits (with a corresponding reduction in telehealth visits) while maintaining stringent safety protocols to minimize the potential transmission of COVID-19. For the foreseeable future, we expect to continue to leverage our telehealth capabilities as a means of interacting with our patients to the extent an in-person visit is not required or preferred;

•

Made operational changes to the staffing and operations of our centers, which remain open as “essential” businesses, to minimize potential exposure to and transmission of COVID-19;

•

Temporarily delayed planned openings of new centers through August 2020 but have restarted our growth efforts through patient outreach and starting August 2020, we resumed opening new centers and are currently opening centers consistent with our pre-COVID operations;

•

Temporarily halted community outreach and other marketing initiatives which drive new patients to our platform through June 2020 but have recommenced marketing initiatives during the third quarter of 2020 through the present;

•

Acquired and deployed significantly greater amounts of personal protective equipment (“PPE”) to ensure the safety of our employees and patients;

•

Created a program called “COVID Care,” which continues to be in full operation, to actively monitor our patients for suspected COVID-19 infections with the goal of managing those symptoms to keep our patients safely out of the hospital unless and until necessary due to the potential infection risks in the hospital environment;

•

Redeployed our contracted and employed drivers, who typically transport patients to our centers, to deliver food from food pantries to our patients to address food supply issues or challenges;

•

Provided free rapid COVID-19 tests to all members of the Chicago community;

•

Launched an effort in January 2021 to vaccinate frontline healthcare workers (both employees of Oak Street Health and non-employees), our patients, and other eligible members of our communities. While this work is critically important for our communities, we also expect our agile vaccination efforts will result in greater brand awareness and loyalty and incremental patient growth; and

•

As of April 13, 2021, we have administered more than 150,000 total COVID-19 vaccine doses across 12 states.

We do expect COVID-19 to impact both our per-patient capitated revenue due to lower risk scores for new patients and our medical claims expense. Although we expect risk scores for existing Oak Street Health patients to be consistent with our historical experience, due to a lack of availability of care and inadequate documentation as discussed in more detail below, we expect lower risk scores for new patients in 2021, which will result in lower per-patient capitated revenue. As future patients not served by Oak Street Health in 2020 were unable to access the healthcare system for several months in 2020 due to local COVID-19 restrictions and therefore had fewer interactions with healthcare providers than a typical year, we expect the risk scores for these new patients in 2021 to be lower than they have been historically.

As we are financially responsible for essentially all of the healthcare costs associated with our at-risk patients whether we provide that care or a third party provides that care, we suspect that the healthcare costs of patients infected with COVID-19 will be greater than had COVID-19 not occurred. It is impossible, however, to know what other healthcare issues these patients may have encountered in their pre-COVID-19 lives and whether the COVID-19 costs are or will be greater or lesser than the costs these patients would otherwise incur. Additionally, because of the extraordinary measures taken by local governments in our markets particularly in the second quarter of 2020, all of our patients had more limited access to healthcare services, including healthcare specialists such as cardiologists or orthopedists, to schedule both inpatient and outpatient surgeries, and to some extent hospital care. Beginning in late March 2020 and

extending through most of the second quarter of 2020, our patients who were not infected with COVID-19, which to date represents over 96% of our at-risk patients, incurred lower healthcare costs than we would have otherwise expected, which will result in lower medical claims expense that we incur. We expect the vast majority of these costs are just delayed and will be incurred at future points in time and it is possible that the deferral of healthcare services could cause additional health problems in our existing patients, which could increase our costs in the future. In the third and fourth quarters of 2020, we did experience an increase in medical costs to levels above historical norms. Because of the COVID-19 related volatility in medical cost data in 2020, we do not believe that our 2020 medical cost data can serve as a reliable basis for estimating our 2021 performance. We also do not know what the net impact to medical costs will be as a result of the surge in COVID-19 cases at the end of 2020 and the beginning of 2021. Given these factors, per-patient medical costs may be greater in 2021 than the levels we experienced in our recent historical results. Furthermore, due to the time it takes for medical claims to be submitted to MA plans, adjudicated, and sent to us, we believe it will be several quarters before we will be able to accurately calculate the impact on medical claims expense from the COVID-19 pandemic. We do believe, however, that the impact of on per-patient revenue and medical claims related to COVID-19 that we expect to experience will not have a materially detrimental effect on our long-term financial performance.

The full extent to which the COVID-19 pandemic has and will continue to directly or indirectly impact our business, future results of operations and financial condition will depend on future factors that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 including the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on our markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, rate and effectiveness of vaccinations in the U.S., government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these and other uncertainties, we cannot estimate the length or severity of the impact of the pandemic on our business. Furthermore, because of our business model, the full impact of the COVID-19 pandemic may not be fully reflected in our results of operations and overall financial condition until future periods. We will continue to closely evaluate and monitor the nature and extent of these potential impacts to our business, results of operations and liquidity.

For additional information on the various risks posed by the COVID-19 pandemic, please see “Risk Factors” included in our Form 10-K for the year ended December 31, 2020.

Key Factors Affecting Our Performance

•

Adding New Patients in Existing Centers: Our ability to add new patients is a key indicator of the market’s recognition of the attractiveness of the Oak Street Platform, both to our patients and MA plan partners, and a key growth driver for the business. As we add patients to our existing centers, we expect these patients to contribute significant incremental economics to Oak Street Health as we leverage our fixed cost base at each center. We grow our patient base through our own internal sales and marketing efforts, which drive most of our new patient growth, as well as assignments from our MA plan partners. We grew our patient base from approximately 85,500 patients as of March 31, 2020 to approximately 109,500 as of March 31, 2021.

•

Expand our Center Base within Existing and New Markets: We believe that we currently serve less than 3% of the total patients in the markets where we currently have centers. As a result, there is significant opportunity to expand in our existing markets through the acquisition of new patients to existing centers and addition of new centers. For the long term, these strategically developed new sites allow us to access additional neighborhoods while leveraging our established brand and infrastructure in a market. Our existing markets today represent a small fraction of the overall market opportunity. Based upon our experience to date, we believe our care model can scale nationally, and we therefore expect to selectively and strategically expand into new geographies. Additionally, we are hopeful that the Direct Contracting model will allow us to convert existing fee-for-service patients into at-risk patients.

•

Contract with Payors: Our economic model relies on our capitated partnerships with payors and CMS, which manage and market MA plans across the United States. In our short history, we have been able to establish strategic value-based relationships with 25 different payors as of March 31, 2021, including each of the top 5 national payors by number of MA patients. These existing contracts and relationships and our partners’ understanding of the value of our model reduces the risk of entering into new markets as we typically have payor contracts before entering a new market. Maintaining, supporting, and growing these relationships, particularly as we enter new geographies, is critical to our long-term success.

•

Effectively Manage the Cost of Care for Our Patients: The capitated nature of our contracting with payors requires us to prudently manage the medical expense of our patients. Our care model focuses on leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as acute hospital admissions. Our patients, however, retain the freedom to seek care at emergency rooms or hospitals; we do not restrict their access to care beyond the limits of their MA

plan, although we have developed many capabilities to manage and control the associated costs of this care. Therefore, we are liable for potentially large medical claims should we not effectively manage our patients’ health.

•

Center-Level Contribution Margin: We endeavor to expand our number of centers and number of patients at each center over time. Due to the significant fixed costs associated with operating and managing our centers and the increases we experience in patient contribution on a per-patient basis the longer a patient is part of the Oak Street Platform, we generate significantly better center-level contribution margins (defined as (i) patient revenue, excluding Medicare Part D revenue minus (ii) the sum of (a) medical claims expense, excluding Medicare Part D related expenses, and (b) cost of care, excluding depreciation and amortization) as the patient base within our centers increases and matures and our costs decrease as a percent of revenue. As a result, the value of a center to our business increases over time.

•

Seasonality to our Business: Our operational and financial results, including at-risk patient growth, per-patient revenue, and medical costs, will experience some variability depending upon the time of year in which they are measured. We typically experience the largest portion of our at-risk patient growth during the first quarter, when plan enrollment selections made during the prior Annual Enrollment Period (“AEP”) from October 15th through December 7th of the prior year take effect. Our per-patient revenue will generally decline over the course of the year. As the year progresses, our per-patient revenue declines as new patients join us typically with less complete or accurate documentation (and therefore lower risk-adjustment scores) and our attrition skews towards our higher-risk (and therefore greater revenue) patients. Finally, medical costs will vary seasonally depending on a number of factors, including the weather which can be a driver of certain illnesses, such as the influenza virus. We would therefore expect to see higher levels of per-patient medical costs in the first and fourth quarters. Medical costs also depend upon the number of business days in a period as periods with fewer business days will have lower medical costs all else equal.

•

Investments in Growth: We expect to continue to focus on long-term growth through investments in our centers, care model, and sales and marketing. In addition, we expect our corporate, general and administrative expenses to increase in absolute dollars for the foreseeable future to support our growth and because of additional costs of being a public company.

Executive Summary

The following table presents key financial statistics for the three-months ended March 31, 2021 and 2020, respectively ($ in millions):

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020
Centers			86				54
Total patients			109,500				85,500
At-risk			75,500				55,000
Fee-for-service			34,000				30,500
Total revenues	$		296.7		$		201.8
Loss from operations¹	$		(63.8	)	$		(13.0	)
Net loss¹	$		(64.0	)	$		(15.4	)
Platform contribution (Non-GAAP)²	$		36.7		$		25.7
Patient contribution (Non-GAAP)²	$		91.5		$		64.3
Adjusted EBITDA (Non-GAAP)²	$		(17.4	)	$		(8.7	)

Includes stock and unit-based compensation as shown in the table in the Results of Operations section below.

See “—Non-GAAP Reconciliations” below for reconciliations to the most directly comparable financial measures calculated in accordance with GAAP and related disclosures.

Centers

We define our centers as those primary care centers open for business and attending to patients at the end of a particular period. Our centers are leased or licensed by Oak Street Health MSO, LLC or an affiliated entity and, pursuant to the terms of certain contractual relationships between Oak Street Health MSO, LLC and our affiliated medical practices, made available for use by the medical practices in the provision of primary care services.

Total Patients

Total patients includes both at-risk MA patients (those patients for whom we are financially responsible for their total healthcare costs) as well as fee-for-service Medicare patients (those patients for whom our affiliated medical groups submit claims to the federal government for direct reimbursement under the Medicare program or to MA plans with which we do not have value-based arrangements). We define our total at-risk patients as at-risk patients who have selected one of our affiliated medical groups as their provider of primary care medical services as of the end of a particular period. We define our total fee-for-service Medicare patients as fee-for-service Medicare patients who come to one of our centers for medical care at least once per year. A fee-for-service patient continues to be included in our patient count until the earlier to occur of (a) more than one year since the patient’s last visit, (b) the patient communicates a desire to stop receiving care from us or (c) the patient passes away.

Non-GAAP Financial Measures

We utilize certain financial measures that are not calculated based on GAAP. Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors.

To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following Non-GAAP measures: patient contribution, platform contribution and Adjusted EBITDA as these are performance measures that our management uses to assess our operating performance. Because patient contribution, platform contribution and Adjusted EBITDA facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Patient and platform contribution are reconciled to loss from operations as the most directly comparable GAAP measure as set forth in the below tables under “Non-GAAP Reconciliations.” Adjusted EBITDA is reconciled to net loss as the most directly comparable GAAP measure as set forth in the below table under “Non-GAAP Reconciliations.”

Our definitions of patient contribution, platform contribution and Adjusted EBITDA may differ from the definition used by other companies and therefore comparability may be limited. In addition, other companies may not publish this or similar metrics. Thus, our Non-GAAP Financial Measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net loss and loss from operations.

We provide investors and other users of our financial information with reconciliations of patient contribution, platform contribution and Adjusted EBITDA to loss from operations and net loss, respectively. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure and to view patient contribution, platform contribution and Adjusted EBITDA in conjunction with loss from operations and net loss, respectively.

Patient Contribution

We define patient contribution as capitated revenue less medical claims expense. We view patient contribution as all of the dollars available for us to manage our business, including providing care to our patients, investing in marketing to attract new patients to the Oak Street Platform, and supporting the organization through our central corporate infrastructure. We expect that patient contribution will grow year-over-year in absolute dollars as our at-risk patient base continues to grow. We would also expect that our patient contribution per-patient-per-month economics on our at-risk patients will continue to improve the longer our patients are part of the Oak Street Platform as we better understand their health conditions and the patients better engage with our care model. We would expect, however, that our aggregate patient contribution per-patient-per-month economics on our at-risk patients may decrease at an aggregate level to the extent our patient growth skews our mix of patients towards patients newer to the Oak Street Platform. We would also expect to experience seasonality in patient contribution per-patient-per-month with Q1 generally generating the greatest patient contribution per-patient-per-month, decreasing for the rest of the year. This seasonality is primarily driven by our adding new patients to the Oak Street Platform throughout the year, who generally have lower per-patient capitated revenue compared to our existing patient base.

Platform Contribution

We define platform contribution as total revenues less the sum of medical claims expense and cost of care, excluding depreciation and amortization. We believe this metric best reflects the economics of our care model as it includes all medical claims expense associated with our patients’ care as well as the costs we incur to care for our patients via the Oak Street Platform. As a center matures, we expect the platform contribution from that center to increase both in terms of absolute dollars as well as a percent of capitated

revenue. This increase will be driven by improving patient contribution economics over time as well as our ability to generate operating leverage on the costs of our centers. Our aggregate platform contribution may not increase despite improving economics at our existing centers should we open new centers at a pace that skews our mix of centers towards newer centers. We would expect to experience seasonality in platform contribution due to seasonality in our patient contribution.

Adjusted EBITDA

We define adjusted EBITDA as net loss excluding other income (expense), income taxes, depreciation and amortization, transaction/ offering costs and stock and unit-based compensation. We include adjusted EBITDA in this Quarterly Report because it is an important measure upon which our management assesses and believes investors should assess our operating performance. We also consider adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

Results of Operations

The following tables set forth our results of operations for the periods presented and as a percentage of our total revenues for those periods. Percentages presented in the following tables may not sum due to rounding.

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020				$ Change			% Change
Revenues:
Capitated revenue	$		291.2		$		196.6		$		94.6			48	%
Other patient service revenue			5.5				5.2				0.3			6	%
Total revenues			296.7				201.8				94.9			47	%

Operating expenses:
Medical claims expense			199.7				132.3				67.4			51	%
Cost of care, excluding depreciation and amortization (1)			60.3				43.8				16.5			38	%
Sales and marketing (2)			24.1				11.9				12.2			103	%
Corporate, general and administrative (3)			73.1				24.3				48.8			201	%
Depreciation and amortization			3.3				2.5				0.8			32	%
Total operating expenses			360.5				214.8				145.7			68	%

Loss from operations	$		(63.8	)	$		(13.0	)	$		(50.8	)		391	%

Other (expense)/ income
Interest expense, net			(0.2	)			(2.5	)			2.3			(92	)%
Other			-				0.1				(0.1	)		(100	)%
Total other (expense)/ income			(0.2	)			(2.4	)			2.2			(92	)%
Net loss	$		(64.0	)	$		(15.4	)	$		(48.6	)		316	%

Net loss attributable to noncontrolling interests			0.6				0.4				0.2			50	%
Net loss attributable to the Company	$		(63.4	)	$		(15.0	)	$		(48.4	)		323	%


(1) Includes stock-based compensation, as follows:	$		0.3		$		0.0		$		0.3		*
(2) Includes stock-based compensation, as follows:			0.8				0.0				0.8		*
(3) Includes stock-based compensation, as follows:	$		41.2		$		1.8		$		39.4		*

____________

* Percentage not meaningful

	For the Quarter Ended
	March 31, 2021			March 31, 2020
Revenues:
Capitated revenue		98	%		97	%
Other patient service revenue		2	%		3	%
Total revenues		100	%		100	%

Operating expenses:
Medical claims expense		67	%		66	%
Cost of care, excluding depreciation and amortization		20	%		22	%
Sales and marketing		8	%		5	%
Corporate, general and administrative		26	%		12	%
Depreciation and amortization		1	%		1	%
Total operating expenses		122	%		106	%

Loss from operations		(22	)%		(6	)%

Other income/(expense):
Interest expense, net		(0	)%		(1	)%
Other		0	%		0	%
Total other expense		(0	)%		(1	)%
Net loss		(22	)%		(7	)%

Net loss attributable to noncontrolling interests		0	%		0	%
Net loss attributable to the Company		(22	)%		(7	)%

Total Revenues

		For the Quarter Ended March 31,						Change
(dollars in millions)		2021			2020			$		%
Revenues:
Capitated revenue	$		291.2	$		196.6	$		94.6		48	%
Other patient service revenue			5.5			5.2			0.3		6	%
Total revenues	$		296.7	$		201.8	$		94.9		47	%

Capitated revenue was $291.2 million for the three-months ended March 31, 2021, an increase of $94.6 million, or 48%, compared to $196.6 million for the three-months ended March 31, 2020. This increase was driven primarily by a 37% increase in total patients under capitated arrangements, and an increase of approximately 8% in capitated revenue rates primarily due to increased premiums from patients with a higher average level of acuity. Additionally, for the three-months ended March 31, 2021, capitated revenue of $6.9 million was recorded related to prior periods primarily driven by an increase in our at-risk patients managed in fiscal year 2020.

Operating Expenses

		For the Quarter Ended March 31,						Change
(dollars in millions)		2021			2020			$		%
Medical claims expense	$		199.7	$		132.3	$		67.4		51	%
Cost of care, excluding depreciation and amortization			60.3			43.8			16.5		38	%
Sales and marketing			24.1			11.9			12.2		103	%
Corporate, general and administrative			73.1			24.3			48.8		201	%
Depreciation and amortization			3.3			2.5			0.8		32	%
Total operating expenses	$		360.5	$		214.8	$		145.7		68	%

Medical claims expense was $199.7 million or 67% of total revenues for the three-months ended March 31, 2021, an increase of $67.4 million, or 51%, compared to $132.3 million or 66% of total revenues for the three-months ended March 31, 2020. The increase

was primarily due to a 37% increase in total patients under capitated arrangements and a 10% increase in cost per patient. Additionally, for the three-months ended March 31, 2021, medical claims expense of $6.6 million was recorded as a result of an increase in prior period incurred claims, primarily driven by an increase in our at-risk patients managed in fiscal year 2020.

Cost of care, excluding depreciation and amortization was $60.3 million or 20% of total revenues for the three-months ended March 31, 2021, an increase of $16.5 million or 38%, compared to $43.8 million or 22% of total revenues for the three-months ended March 31, 2020. The increase was driven by increases in salaries and benefits of $9.3 million, occupancy costs of $4.8 million, and medical supplies and patient transportation costs of $2.0 million, due to increases in both the number of centers we operate and our patient base. Also, expenses related to our COVID-19 response (including our vaccination efforts) of $1.9 million were incurred for the three-months ended March 31, 2021 but were offset by the recognition of the CARES Act provider relief funds.

Sales and marketing expense was $24.1 million or 8% of total revenues for the three-months ended March 31, 2021, an increase of $12.2 million, or 103%, compared to $11.9 million or 5% of total revenues for the three-months ended March 31, 2020. The increase was driven by greater advertising spend of $8.0 million to drive new patients to our clinics; net headcount growth of $3.8 million, which includes an increase in share and unit-based compensation expense of $0.8 million primarily due to the modification of vesting terms for pre-IPO equity awards that occurred post-IPO.

Corporate, general and administrative expense was $73.1 million or 26% of total revenues for the three-months ended March 31, 2021, an increase of $48.8 million, or 201%, compared to $24.3 million or 12% of total revenues for the three-months ended March 31, 2020. The increase was primarily driven by greater salaries and benefits of $45.5 million, which included an increase in share and unit-based compensation expense of $39.4 million primarily due to pre-IPO equity issuances and the modification of vesting terms for pre-IPO equity awards that occurred post-IPO. The remainder of the increases in corporate, general and administrative expense were primarily to support the continued growth of our business.

Depreciation and amortization expense was $3.3 million or 1% of total revenues for the three-months ended March 31, 2021, an increase of $0.8 million, or 32%, compared to $2.5 million or 1% of total revenues for the three-months ended March 31, 2020. The increases were primarily due to capital expenditures purchased to support the continued growth of our business.

Other (Expense) Income

		For the Quarter Ended March 31,								Change
(dollars in millions)		2021				2020				$			%
Other income (expense):
Interest expense, net	$		(0.2	)	$		(2.5	)	$		2.3			(92	)%
Other			-				0.1				(0.1	)		(100	)%
Total other (expense) income	$		(0.2	)	$		(2.4	)	$		2.2			(92	)%

Interest expense was $(0.2) million for the three-months ended March 31, 2021, a decrease of $2.3 million, or (92)%, compared to $(2.5) million for the three-months ended March 31, 2020. The decrease was primarily due to the payoff of outstanding debt and related interest from the Hercules Loan Agreement on August 11, 2020, slightly offset by the amortization of debt issuance and offering costs related to the Convertible Senior Notes issued in March 2021.

Non-GAAP Reconciliations

The following table provides a reconciliation of loss from operations, the most closely comparable GAAP financial measure, to platform contribution:

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020
Loss from operations	$		(63.8	)	$		(13.0	)
Depreciation and amortization			3.3				2.5
Corporate, general and administrative			73.1				24.3
Sales and marketing			24.1				11.9
Platform contribution	$		36.7		$		25.7

The following table provides a reconciliation of loss from operations, the most closely comparable GAAP financial measure, to patient contribution.

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020
Loss from operations	$		(63.8	)	$		(13.0	)
Other patient service revenue			(5.5	)			(5.2	)
Cost of care, excluding depreciation and amortization			60.3				43.8
Sales and marketing			24.1				11.9
Corporate, general and administrative expenses			73.1				24.3
Depreciation and amortization			3.3				2.5
Patient contribution	$		91.5		$		64.3

The following table provides a reconciliation of net loss, the most closely comparable GAAP financial measure, to Adjusted EBITDA:

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020
Net loss	$		(64.0	)	$		(15.4	)
Interest expense and other income			0.2				2.4
Depreciation and amortization			3.3				2.5
Stock and unit-based compensation			42.3				1.8
Transaction/offering related costs			0.8				-
Adjusted EBITDA	$		(17.4	)	$		(8.7	)

Liquidity and Capital Resources

Overview

We have funded our operations through the issuance of equity and debt. As of March 31, 2021, we had cash, restricted cash and cash equivalents of $1,156.8 million. Our restricted cash balance was $10.4 million as of March 31, 2021. Our cash and cash equivalents primarily consist of highly liquid investments in money market funds and cash. Since our inception and through March 31, 2021, we have generated significant operating losses from our operations as reflected in our accumulated deficit and negative cash flows from operations.

We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our operations and sales and marketing and due to additional general and administrative costs we expect to incur in connection with operating as a public company. As a result, we may require additional capital resources to execute strategic initiatives to grow our business.

We believe that the proceeds from the convertible debt offering described below and IPO are sufficient to satisfy our anticipated cash requirements, which consist of capital expenditures, working capital, and potential acquisition and strategic transactions, for the next twelve months even with the uncertainty arising from the COVID-19 pandemic. Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Our actual results and our future capital requirements could vary because of, many factors, including our growth rate, the timing and extent of spending to open new centers and expand into new markets and the expansion of sales and marketing activities. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies, including intellectual property rights. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would be adversely affected.

Convertible Senior Notes and Capped Call Transactions

In March 2021, we issued $920.0 million aggregate principal amount of 0% Convertible Senior Notes (the “Convertible Senior Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $120.0 million, in a private offering exempt from registration under the Securities Act of 1933. The Convertible Senior Notes are governed by an indenture (“Indenture”), dated as of March 16, 2021, between the Company and U.S. Bank National Association, as trustee. Total proceeds realized from the sale of the Convertible Senior Notes, net of debt issuance and offering costs of $22.1 million, were $897.9 million. The Convertible Senior Notes will not bear regular interest and the principal amount of the Convertible Senior Notes will not accrete. We will pay special interest, if any, as the sole remedy, at our election, relating to the failure to comply with our reporting and certain other obligations under the Indenture for the first 365 days after the occurrence of such an event. The Convertible Senior Notes are general senior, unsecured

obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted. Refer to Note 10, Convertible Senior Notes, of the Notes to Consolidated Financial Statements included in this quarterly report.

We used approximately $123.6 million of the net proceeds to pay the cost of the capped call transactions. We intend to use the remainder of the net proceeds for general corporate purposes, which may include working capital, capital expenditures, and potential acquisitions and strategic transactions.

The Indenture contains customary covenants related to timely filings and reporting, and customary events of default. As of March 31, 2021, we were in compliance with all covenants under the Indenture.

Changes in Cash Flows

The following table presents a summary of our consolidated cash flows from operating, investing and financing activities for the periods indicated.

		For the Quarter Ended
(dollars in millions)		March 31, 2021				March 31, 2020				$ Change			% Change
Net cash used in operating activities	$		(28.8	)	$		(36.9	)	$		8.1			(22	)%
Net cash used in investing activities			(8.8	)			(3.4	)			(5.4	)		159	%
Net cash provided by financing activities			774.7				224.4				550.3			245	%
Net change in cash	$		737.1		$		184.1		$		553.0			300	%

Operating Activities

For the three-months ended March 31, 2021, net cash used in operating activities was $28.8 million, a decrease of $8.1 million in cash outflows compared to net cash used in operating activities of $36.9 million for the three-months ended March 31, 2020. The principal contributors to the year-over-year change in the operating cash flows were as follows:

•

A decrease of $12.0 million in cash outflows related to operating assets and liabilities resulting from

Changes in accounts receivable due to the timing of collections and the growth in the number of at-risk patients;

Changes in liability for unpaid claims due to the growth in the number of at-risk patients; and

Changes in accrued compensation and benefits due to the payment of employee bonuses.

•

A net change of $3.9 million in net loss and non-cash charges and credits, primarily due to an increase in net loss for the business, as noted above under “Results of Operations” offset by increased stock and unit-based compensation, non-cash operating lease charges and depreciation and amortization.

Investing Activities

For the three-months ended March 31, 2021, net cash used in investing activities was $8.8 million, an increase of $5.4 million in cash outflows compared to net cash used in investing activities of $3.4 million for the three-months ended March 31, 2020 due to an increase in capital expenditures primarily related to the buildout of new centers that will be opened throughout the year.

Financing Activities

Cash provided by financing activities for the three-months ended March 31, 2021 was $774.7 million, an increase of $550.3 million in cash inflows compared to cash provided by financing activities of $224.4 million for the three-months ended March 31, 2020 due to $898.2 million in proceeds from the issuance of the Convertible Senior Notes and cash outflows of $123.6 million related to the capped call transactions completed in March 2021, discussed in Note 10 of our financial statements included in this Quarterly Report on Form 10-Q. Cash provided by financing activities for the three-months ended March 31, 2020 was due to proceeds from the issuance of redeemable investor units.

Contractual Obligations and Commitments

As of March 31, 2021, our contractual obligations are summarized in the table below.

(dollars in millions)		Total			Less than 1 Year			1-3 Years			3-5 Years			More than 5 Years
Convertible Senior Notes	$		920.0	$		-	$		-	$		920.0	$		-
Operating Lease Obligations			165.6			18.3			33.3			28.3			85.7
Other Obligations			8.6			2.7			4.2			1.0			0.7
Total	$		1,094.2	$		21.0	$		37.5	$		949.3	$		86.4

Off-Balance Sheet Obligations

As of March 31, 2021, we did not have any significant off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported amounts of assets, liabilities, revenue and expenses, and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The future effects of the COVID-19 pandemic on our results of operations, cash flows and financial position are unclear, however, we believe we have made reasonable estimates and assumptions in preparing the financial statements. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and our actual results, our future financial statements will be affected.

For a description of our policies regarding our critical accounting policies, see “Critical Accounting Policies” in our Form 10-K for the year ended December 31, 2020. There have been no significant changes in our critical accounting estimate policies or methodologies to our condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

For a description of recently issued accounting pronouncements, see Note 1 to our consolidated financial statements of this Quarterly Report on Form 10-Q.

Emerging Growth Company Status

We are an emerging growth company, as defined in the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period under the JOBS Act until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

ITEM 3. QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For information regarding our exposure to certain market risks, see “Quantitative and Qualitative Disclosures about Market Risk,” in Part II, Item 7A of our Form 10-K for the year ended December 31, 2020. There have been no material changes in our market risk exposures for the three-months ended March 31, 2021, as compared to those discussed in our Annual Report on Form 10-K for the year ended December 31, 2020.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of March 31, 2021.

Changes to our Internal Controls over Financial Reporting

There were no material changes in our internal control over financial reporting during the three-months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As a result of the COVID-19 pandemic, certain employees began working remotely in March 2020. We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment, in part because our internal control over financial reporting was designed to operate in a remote working environment. We are continually monitoring and assessing the COVID-19 situation to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 14, Commitments – Litigation and Contingencies to Oak Street Health, Inc.’s Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, except that the risk factors set forth are added.

Our indebtedness and liabilities could limit the cash flow available for operations, expose us to risks that could adversely affect our business, financial condition and results of operations.

In March 2021, we issued $920.0 million aggregate principal amount of Convertible Senior Notes in a private offering exempt from registration under the Securities Act of 1933. In the future, we may incur additional indebtedness to meet financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:

•

increasing our vulnerability to adverse economic and industry conditions;

•

limiting our ability to obtain additional financing;

•

in the event special interest accrues on the Convertible Senior Notes, requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;

•

limiting our flexibility to plan for, or react to, changes in our business; and

•

placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.

Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the Convertible Senior Notes or any additional indebtedness that we may incur. In addition, any future indebtedness that we may incur may contain restrictive covenants that may limit our ability to operate our business, raise capital or make payments under our indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that indebtedness becoming immediately payable in full.

The conditional conversion feature of the Convertible Senior Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditions to convert the notes are satisfied, holders will be entitled to convert their notes at any time during specified periods at their option. If one or more holders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

Conversion of the Convertible Senior Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.

The conversion of some or all of the notes may dilute the ownership interests of our stockholders. Upon conversion of the notes, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock. If we elect to settle our conversion obligation in shares of our common stock or a combination of cash and shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.

The capped call transactions may affect the value of the Convertible Senior Notes and our common stock.

In connection with the pricing of the notes, we entered into capped call transactions with one or more of the purchasers or their affiliates and/or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce

potential dilution to our common stock upon conversion of any notes and/or offset any cash payments we are required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap.

In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates purchased shares of our common stock and/or entered into various derivative transactions with respect to our common stock. This activity could have increased (or reduced the size of any decrease in) the market price of our common stock or the notes at that time.

The option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the notes (and are likely to do so on each exercise date for the capped call transactions, which are expected to occur on each trading day during the 40 trading day period beginning on the 41st scheduled trading day prior to the maturity date of the notes, or following any termination of any portion of the capped call transactions in connection with any repurchase, redemption or early conversion of the notes). This activity could cause a decrease or avoid an increase in the market price of our common stock.

We do not make any representation or prediction as to the direction or magnitude of any potential effect that the transactions described above may have on the price of our common stock. In addition, we do not make any representation that the option counterparties will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

We are subject to counterparty risk with respect to the capped call transactions.

The option counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the capped call transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral. Past global economic conditions have resulted in the actual or perceived failure or financial difficulties of many financial institutions. If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the capped call transactions with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer more dilution than we currently anticipate with respect to our common stock. We can provide no assurance as to the financial stability or viability of the option counterparties.

Certain provisions in the indenture governing the Convertible Senior Notes may delay or prevent an otherwise beneficial takeover attempt of us.

Certain provisions in the indenture governing the Convertible Senior Notes may make it more difficult or expensive for a third party to acquire us. For example, the indenture governing the notes will require us, subject to certain exemptions, to repurchase the notes for cash upon the occurrence of a fundamental change and, in certain circumstances, to increase the conversion rate for a holder that converts its notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we repurchase the notes and/or increase the conversion rate, which could make it more costly for a potential acquirer to engage in such takeover. Such additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

Information regarding the issuance of the Convertible Senior Notes was previously provided in the Current Report on Form 8-K filed with the SEC on March 16, 2021, and therefore is not required to be furnished herein.

Use of Proceeds

Initial Public Offering

On August 10, 2020, we completed the IPO of our common stock pursuant to a Registration Statement (File No. 333-239818) which was declared effective on August 5, 2020. There have been no material change in the planned use of proceeds from the IPO from those that were described in the final prospectus filed pursuant to Rule 424(b) under the Securities Act and our Annual Report on Form 10-K for the year ended December 31, 2020.

ITEM 3. DEFAULT UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS


Exhibit No.		Description

4.1		Indenture, dated March 16, 2021, between Oak Street Health, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Current Report filed with the SEC on March 16, 2021).

4.2		Form 0% Convertible Senior Notes due 2026 (incorporated by reference to Exhibit 4.2 to the Current Report filed with the SEC on March 16, 2021).

10.1		Form of Capped Call Confirmation (incorporated by reference to Exhibit 10.1 to the Current Report filed with the SEC on March 16, 2021).)
31.1		Certification of the Chief Executive Officer pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2020, filed herewith.
31.2		Certification of the Chief Financial Officer pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2020, filed herewith.
32.1*		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, filed herewith.
32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, filed herewith.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Oak Street Health, Inc. (Registrant)

Date: May 10, 2021	By:	/s/Timothy Cook
		Timothy Cook
		Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 osh-ex311_6.htm EX-31.1 osh-ex311_6.htm

Exhibit 31.1

Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Michael Pykosz, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Oak Street Health, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2021

/s/ Michael Pykosz

Michael Pykosz

Chief Executive Officer

EX-31.2 3 osh-ex312_8.htm EX-31.2 osh-ex312_8.htm

Exhibit 31.2

Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Timothy Cook, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Oak Street Health, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2021

/s/ Timothy Cook

Timothy Cook

Chief Financial Officer

EX-32.1 4 osh-ex321_7.htm EX-32.1 osh-ex321_7.htm

Exhibit 32.1

Certification of the Chief Executive Officer

Pursuant to Rule 18 U.S.C. Section 1350

In connection with the Quarterly Report on Form 10-Q of Oak Street Health, Inc. (the “Company”) for the period ended March 31, 2021, as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Michael Pykosz, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2021

/s/ Michael Pykosz

Michael Pykosz

Chief Executive Officer

EX-32.2 5 osh-ex322_9.htm EX-32.2 osh-ex322_9.htm

Exhibit 32.2

Certification of the Chief Financial Officer

Pursuant to Rule 18 U.S.C. Section 1350

In connection with the Quarterly Report on Form 10-Q of Oak Street Health, Inc. (the “Company”) for the period ended March 31, 2021 as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Timothy Cook, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2021

/s/ Timothy Cook

Timothy Cook

Chief Financial Officer

EX-101.INS 6 osh-20210331.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure osh:Day 0001564406 2021-01-01 2021-03-31 0001564406 2021-05-04 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:OtherPatientServiceRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OtherPatientServiceRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicalClaimsExpensesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicalClaimsExpensesMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CostOfCareMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CostOfCareMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OtherPatientServiceRevenuesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:OtherPatientServiceRevenuesMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:MedicalClaimsExpensesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:MedicalClaimsExpensesMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:CostOfCareMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:CostOfCareMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:RedeemableInvestorUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2019-12-31 0001564406 us-gaap:MemberUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2019-12-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2019-12-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2019-12-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2019-12-31 0001564406 osh:RedeemableInvestorUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 us-gaap:MemberUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:RedeemableInvestorUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 us-gaap:MemberUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 osh:RedeemableInvestorUnitsMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:CommonStockMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:AdditionalPaidInCapitalMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:AdditionalPaidInCapitalMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 us-gaap:CommonStockMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 us-gaap:CommonStockMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:AdditionalPaidInCapitalMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:RetainedEarningsMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:NoncontrollingInterestMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 2020-01-01 2020-03-31 0001564406 2020-12-31 0001564406 2019-12-31 0001564406 2021-03-31 0001564406 2020-03-31 0001564406 osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:OtherPatientServiceRevenuesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthLLCAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:RestrictedStockAwardsRSAMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001564406 us-gaap:IPOMember osh:OakStreetHealthIncAndAffiliatesMember 2020-08-10 2020-08-10 0001564406 us-gaap:IPOMember osh:OakStreetHealthIncAndAffiliatesMember 2020-08-10 0001564406 us-gaap:OverAllotmentOptionMember osh:OakStreetHealthIncAndAffiliatesMember 2020-08-10 2020-08-10 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-08-10 2020-08-10 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-08-10 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CommonStockOptionToPurchaseMember 2020-08-10 2020-08-10 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CommonStockSubjectToVestingMember 2020-08-10 2020-08-10 0001564406 osh:OakStreetHealthMsoLlcMember 2021-03-31 0001564406 osh:PrimaryCarePhysiciansOfJolietMember 2021-03-31 0001564406 us-gaap:SalesRevenueNetMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GrantMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GrantMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GrantMember osh:CostOfCareMember osh:CaresActMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GrantMember osh:CostOfCareMember osh:CaresActMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GrantMember us-gaap:OtherCurrentLiabilitiesMember 2021-06-01 2021-06-30 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicareAcceleratedAdvancedPaymentSchemeMember osh:CaresActMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicareAcceleratedAdvancedPaymentSchemeMember osh:CaresActMember osh:RepaymentPeriodOneMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicareAcceleratedAdvancedPaymentSchemeMember osh:CaresActMember osh:RepaymentPeriodTwoMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicareAcceleratedAdvancedPaymentSchemeMember osh:CaresActMember 2020-01-01 2020-12-31 0001564406 us-gaap:OtherCurrentLiabilitiesMember 2021-03-31 0001564406 us-gaap:OtherNoncurrentLiabilitiesMember 2021-03-31 0001564406 us-gaap:AccountingStandardsUpdate201809Member 2021-03-31 0001564406 us-gaap:AccountingStandardsUpdate201813Member 2021-03-31 0001564406 us-gaap:AccountingStandardsUpdate201409Member osh:AcuityAdjustmentMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:AccountingStandardsUpdate201409Member osh:AcuityAdjustmentMember osh:OakStreetHealthIncAndAffiliatesMember 2020-03-31 0001564406 osh:MedicarePartDMember osh:MedicalClaimsExpenditureMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:MedicarePartDMember osh:MedicalClaimsExpenditureMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:MedicarePartDMember osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:MedicarePartDMember osh:CapitatedRevenueMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:WellcareMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2021-01-01 2021-03-31 0001564406 osh:WellcareMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2020-01-01 2020-03-31 0001564406 osh:CignaHealthSpringMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2021-01-01 2021-03-31 0001564406 osh:CignaHealthSpringMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2020-01-01 2020-03-31 0001564406 osh:OthersMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2021-01-01 2021-03-31 0001564406 osh:OthersMember osh:OakStreetHealthIncAndAffiliatesMember osh:CapitatedRevenueMember 2020-01-01 2020-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:CareCoordinationAndCareManagementMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:CareCoordinationAndCareManagementMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:FeeForServiceMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:FeeForServiceMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OtherPatientServiceRevenuesMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:MedicareMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2021-01-01 2021-03-31 0001564406 osh:MedicareMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2020-01-01 2020-03-31 0001564406 osh:OthersMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2021-01-01 2021-03-31 0001564406 osh:OthersMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceMember osh:OtherPatientServiceRevenuesMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:FinancialSupportWaivedFeesMember osh:CostOfCareMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:FinancialSupportWaivedFeesMember osh:CostOfCareMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001564406 us-gaap:LeaseholdImprovementsMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:LeaseholdImprovementsMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:FurnitureAndFixturesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:FurnitureAndFixturesMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:ComputerEquipmentMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:ComputerEquipmentMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:SoftwareDevelopmentMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:SoftwareDevelopmentMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:OfficeEquipmentMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:OfficeEquipmentMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 us-gaap:ConstructionInProgressMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 us-gaap:ConstructionInProgressMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:MedicalPracticeRelatedAssetsMember 2021-01-22 0001564406 osh:HumanaLicenseFeeMember 2020-01-01 2020-03-31 0001564406 osh:ProviderExcessInsuranceSchemeMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:ProviderExcessInsuranceSchemeMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:ProviderExcessInsuranceSchemeMember osh:OakStreetHealthIncAndAffiliatesMember srt:MaximumMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CurrentYearExpenseMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:CurrentYearExpenseMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:PriorYearsExpenseMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-03-16 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-03-16 2021-03-16 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-06-01 2021-06-30 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-06-30 0001564406 us-gaap:NotesPayableOtherPayablesMember osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-01-01 2021-03-31 0001564406 us-gaap:NotesPayableOtherPayablesMember osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-03-31 0001564406 srt:MaximumMember us-gaap:NotesPayableOtherPayablesMember osh:OakStreetHealthIncAndAffiliatesMember osh:ConvertibleSeniorNotesMember 2021-01-01 2021-03-31 0001564406 osh:ConvertibleSeniorNotesMember srt:MaximumMember 2021-01-01 2021-03-31 0001564406 osh:ConvertibleSeniorNotesMember srt:MinimumMember 2021-01-01 2021-03-31 0001564406 osh:ConvertibleSeniorNotesMember 2021-01-01 2021-03-31 0001564406 osh:ConvertibleSeniorNotesMember 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CallOptionMember 2021-03-31 0001564406 us-gaap:IPOMember 2020-08-01 2020-08-31 0001564406 us-gaap:IPOMember 2020-08-31 0001564406 us-gaap:OverAllotmentOptionMember 2020-08-01 2020-08-31 0001564406 2020-08-31 0001564406 2018-03-01 2018-03-31 0001564406 osh:CommonStockSubjectToVestingMember 2018-03-01 2018-03-31 0001564406 2018-03-31 0001564406 us-gaap:IPOMember 2021-03-31 0001564406 osh:TwentyTwentyOmnibusIncentivePlanMember 2020-08-05 0001564406 osh:TwentyTwentyOmnibusIncentivePlanMember 2020-08-05 2020-08-05 0001564406 osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-12-31 0001564406 osh:RestrictedStockAwardsRSAMember 2020-12-31 0001564406 osh:RestrictedStockAwardsRSAMember 2021-01-01 2021-03-31 0001564406 osh:RestrictedStockAwardsRSAMember 2021-03-31 0001564406 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001564406 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001564406 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001564406 osh:TwentyTwentyEmployeeStockPurchasePlanMember 2020-08-05 0001564406 osh:TwentyTwentyEmployeeStockPurchasePlanMember 2020-08-05 2020-08-05 0001564406 osh:TwentyTwentyEmployeeStockPurchasePlanMember srt:MaximumMember 2020-08-05 0001564406 us-gaap:CommonStockMember osh:TwentyTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ProfitsInterestAwardMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:ProfitsInterestAwardMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:RestrictedStockUnitsRSUMember osh:RSAAndOptionMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:RestrictedStockUnitsRSUMember osh:RSAAndOptionMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001564406 osh:SponsorsExitServiceBasedVestingMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:NonVestedAwardsMember 2021-03-31 0001564406 osh:NonVestedAwardsMember 2021-01-01 2021-03-31 0001564406 osh:BlackScholesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-12-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember osh:MedicalClaimsExpenseMember 2021-01-01 2021-03-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember osh:MedicalClaimsExpenseMember 2020-01-01 2020-03-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember osh:CostOfCareExcludingDepreciationAndAmortizationMember 2021-01-01 2021-03-31 0001564406 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember osh:OakStreetHealthIncAndAffiliatesMember osh:CostOfCareExcludingDepreciationAndAmortizationMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember 2020-12-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceRevenueMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceRevenueMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:CareCoordinationRevenueMember 2021-01-01 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:CareCoordinationRevenueMember 2020-01-01 2020-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceRevenueMember 2021-03-31 0001564406 osh:HumanaMember osh:OakStreetHealthIncAndAffiliatesMember osh:FeeForServiceRevenueMember 2020-12-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:HumanaMember osh:LicenseFeeMember 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember osh:HumanaMember osh:LicenseFeeMember 2020-12-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:BCBSRIMember 2020-12-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:BCBSRIMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:ZingHealthMember 2021-01-01 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:ZingHealthMember 2020-01-01 2020-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:ZingHealthMember 2021-03-31 0001564406 osh:OakStreetHealthIncAndAffiliatesMember us-gaap:CorporateJointVentureMember osh:ZingHealthMember 2020-12-31 0001564406 osh:StockOptionsMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 0001564406 osh:ConvertibleSeniorNotesMember osh:OakStreetHealthIncAndAffiliatesMember 2021-01-01 2021-03-31 10-Q false 2021-03-31 2021 Q1 true false Yes Oak Street Health, Inc. 0001564406 --12-31 Yes false Non-accelerated Filer false true false DE 30 W. Monroe Street Suite 1200 Chicago IL 60603 312 733-9730 Common Stock, $0.001 par value OSH NYSE 240790848 001-39427 84-3446686

1146400000

409300000

10400000

1100000

7600000

293600000

248900000

6000000

6800000

5100000

4200000

1462600000

687200000

84100000

78800000

1400000

1300000

112600000

11400000

9600000

2900000

3000000

1000000

1100000

1676000000

781000000

11500000

8800000

39200000

32000000

274600000

262100000

30300000

12600000

355600000

315500000

118300000

13500000

26000000

28800000

898100000

1398000000

357800000

200000

891700000

971800000

-619200000

-555800000

272700000

416200000

5300000

7000000

278000000

423200000

1676000000

781000000

100000

87200000

65700000

40600000

78800000

78500000

10800000

4600000

37800000

800000

22500000

20100000

0.001

500000000

240784438

240756714

240784438

240756714

0.001

50000000

291200000

196600000

5500000

5200000

296700000

201800000

199700000

132300000

60300000

43800000

24100000

11900000

73100000

24300000

3300000

2500000

360500000

214800000

-63800000

-13000000

200000

2500000

100000

-200000

-2400000

-64000000

-15400000

-600000

-400000

-63400000

-15000000

9600000

-63400000

-24600000

220736845

-0.29

121400000

96500000

1200000

800000

73000000

59800000

2000000

1200000

320639000000

11000619

2530864

4200000

-354400000

5300000

-344900000

1471623

224400000

265500

-5531

438

1800000

-15000000

-400000

545000000

12472242

2790395

6000000

-369400000

4900000

-358500000

320639000000

240756714

200000

971800000

-555800000

7000000

-123600000 -123600000

17864

53307

1200000

43447

100000

42400000

-1100000 -1100000

-63400000

-600000

240784438

200000

891700000

-619200000

5300000

-64000000

-15400000

200000

400000

3300000

2500000

3500000

42300000

1800000

100000

38200000

58300000

1000000

-3700000

-100000 -100000

1700000

-300000

7200000

-13000000

12500000

41000000

-3000000

4300000

200000

2300000

400000

100000

-28800000

-36900000

1000000

7800000

3400000

-8800000

-3400000

898200000

123600000

224400000

1100000

1200000

774700000

224400000

737100000

184100000

419700000

42300000

1156800000

226400000

2000000

300000

600000

100000

Note 4. Fair Value of Financial Instruments The carrying amounts of financial instruments including cash, accounts receivable, accounts payable, accrued liabilities and short-term borrowings approximate fair value due to the short maturity of these instruments. The Company's Convertible Senior Notes are classified within Level 2 of the fair value hierarchy as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of March 31, 2021, the fair value of the Convertible Senior Notes was $918.3 million compared to their carrying value of $898.1 million, which is net of unamortized debt issuance and offering costs.

NOTE 8. OTHER CURRENT AND LONG-TERM LIABILITIES Accrued compensation and benefits consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued paid time off</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus and commission</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan contributions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and taxes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act deferred payroll taxes</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.2</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.0</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Other current liabilities consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana license fee</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities, current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual for goods or services received, not invoiced</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act Medicare advances & Provider Relief Funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.3</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Other long-term liabilities consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana license fee, net of current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities, net of current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease incentive obligation, net of current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act deferred payroll taxes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.8</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

NOTE 13. STOCK AND UNIT-BASED COMPENSATION 2020 Omnibus Incentive Plan <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-right:1.85%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 5, 2020, the Company’s Board of Directors adopted the 2020 Omnibus Incentive Plan (the “2020 Plan,”). Under the 2020 Plan, employees, consultants and directors of our company and our affiliates that perform services for us are eligible to receive awards. The 2020 Plan provides for the grant of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights, RSAs, performance awards, other share-based awards (including restricted stock units (“RSUs”)) and other cash-based awards. The maximum number of shares available for issuance under the 2020 Plan may not exceed 48,138,967 shares (subject to annual increases as approved by the Board of Directors). Stock Options Activity <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted by the Company generally vest over four years with 25% of the option shares vesting each year. Options generally expire ten years from the date of the grant.    <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity transactions as of and for the three-months ended March 31, 2021 ($ in millions):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding, December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,958,969</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,505</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,307</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,582</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding, March 31, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,185,585</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.36</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375,304</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options exercised in the three-months ended March 31, 2021 and 2020 was $1.8 million and $0.0 million, respectively.  Aggregate intrinsic value represents the difference between the exercise price of the option and the closing price of the Company’s common stock on the date of exercise. The fair value of options granted for the three-months ended March 31, 2021 and 2020 was $8.8 million and $0.0 million, respectively. RSA Activity <p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSAs were granted as part of the pre-IPO conversion (see Note 12). The following is a summary of RSA transactions as of and for the three-months ended March 31, 2021: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,599,118</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,701,267</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled and forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,447</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,854,404</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> RSU Activity <p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs granted generally vest over four years. RSUs are accounted for as equity using the fair value method, which requires measurement and recognition of compensation expense for all awards granted to our employees, directors and consultants based upon the grant-date fair value. The following is a summary of RSU transactions as of and for the three-months ended March 31, 2021: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,804</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.21</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,272</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.63</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.46</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled and forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,130</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,082</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-right:1.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 5, 2020, the Board of Directors adopted, and the OSH LLC’s and OSH MH LLC’s majority unitholders approved, the 2020 Employee Stock Purchase Plan (the “ESPP”) for the issuance of up to a total of 2,386,875 shares of common stock. In addition, the number of shares available for issuance under the ESPP will be increased annually on January 1 of each calendar year beginning in 2021 and ending in and including 2030, by an amount equal to the lesser of (A) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by our Board of Directors, subject to an increase each January. In no event will more than 30,000,000 shares of our common stock will be available for issuance under the ESPP. Each offering period will be approximately six months in duration commencing on January and July 1 of each year and terminating on June 30 or December 31. The ESPP allows participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the grant date or purchase date. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, no shares of common stock have been purchased under our ESPP. Stock and Unit-Based Compensation Expense The Company recognized $0.0 million and $1.8 million in unit-based compensation expense related to the profits interests for the three-months ended March 31, 2021 and 2020, respectively. The Company recorded $1.8 million in corporate, general and administrative expenses. The Company recognized $42.3 million and $0.0 million related to RSAs, options and RSUs for the three-months ended March 31, 2021 and 2020, respectively. The Company recorded $41.2 million in corporate, general and administrative expenses, $0.8 million in sales and marketing, and $0.3 million in cost of care. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-right:1.48%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the pre-IPO equity conversion discussed in Note 12, the profits interests that were subject to vesting over a period of continuous employment or service and were unvested upon the conversion were converted into RSAs and options that vest over the remaining requisite service period from the original grant dates. The unvested profits interests that were subject to vesting upon the “Sponsor’s Exit” performance condition were converted into RSAs and options that cliff vest between two years post IPO and four years from the original grant dates. A Sponsor's Exit is defined to occur if either (1) a Sponsor sells down to one or more third parties their direct or indirect equity investment in OSH LLC to less than 20% of the units owned by such sponsor, or (2) a sale, transfer or other disposition of all or substantially all of the assets of OSH LLC to one or more third parties. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-right:1.48%;text-indent:4.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of this conversion and modification of vesting terms from Sponsor’s Exit to service-based vesting at the IPO, the Company determined that RSAs and options should be accounted for as a Type III modification (the award was not probable to vest prior to the modification but it was probable of vesting under the modified condition). The stock compensation expense, net of forfeitures, recorded for these modifications was $29.3 million for the three-months ended March 31, 2021. As of March 31, 2021, the Company had approximately $251.1 million in unrecognized compensation expense related to all non-vested awards (RSAs, options and RSUs) that will be recognized over the weighted-average period of 1.49 years.   Valuation of Stock Options The grant date fair value of stock options that were granted post-IPO was estimated using a Black-Scholes option-pricing model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term to expiration (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated fair value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The determination of fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company’s common stock as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgement to determine. The valuation assumptions were determined as follows: Fair Value of Common Stock The fair value of the Company’s common stock is determined by the closing price, on the date before the grant, of its common stock, which is traded on the NYSE.   Expected Term We determine the expected term of awards using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. Expected Volatility We use an average historical stock price volatility of a peer group of comparable publicly traded healthcare companies representative of our expected future stock price volatility, as we do not have sufficient trading history for our common stock. For purposes of identifying these peer companies, we consider the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measure historical volatility over a period equivalent to the expected term. Risk-Free Interest Rate The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with maturities similar to the expected term of the award. Expected Dividend Yield We have not paid and do not anticipate paying any dividends in the foreseeable future. Accordingly, we estimate the dividend yield to be zero.

Initial Public Offering and Reorganization Transactions On August 10, 2020, we completed our IPO in which we issued and sold 17,968,750 shares of common stock, par value $0.001 per share, at an offering price of $21.00 per share. The share amount included the exercise in full of the underwriters’ options to purchase 2,343,750 additional shares of common stock. We received net proceeds of $351.2 million, after deducting underwriting discounts and commissions of $22.6 million and deferred offering costs of $3.5 million. Deferred, direct offering costs were capitalized and recorded against proceeds from the offering and consisted of fees and expenses incurred in connection with the sale of our common stock in the IPO, including the legal, accounting, printing and other offering related costs. In conjunction with the IPO, OSH LLC completed a series of transactions that resulted in Oak Street Health, Inc. becoming the ultimate parent company of OSH LLC and subsidiaries. Additionally, immediately prior to the closing of the IPO, unitholders of OSH LLC exchanged their membership interests for common stock in Oak Street Health, Inc. as part of the related IPO reorganization transactions. All 15,928,876 units of our then outstanding redeemable investor units (preferred stock including their respective undeclared and deemed dividends) and members’ capital (former founders’ units and incentive units/profits interests) plus 1,924 of options to purchase incentive units were converted into 200,286,312 shares of common stock of the Company and 22,612,472 shares of restricted common stock subject to service-based vesting (“RSA”) of the Company.

Basis of Presentation and Consolidation The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2020 in the Company’s Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-months ended March 31, 2021, including the impact of COVID-19, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“variable interest entities” or “VIEs”). These evaluations are complex, involve judgment and the use of estimates and assumptions based on available historical information, among other factors. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. Upon completion of our IPO, OSH’s sole material asset is its interest in OSH LLC and its affiliates. In accordance with the master structuring agreement dated August 10, 2020, by and among OSH and the other signatories party thereto (the “Master Structuring Agreement”), we have all management powers over the business and affairs of OSH LLC and to conduct, direct and exercise full control over the activities of OSH LLC. Due to our power to control the activities most directly affecting the results of OSH LLC, we are considered the primary beneficiary of the VIE. Accordingly, following the effective date of the IPO, we consolidate the financial results of OSH LLC and its affiliates and the financial statements for the periods prior to the IPO have been adjusted to combine the previously separate entities for presentation purposes. Oak Street Health MSO LLC (“MSO”), a wholly owned subsidiary of OSH LLC, was formed in 2013 to provide a wide range of management services to the Physician Groups (as defined below). Activities include but are not limited to operational support of the centers, marketing, information technology infrastructure and the sourcing and managing of health plan contracts. Oak Street Health Physicians Group PC, OSH-IN Physicians Group PC, OSH-MI Physicians Group PC, OSH-OH Physicians Group LLC, OSH-PA Physicians Group PC, OSH-RI Physicians Group PC, Oak Street Health of Texas, PLLC, Griffin Myers Medical PC, Oak Street Health Physicians Group of South Carolina LLC, Oak Street Health Physicians Group of Louisiana LLC and Oak Street Health Physicians Group of Mississippi LLC (collectively, the “Physician Groups”) employ healthcare providers to deliver primary care services to the Medicare covered population of Illinois, Indiana, Louisiana, Michigan, Mississippi, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas and New York. These entities are consolidated as each are considered variable interest entities where the Company has a controlling financial interest (see Note 15). In addition, Oak Street Health is the majority interest owner in three joint ventures: OSH-PCJ Joliet, LLC, OSH-RI, LLC and OSH-ESC Joint Venture, LLC, which are consolidated in the Company’s financial statements. In March 2021, distributions were made from OSH-PCJ Joliet, LLC to Oak Street Health MSO, LLC (50.1% ownership) and Primary Care Physicians of Joliet (49.9% ownership) totaling $1.1 million to each owner.

<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have elected to avail ourselves of this extended transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.

Leases The Company leases offices, operating facilities, vehicles and IT equipment, which are accounted for as operating leases. These leases have remaining lease terms of up to 30 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company determines if an arrangement is a lease at inception and evaluates the lease classification (i.e., operating lease or financing lease) at that time. Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the term of the lease. <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.06%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities, current portion (recorded within other current liabilities) and long-term operating lease liabilities on the Company’s consolidated balance sheets. Operating lease right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company has no financing leases. <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.06%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses its incremental borrowing rate on the commencement date for determining the present value of lease payments. The Company considers the likelihood of exercising options to extend or terminate the lease when determining the lease term. <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.06%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has lease agreements with lease and non-lease components. The Company has elected the practical expedient to account for the lease and non-lease components as a single lease component for all leases.

Recently Adopted Accounting Pronouncements <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the FASB issued guidance on leases, Accounting Standards Updates 2016-02, Leases (“ASU 2016-02), with amendments issued in 2018 and 2019 (collectively, “ASC 842”). ASC 842 requires lessees to recognize assets and liabilities related to lease arrangements on the balance sheet; leases are to be recorded as a lease liability (on a discounted basis) with a corresponding right-of-use (“ROU”) asset. Leases will be classified as finance or operating, with the classification affecting the pattern and classification of expense recognition over the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. This guidance also expands the required quantitative and qualitative disclosures for leasing arrangements and gives rise to other changes impacting certain aspects of lessee and lessor accounting. The two permitted transition methods under the guidance are the modified retrospective transition approach, which requires application of the guidance for all comparative periods, and the cumulative effect adjustment approach, which requires prospective application the adoption date. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC 842 as of January 1, 2021 on a prospective basis, did not adjust the comparative reporting periods and applied the lessee package of practical expedients. The package of practical expedients included that the Company was not required to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Also, as part of the adoption, the Company elected to not recognize short-term leases (those with lease terms less than a year) on the consolidated balance sheets, not separate lease and non-lease components and did not use hindsight to determine lease term. The most significant impact was the recognition of ROU assets and lease liabilities for our operating leases. The ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease at lease commencement date. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its consolidated balance sheets, however it did not have a material impact on the consolidated statements of operations or cash flows for the three- months ended March 31, 2021. The Company recognized ROU assets and lease liabilities for operating leases of $108.1 million and $126.8 million, respectively, upon adoption as of January 1, 2021. The difference between the lease liability and right-of-use asset mainly related to the reversal of existing deferred rent balances. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized a comprehensive approach to assess the impact of this guidance on the consolidated financial statements and related disclosures, including the increase in assets and liabilities on the consolidated balance sheets and the impact on the current lease portfolio. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 7 in this Quarterly Report for our lease accounting policy and the quarterly impact of our adoption of ASC 842. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share and updates the disclosure requirements in ASC 470-20, making them easier to understand for financial statement preparers and improving the decision-usefulness and relevance of the information for financial statement users. This ASU was early adopted on January 1, 2021 and applied to the Company’s 0% Convertible Senior Notes due 2026 issued in March 2021 (Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s Convertible Senior Notes). The Company had no other debt arrangements to apply this guidance to.   <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  In December 2019, the FASB issued ASU 2019-12, “Income Taxes Topic 740-Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of ASC 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures. In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures.

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had agreements in place with the payors listed below and payor sources of capitated revenue for each period presented were as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellcare/Meridian</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cigna-HealthSpring</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

Other patient service revenue is comprised of ancillary fees earned under contracts with certain managed care organizations for the provision of certain care coordination services and care management services and is also comprised of fee-for-service revenue. The composition of other patient service revenue for each period was as follows ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Care coordination and care management</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fee for service</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other patient service revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fee-for-service revenue by payor source for each period presented were as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

Property and equipment consisted of the following as of March 31, 2021 and December 31, 2020 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal use software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, at cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The components of lease expense for the Company’s operating leases were as follows for the three-months ended March 31, 2021 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.07</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents the future minimum lease payments under the noncancelable operating leases as of March 31, 2021 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current (1)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, noncurrent</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Included in other liabilities on the consolidated balance sheet</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Accrued compensation and benefits consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued paid time off</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus and commission</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan contributions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and taxes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act deferred payroll taxes</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.2</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.0</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Other current liabilities consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana license fee</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities, current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual for goods or services received, not invoiced</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act Medicare advances & Provider Relief Funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.3</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Other long-term liabilities consisted of the following as of ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humana license fee, net of current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities, net of current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease incentive obligation, net of current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES Act deferred payroll taxes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.8</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity within liabilities for unpaid claims was as follows for the three-months ended March 31, 2021 and 2020 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incurred health care costs:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total claims incurred</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims paid:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total claims paid</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to other claims-related liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the Consolidated Balance Sheet as of March 31, 2021 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt issuance costs, net of amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net carrying amount</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity component recorded at issuance:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capped call transactions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table sets forth the debt issuance and offering costs recognized in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three-months ended March 31, 2021 ($ in millions): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs, net of amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective interest rate of the liability component</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity transactions as of and for the three-months ended March 31, 2021 ($ in millions):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding, December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,958,969</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,505</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,307</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,582</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.07</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding, March 31, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,185,585</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.36</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375,304</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSAs were granted as part of the pre-IPO conversion (see Note 12). The following is a summary of RSA transactions as of and for the three-months ended March 31, 2021: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,599,118</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,701,267</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled and forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,447</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,854,404</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-right:1.67%;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs granted generally vest over four years. RSUs are accounted for as equity using the fair value method, which requires measurement and recognition of compensation expense for all awards granted to our employees, directors and consultants based upon the grant-date fair value. The following is a summary of RSU transactions as of and for the three-months ended March 31, 2021: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,804</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.21</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,272</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.63</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.46</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled and forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,130</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,082</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The grant date fair value of stock options that were granted post-IPO was estimated using a Black-Scholes option-pricing model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term to expiration (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated fair value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

<div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical claims expense</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131.4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of care</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per common share for the three-months ended March 31, 2021: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three-months ended March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Net loss attributable to non-controlling interests</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to OSH Inc. stockholders</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63.4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common stock outstanding - basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,736,845</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share – basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three-months ended March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,185,585</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,082</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSAs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,854,404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Senior Notes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,622,176</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,037,247</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  *The Company entered into capped call transactions to mitigate the impact of potential economic dilution to our common stock upon any conversion of our Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of the Convertible Senior Notes up to a cap price of $138.8750 per share. See Note 10 for further details on the capped call transactions. 2019-10-22

17968750

0.001

21.00

2343750

351200000

22600000

3500000

15928876

1924

200286312

22612472

1100000

0.501

0.499

0.98

2600000

1900000

1600000

1.00 P1Y P11M 0.25 0.50

1500000

7000000

3500000

P30Y

true

2021-01-01

true

2021-01-01

true

32200000

23500000

0.03

0.04

0.02

0.42

0.49

0.18

0.14

0.10

0.11

0.30

0.26

3900000

4100000

1600000

1100000

5500000

5200000

18200000

16600000

0.38

0.46

0.11

0.08

0.51

0.46

3500000 2500000 1200000 1500000

918300000

898100000

67500000

63600000

5100000

4900000

20600000

17800000

7700000

6100000

9900000

9700000

4000000

4200000

114800000

106300000

30700000

27500000

3200000

2400000

300000

100000

1800000

100000

4500000

4900000

9400000

7600000

P10Y7M6D

0.0407

13700000

17700000

16300000

14700000

13900000

13700000 75400000

165400000

34000000

131400000

13100000

118300000

4600000

900000

13500000

6100000

5000000

20900000

19100000

1400000

5700000

1800000

3500000 3500000

1600000

2600000

2700000 600000

13100000

4400000

4300000

4500000 3600000 3100000 2300000

2500000

1800000

8400000 7300000

14100000

12800000

5100000

100000

900000

800000

400000

300000

5000000

170600000

192300000

131400000

6600000

198900000

131400000

20600000

59700000

165500000

30500000

186100000

90200000

-300000 -200000

211600000

920000000

0.00

120000000

22100000

897900000

123600000

2026-03-15

0.0050

365 days

12.6328

1000000000

79.16

40 trading-day

16561656

1.30

0.98

1.30

1.00

150000000

123600000

79.16

138.8750

2026-03-12 11622176 0.001

920000000

21900000

898100000

123600000

22100000

200000

0.0049

0.000

17968750

21.00

2343750

0.001

1000

500000000

12472242

103600000

184787783

545000000

3456634

22612472

38111001

7000000

50000000

0.001

48138967

2020-08-05

P10Y

0.25

14958969

305505

53307

25582

15185585

2375304

21.01

59.63

21.00

21.07

21.79

21.00

P9Y7M6D

P9Y4M9D

P9Y4M6D

600600000

494900000

79000000

1800000

8800000

21599118

1701267

43447

19854404

11.77

1.50

14.05

12.65

216804

182272

17864

6130

375082

32.21

59.63

50.46

21.52

44.84

2386875

0.01

0.15 0.85

30000000

1800000

42300000

41200000

800000

300000

29300000

251100000

P1Y5M26D

0.0079

0.5000

P6Y3M

0.0000

28.69

394200000

286100000

337700000

332100000

294300000

198500000

198900000

131400000

32900000

15300000

231700000

146700000

0.05

121400000

96500000

87200000

65700000

100000

1100000

700000

100000

4100000

2600000

14100000

5000000

73000000

59800000

78800000

78500000

700000 700000

2700000

600000

8400000

7300000

1300000

500000

800000

40600000 41800000

0.499

2300000

10000000

1600000

11100000

1200000

600000

800000

200000

1000000

400000

1200000

700000

-64000000

15185585 375082 19854404 11622176 47037247 138.8750 Included in other liabilities on the consolidated balance sheet The Company entered into capped call transactions to mitigate the impact of potential economic dilution to our common stock upon any conversion of our Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of the Convertible Senior Notes up to a cap price of $138.8750 per share. See Note 10 for further details on the capped call transactions.

EX-101.SCH 7 osh-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Operations - (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Changes in Redeemable Investor Units and Stockholders' Equity/Members' (Deficit) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Nature of Business link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Revenue Recognition link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property And Equipment link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Goodwill And Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Other Current And Long-Term Liabilities link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Liability For Unpaid Claims link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Long- Term Debt link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Tax link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Stock And Unit-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Commitments - Litigation And Contingencies link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Variable Interest Entities link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Related Parties link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Segment Financial Information link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies - (Policies) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Revenue Recognition (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Property And Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Other Current And Long-Term Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Liability For Unpaid Claims (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Long- Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stock And Unit-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Variable Interest Entities (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Organization and Nature of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Revenue Recognition - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Revenue Recognition - Summary of Sources of Capitated Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Revenue Recognition - Summary of Composition Of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Revenue Recognition - Summary of Sources of Fee for Service Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Fair Value of Financial Measurement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Property And Equipment - Summary of Property Plant and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Property And Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Goodwill And Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Leases - Summary of Components of Lease Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Non Cancelable Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Non Cancelable Operating Leases (Details)2 link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Other Current And Long -Term Liabilities - Summary of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Other Current And Long -Term Liabilities - Summary of Other Current Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Other Current And Long -Term Liabilities - Summary of Other Noncurrent Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Liability For Unpaid Claims- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Liability For Unpaid Claims - Summary of Liability for Unpaid Claims and Claims Adjustment Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Long- Term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Long- Term Debt - Summary of Long-term Debt Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Long- Term Debt - Summary of Debt Issuance Costs (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Income Tax - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Stock And Unit-Based Compensation- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Stock And Unit-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Stock And Unit-Based Compensation - Summary of Restricted Stock Awards (RSA) (Detail) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Stock And Unit-Based Compensation - Summary of Restricted Stock Unit (RSU) (Detail) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Stock And Unit-Based Compensation - Summary of Valuation Of Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Variable Interest Entities - Summary of VIE Assets and Liabilities and Performance for the Physician Groups (Detail) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Related Parties - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Common Unit (Detail) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Detail) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 osh-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 osh-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 osh-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lessee operating lease liability payments due year six. Lessee operating lease liability payments due after year six. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Interactive Data Current Entity Interactive Data Current Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] Oak Street Health, Inc. and Affiliates member. OAK Street Health Inc and Affiliates [Member] Oak Street Health Inc And Affiliates [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash Cash Restricted cash Restricted Cash Current Other patient service receivables, net (Humana comprised $0.1 and $0.0 as of March 31, 2021 and December 31, 2020, respectively) Other Receivables Net Current Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively) Accounts Receivable Net Current Prepaid expenses Prepaid Expense Current Other current assets Other Assets Current Total current assets Assets Current Long-term assets: Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Security deposits Deposits Assets Noncurrent Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively) Operating Lease Right Of Use Asset Goodwill Goodwill Intangible assets, net Finite Lived Intangible Assets Net Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued compensation and benefits Employee Related Liabilities Current Liability for unpaid claims (Humana comprised $78.8 and $78.5 as of March 31, 2021 and December 31, 2020, respectively) Liability For Claims And Claims Adjustment Expense Other liabilities (Humana comprised $10.8 and $4.6 as of March 31, 2021 and December 31, 2020, respectively) Other Liabilities Current Total current liabilities Liabilities Current Long-term liabilities: Liabilities Noncurrent [Abstract] Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively) Operating Lease Liability Noncurrent Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively) Deferred Rent Credit Noncurrent Other long-term liabilities (Humana comprised $22.5 and $20.1 as of March 31, 2021 and December 31, 2020, respectively) Other Liabilities Noncurrent Long-term debt Convertible Long Term Notes Payable Total liabilities Liabilities Commitments and contingencies (See Notes 7 & 14) Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred Stock, par value $0.001; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020 Preferred Stock Value Common stock, par value $0.001; 500,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 240,784,438 and 240,756,714 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively Common Stock Value Additional paid-in capital (Humana comprised $50.0 and $50.0 as of March 31, 2021 and December 31, 2020, respectively) Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity allocated to Oak Street Health, Inc. Stockholders Equity Non-controlling interests Minority Interest Total stockholders' equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and stockholders' equity Liabilities And Stockholders Equity Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Humana Member Humana [Member] Humana [Member] Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Other nonoperating income (expense)1. Income Statement [Abstract] OAK Street Health Inc and Affiliates [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Capitated Revenue [Member]. Capitated Revenue [Member] Capitated Revenue [Member] Other Patient Service Revenue [Member]. Other Patient Service Revenue [Member] Other Patient Service Revenue [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Medical Claims Expenses [Member]. Medical Claims Expenses [Member] Medical Claims Expenses [Member] Cost Of Care [Member]. Cost of Care [Member] Cost Of Care [Member] Total revenues Revenues Operating expenses: Operating Income Loss [Abstract] Cost of providing patient care in relation to revenue waived Cost Of Goods And Service Excluding Depreciation Depletion And Amortization Sales and marketing Selling And Marketing Expense Corporate, general and administrative expenses General And Administrative Expense Depreciation and amortization Cost Of Goods And Services Sold Depreciation And Amortization Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other (expense)/ income: Nonoperating Income Expense [Abstract] Interest expense, net Interest Expense Other Other Nonoperating Income Expense1 Total other (expense)/ income, net Other Nonoperating Income Expense Net loss Profit Loss Net loss attributable to non-controlling interests Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to the Oak Street Health, Inc. Net Income Loss Undeclared and deemed dividends Undistributed Earnings Loss Allocated To Participating Securities Basic Net loss attributable to common stock/unitholders Net Income Loss Available To Common Stockholders Basic Weighted average common stock outstanding - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Net loss per share – basic and diluted Earnings Per Share Basic And Diluted Other Patient Service Revenues. Other Patient Service Revenue [Member] Other Patient Service Revenues [Member] Temporary equity shares issued during the period,shares. Purchase of capped calls. Non-controlling interest increase to subsidiary equity issuance. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Redeemable Investor Units [Member] Redeemable Investor Units [Member] Redeemable Investor Units [Member] Members' Capital [Member] Member Units [Member] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Non-controlling Interest [Member] Noncontrolling Interest [Member] Redeemable Investor, Beginning balance Temporary Equity Value Excluding Additional Paid In Capital Beginning balance Beginning balance (In Shares) Shares Outstanding Purchase of capped calls Purchase Of Capped Calls Issuance of common stock upon vesting of restricted stock units Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of common stock upon vesting of restricted stock units, (in shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Issuance of common stock upon exercise of options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of options, ( in shares) Stock Issued During Period Shares Stock Options Exercised Issuance of series I, II and III investor units Temporary Equity Stock Issued During Period Value New Issues Issuance of Series I, II and III Investor Units (In Shares) Temporary Equity Shares Issued During The Period Shares Issuance of common units Stock Issued During Period Shares New Issues Repurchases – profits interests Stock Repurchased During Period Shares Forfeitures – profits interests Stock Granted During Period Value Sharebased Compensation Forfeited Forfeitures - Profits Interests (In Shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Stock and Unit-based compensation expense Allocated Share Based Compensation Expense Payments to non-controlling interest Non Controlling Interest Increase To Subsidiary Equity Issuance Net loss Redeemable Investor, Ending balance Ending balance Ending balance (In Shares) Non-cash lease expense. Increase decrease in security deposits and other long term assets. Increase Decrease In Operating Lease Liabilities. Proceeds from issuance of investor units. Unpaid offering costs in accounts payable and accrued liabilities. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Amortization of discount on debt and related issuance costs Amortization Of Financing Costs And Discounts Depreciation and amortization Depreciation Depletion And Amortization Non-cash operating lease costs Non Cash Lease Expense Stock and unit-based compensation, net of forfeitures Share Based Compensation Change in fair value of bifurcated derivative Unrealized Gain Loss On Derivatives Change in operating assets and liabilities, net of impact of acquisitions: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Security deposits and other long-term assets Increase Decrease In Security Deposits And Other Long Term Assets Accounts payable Increase Decrease In Accounts Payable Accrued compensation and benefits Increase Decrease In Employee Related Liabilities Liability for unpaid claims Increase Decrease In Other Accrued Liabilities Operating lease liabilities Increase Decrease In Operating Lease Liabilities Other current liabilities Increase Decrease In Other Current Liabilities Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Other Other Operating Activities Cash Flow Statement Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchase of business Payments To Acquire Businesses Gross Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from borrowings on convertible senior notes, net Proceeds From Convertible Debt Purchase of capped calls Payments For Derivative Instrument Financing Activities Proceeds from issuance of redeemable investor units Proceeds From Issuance Of Investor Units Capital distributions to non-controlling interests Payments To Minority Shareholders Proceeds from exercise of options Proceeds From Stock Options Exercised Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net change in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Supplemental disclosures Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Unpaid debt offering costs in accounts payable and accrued liabilities Unpaid Offering Costs In Accounts Payable And Accrued Liabilities Additions to construction in process funded through accounts payable Capital Expenditures Incurred But Not Yet Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization And Nature Of Business. Organization And Nature Of Business [Line Items] Organization And Nature Of Business [Line Items] Organization and Nature of Business Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Line Items] Significant Accounting Policies Table. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue Recognition And Deferred Revenue [Abstract] Revenue Recognition [Line Items] Revenue Recognition [Table] Revenue Recognition [Table] Revenue Recognition [Table] Revenue Recognition [Line Items] Revenue Recognition [Line Items] Revenue Recognition EX-101.PRE 11 osh-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Registrant Name	Oak Street Health, Inc.
Entity Central Index Key	0001564406
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	30 W. Monroe Street Suite 1200
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60603
City Area Code	312
Local Phone Number	733-9730
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OSH
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		240,790,848
Entity File Number	001-39427
Entity Tax Identification Number	84-3446686

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance sheets - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Long-term liabilities:
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	$ 118.3
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)		$ 13.5
OAK Street Health Inc and Affiliates [Member]
Current assets:
Cash	1,146.4	409.3
Restricted cash	10.4	10.4
Other patient service receivables, net (Humana comprised $0.1 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	1.1	7.6
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	293.6	248.9
Prepaid expenses	6.0	6.8
Other current assets	5.1	4.2
Total current assets	1,462.6	687.2
Long-term assets:
Property and equipment, net	84.1	78.8
Security deposits	1.4	1.3
Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	112.6
Goodwill	11.4	9.6
Intangible assets, net	2.9	3.0
Other long-term assets	1.0	1.1
Total assets	1,676.0	781.0
Current liabilities:
Accounts payable	11.5	8.8
Accrued compensation and benefits	39.2	32.0
Liability for unpaid claims (Humana comprised $78.8 and $78.5 as of March 31, 2021 and December 31, 2020, respectively)	274.6	262.1
Other liabilities (Humana comprised $10.8 and $4.6 as of March 31, 2021 and December 31, 2020, respectively)	30.3	12.6
Total current liabilities	355.6	315.5
Long-term liabilities:
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	118.3
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)		13.5
Other long-term liabilities (Humana comprised $22.5 and $20.1 as of March 31, 2021 and December 31, 2020, respectively)	26.0	28.8
Long-term debt	898.1
Total liabilities	1,398.0	357.8
Commitments and contingencies (See Notes 7 & 14)
Stockholders' equity:
Preferred Stock, par value $0.001; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020
Common stock, par value $0.001; 500,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 240,784,438 and 240,756,714 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	0.2	0.2
Additional paid-in capital (Humana comprised $50.0 and $50.0 as of March 31, 2021 and December 31, 2020, respectively)	891.7	971.8
Accumulated deficit	(619.2)	(555.8)
Total stockholders' equity allocated to Oak Street Health, Inc.	272.7	416.2
Non-controlling interests	5.3	7.0
Total stockholders' equity	278.0	423.2
Total liabilities and stockholders' equity	$ 1,676.0	$ 781.0

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance sheets (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	$ 118.3
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)		$ 13.5
OAK Street Health Inc and Affiliates [Member]
Other patient service receivables, net (Humana comprised $0.1 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	1.1	7.6
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	293.6	248.9
Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	112.6
Liability for unpaid claims (Humana comprised $78.8 and $78.5 as of March 31, 2021 and December 31, 2020, respectively)	274.6	262.1
Other liabilities (Humana comprised $10.8 and $4.6 as of March 31, 2021 and December 31, 2020, respectively)	30.3	12.6
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	118.3
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)		13.5
Other long-term liabilities (Humana comprised $22.5 and $20.1 as of March 31, 2021 and December 31, 2020, respectively)	$ 26.0	$ 28.8
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	240,784,438	240,756,714
Common stock, shares outstanding	240,784,438	240,756,714
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Additional paid-in capital (Humana comprised $50.0 and $50.0 as of March 31, 2021 and December 31, 2020, respectively)	$ 891.7	$ 971.8
OAK Street Health Inc and Affiliates [Member] \| Humana [Member]
Other patient service receivables, net (Humana comprised $0.1 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	0.1	0.0
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	87.2	65.7
Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	40.6	0.0
Liability for unpaid claims (Humana comprised $78.8 and $78.5 as of March 31, 2021 and December 31, 2020, respectively)	78.8	78.5
Other liabilities (Humana comprised $10.8 and $4.6 as of March 31, 2021 and December 31, 2020, respectively)	10.8	4.6
Long-term operating lease liabilities (Humana comprised $37.8 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)	37.8	0.0
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)	0.0	0.8
Other long-term liabilities (Humana comprised $22.5 and $20.1 as of March 31, 2021 and December 31, 2020, respectively)	22.5	20.1
Additional paid-in capital (Humana comprised $50.0 and $50.0 as of March 31, 2021 and December 31, 2020, respectively)	$ 50.0	$ 50.0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other (expense)/ income:
Net loss	$ (64.0)	$ (15.4)
OAK Street Health Inc and Affiliates [Member]
Total revenues	296.7	201.8
Operating expenses:
Cost of providing patient care in relation to revenue waived	186.1	90.2
Sales and marketing	24.1	11.9
Corporate, general and administrative expenses	73.1	24.3
Depreciation and amortization	3.3	2.5
Total operating expenses	360.5	214.8
Loss from operations	(63.8)	(13.0)
Other (expense)/ income:
Interest expense, net	(0.2)	(2.5)
Other		0.1
Total other (expense)/ income, net	(0.2)	(2.4)
Net loss	(64.0)	(15.4)
Net loss attributable to non-controlling interests	0.6	0.4
Net loss attributable to the Oak Street Health, Inc.	(63.4)	(15.0)
Undeclared and deemed dividends		(9.6)
Net loss attributable to common stock/unitholders	$ (63.4)	(24.6)
Weighted average common stock outstanding - basic and diluted	220,736,845
Net loss per share – basic and diluted	$ (0.29)
OAK Street Health Inc and Affiliates [Member] \| Medical Claims Expenses [Member]
Operating expenses:
Cost of providing patient care in relation to revenue waived	$ 199.7	132.3
OAK Street Health Inc and Affiliates [Member] \| Cost of Care [Member]
Operating expenses:
Cost of providing patient care in relation to revenue waived	60.3	43.8
OAK Street Health Inc and Affiliates [Member] \| Capitated Revenue [Member]
Total revenues	291.2	196.6
OAK Street Health Inc and Affiliates [Member] \| Other Patient Service Revenue [Member]
Total revenues	$ 5.5	$ 5.2

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - (Parenthetical) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenues	$ 296.7	$ 201.8
Cost of providing patient care in relation to revenue waived	186.1	90.2
Medical Claims Expenses [Member]
Cost of providing patient care in relation to revenue waived	199.7	132.3
Medical Claims Expenses [Member] \| Humana [Member]
Cost of providing patient care in relation to revenue waived	73.0	59.8
Cost of Care [Member]
Cost of providing patient care in relation to revenue waived	60.3	43.8
Cost of Care [Member] \| Humana [Member]
Cost of providing patient care in relation to revenue waived	2.0	1.2
Capitated Revenue [Member]
Total revenues	291.2	196.6
Capitated Revenue [Member] \| Humana [Member]
Total revenues	121.4	96.5
Other Patient Service Revenue [Member]
Total revenues	5.5	5.2
Other Patient Service Revenue [Member] \| Humana [Member]
Total revenues	$ 1.2	$ 0.8

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Redeemable Investor Units and Stockholders' Equity/Members' (Deficit) - USD ($) $ in Millions	Total	OAK Street Health Inc and Affiliates [Member]	OAK Street Health Inc and Affiliates [Member] Redeemable Investor Units [Member]	OAK Street Health Inc and Affiliates [Member] Members' Capital [Member]	OAK Street Health Inc and Affiliates [Member] Common Stock [Member]	OAK Street Health Inc and Affiliates [Member] Additional Paid-In Capital [Member]	OAK Street Health Inc and Affiliates [Member] Accumulated Deficit [Member]	OAK Street Health Inc and Affiliates [Member] Non-controlling Interest [Member]
Redeemable Investor, Beginning balance at Dec. 31, 2019			$ 320,639.0
Beginning balance at Dec. 31, 2019		$ (344.9)		$ 4.2			$ (354.4)	$ 5.3
Beginning balance (In Shares) at Dec. 31, 2019			11,000,619	2,530,864
Issuance of series I, II and III investor units			$ 224.4
Issuance of Series I, II and III Investor Units (In Shares)			1,471,623
Issuance of common units				265,500
Repurchases – profits interests				(5,531)
Forfeitures - Profits Interests (In Shares)				(438)
Stock and Unit-based compensation expense		1.8		$ 1.8
Net loss	$ (15.4)	(15.4)					(15.0)	(0.4)
Redeemable Investor, Ending balance at Mar. 31, 2020			$ 545.0
Ending balance at Mar. 31, 2020		(358.5)		$ 6.0			(369.4)	4.9
Ending balance (In Shares) at Mar. 31, 2020			12,472,242	2,790,395
Beginning balance at Dec. 31, 2020		423.2			$ 0.2	$ 971.8	(555.8)	7.0
Beginning balance (In Shares) at Dec. 31, 2020					240,756,714
Purchase of capped calls		(123.6)				(123.6)
Issuance of common stock upon vesting of restricted stock units, (in shares)					17,864
Issuance of common stock upon exercise of options		$ 1.2				1.2
Issuance of common stock upon exercise of options, ( in shares)		53,307			53,307
Forfeitures – profits interests		$ (0.1)				(0.1)
Forfeitures - Profits Interests (In Shares)		(25,582)			(43,447)
Stock and Unit-based compensation expense		$ 42.4				42.4
Payments to non-controlling interest		(1.1)						(1.1)
Net loss	(64.0)	(64.0)					(63.4)	(0.6)
Redeemable Investor, Ending balance at Mar. 31, 2021	$ 545.0		$ 320,639.0
Ending balance at Mar. 31, 2021		$ 278.0			$ 0.2	$ 891.7	$ (619.2)	$ 5.3
Ending balance (In Shares) at Mar. 31, 2021					240,784,438

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (64.0)	$ (15.4)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on debt and related issuance costs	0.2	0.4
Depreciation and amortization	3.3	2.5
Non-cash operating lease costs	3.5
Stock and unit-based compensation, net of forfeitures	42.3	1.8
Change in fair value of bifurcated derivative		(0.1)
Change in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable	(38.2)	(58.3)
Prepaid expenses and other current assets	(1.0)	3.7
Security deposits and other long-term assets	0.1	0.1
Accounts payable	1.7	(0.3)
Accrued compensation and benefits	7.2	(13.0)
Liability for unpaid claims	12.5	41.0
Operating lease liabilities	(3.0)
Other current liabilities	4.3	0.2
Other long-term liabilities	2.3	0.4
Other		0.1
Net cash used in operating activities	(28.8)	(36.9)
Cash flows from investing activities:
Purchase of business	(1.0)
Purchases of property and equipment	(7.8)	(3.4)
Net cash used in investing activities	(8.8)	(3.4)
Cash flows from financing activities:
Proceeds from borrowings on convertible senior notes, net	898.2
Purchase of capped calls	(123.6)
Proceeds from issuance of redeemable investor units		224.4
Capital distributions to non-controlling interests	(1.1)
Proceeds from exercise of options	1.2
Net cash provided by financing activities	774.7	224.4
Net change in cash, cash equivalents and restricted cash	737.1	184.1
Cash, cash equivalents and restricted cash, beginning of period	419.7	42.3
Cash, cash equivalents and restricted cash, end of period	1,156.8	226.4
Supplemental disclosures
Cash paid for interest		2.0
Unpaid debt offering costs in accounts payable and accrued liabilities	0.3
Additions to construction in process funded through accounts payable	$ 0.6	$ 0.1

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization and Nature of Business

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Organization And Nature Of Business [Line Items]

Organization and Nature of Business

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

Description of Business

Initial Public Offering and Reorganization Transactions

Basis of Presentation and Consolidation

The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“variable interest entities” or “VIEs”). These evaluations are complex, involve judgment and the use of estimates and assumptions based on available historical information, among other factors. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.

Emerging Growth Company Status

COVID-19

•

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2021
OAK Street Health Inc and Affiliates [Member]
Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company described its significant accounting policies in Note 2 of the Notes to Consolidated Financial Statements for the year ended December 31, 2020 included in its Form 10-K. During the three-months ended March 31, 2021, there were no significant changes to those accounting policies, other than the adoption of ASC 842 (as defined below), Accounting Standards Update (“ASU”) 2020-06 and those policies impacted by the new accounting pronouncements adopted during the period and further described below as well as in the “Recently Adopted Accounting Pronouncements” section. Leases The Company leases offices, operating facilities, vehicles and IT equipment, which are accounted for as operating leases. These leases have remaining lease terms of up to 30 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company determines if an arrangement is a lease at inception and evaluates the lease classification (i.e., operating lease or financing lease) at that time. Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the term of the lease. Operating leases are included in operating lease right-of-use assets, operating lease liabilities, current portion (recorded within other current liabilities) and long-term operating lease liabilities on the Company’s consolidated balance sheets. Operating lease right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company has no financing leases. The Company uses its incremental borrowing rate on the commencement date for determining the present value of lease payments. The Company considers the likelihood of exercising options to extend or terminate the lease when determining the lease term. The Company has lease agreements with lease and non-lease components. The Company has elected the practical expedient to account for the lease and non-lease components as a single lease component for all leases. Convertible Debt The Company evaluates all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. In accounting for the issuance of the 0% Convertible Senior Notes due 2026 issued in March 2021 (the “Convertible Senior Notes”), the Company recorded a long-term debt liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the debt issuance and offering costs on the Company’s consolidated balance sheets. The conversion feature is not required to be accounted for separately as an embedded derivative. The Company will amortize debt issuance and offering costs over the term of the Convertible Senior Notes as interest expense utilizing the effective interest method on the Company’s consolidated statements of operations. Capped Call Transactions In connection with the issuance of the Convertible Senior Notes, the Company entered into capped call transactions. The capped call transactions are expected generally to reduce the potential dilution to the holders of the Company’s common stock upon any conversion of the Convertible Senior Notes. The capped call transactions are purchased call options on the issuer’s stock that settle by reference to the Company’s stock with no forced cash payment. The terms of the capped call transactions allow the purchased call options to be classified as an equity instrument and will not be subsequently remeasured as long as the conditions for equity classification continue to be met. The Company recorded the cash used to purchase the capped call transactions as a reduction to additional paid-in capital within the Company’s consolidated statements of changes in redeemable investor units and stockholders’ equity/members’ (deficit). Net Income (Loss) Per Share The diluted net income (loss) per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the if-converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, restricted stock awards and contingently issuable shares under our Convertible Senior Notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive. Recently Adopted Accounting Pronouncements In 2016, the FASB issued guidance on leases, Accounting Standards Updates 2016-02, Leases (“ASU 2016-02), with amendments issued in 2018 and 2019 (collectively, “ASC 842”). ASC 842 requires lessees to recognize assets and liabilities related to lease arrangements on the balance sheet; leases are to be recorded as a lease liability (on a discounted basis) with a corresponding right-of-use (“ROU”) asset. Leases will be classified as finance or operating, with the classification affecting the pattern and classification of expense recognition over the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. This guidance also expands the required quantitative and qualitative disclosures for leasing arrangements and gives rise to other changes impacting certain aspects of lessee and lessor accounting. The two permitted transition methods under the guidance are the modified retrospective transition approach, which requires application of the guidance for all comparative periods, and the cumulative effect adjustment approach, which requires prospective application the adoption date. We adopted ASC 842 as of January 1, 2021 on a prospective basis, did not adjust the comparative reporting periods and applied the lessee package of practical expedients. The package of practical expedients included that the Company was not required to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Also, as part of the adoption, the Company elected to not recognize short-term leases (those with lease terms less than a year) on the consolidated balance sheets, not separate lease and non-lease components and did not use hindsight to determine lease term. The most significant impact was the recognition of ROU assets and lease liabilities for our operating leases. The ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease at lease commencement date. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its consolidated balance sheets, however it did not have a material impact on the consolidated statements of operations or cash flows for the three- months ended March 31, 2021. The Company recognized ROU assets and lease liabilities for operating leases of $108.1 million and $126.8 million, respectively, upon adoption as of January 1, 2021. The difference between the lease liability and right-of-use asset mainly related to the reversal of existing deferred rent balances. The Company utilized a comprehensive approach to assess the impact of this guidance on the consolidated financial statements and related disclosures, including the increase in assets and liabilities on the consolidated balance sheets and the impact on the current lease portfolio. See Note 7 in this Quarterly Report for our lease accounting policy and the quarterly impact of our adoption of ASC 842. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share and updates the disclosure requirements in ASC 470-20, making them easier to understand for financial statement preparers and improving the decision-usefulness and relevance of the information for financial statement users. This ASU was early adopted on January 1, 2021 and applied to the Company’s 0% Convertible Senior Notes due 2026 issued in March 2021 (Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s Convertible Senior Notes). The Company had no other debt arrangements to apply this guidance to. In December 2019, the FASB issued ASU 2019-12, “Income Taxes Topic 740-Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of ASC 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures. In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures. Recent Accounting Pronouncements Not Yet Adopted In October 2018, the FASB issued ASU 2018-17, Consolidation – Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810) (“ASU 2018-17”). ASU 2018-17 eliminates the requirement that entities consider indirect interests held through related parties under common control in their entirety when assessing whether a decision-making fee is a variable interest. Instead, the reporting entity will consider such indirect interests on a proportionate basis. ASU 2018-17 is effective for a private company for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. All entities are required to apply the adjustments in ASU 2018-17 retrospectively with a cumulative-effect adjustment to retained earnings at the beginning of the earliest period presented. Early adoption is permitted. The Company is currently evaluating the impact ASU 2018-17 will have on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for us beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements. We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Revenue Recognition [Line Items]

Revenue Recognition

NOTE 3. REVENUE RECOGNITION

Capitated Revenue and Accounts Receivable

The Company had agreements in place with the payors listed below and payor sources of capitated revenue for each period presented were as follows:

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Humana		42	%		49	%
Wellcare/Meridian		18	%		14	%
Cigna-HealthSpring		10	%		11	%
Other		30	%		26	%

Other Patient Service Revenue

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Care coordination and care management	$		3.9	$		4.1
Fee for service			1.6			1.1
Total other patient service revenue	$		5.5	$		5.2

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Medicare		38	%		46	%
Humana		11	%		8	%
Other		51	%		46	%

Remaining Performance Obligations

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair value of Financial Instruments	3 Months Ended
Fair value of Financial Instruments	Mar. 31, 2021
OAK Street Health Inc and Affiliates [Member]
Fair Value Of Financial Instruments [Line Items]
Fair value of Financial Instruments	Note 4. Fair Value of Financial Instruments The carrying amounts of financial instruments including cash, accounts receivable, accounts payable, accrued liabilities and short-term borrowings approximate fair value due to the short maturity of these instruments. The Company's Convertible Senior Notes are classified within Level 2 of the fair value hierarchy as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of March 31, 2021, the fair value of the Convertible Senior Notes was $918.3 million compared to their carrying value of $898.1 million, which is net of unamortized debt issuance and offering costs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Property And Equipment

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Property, Plant and Equipment [Line Items]

Property And Equipment

NOTE 5. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following as of March 31, 2021 and December 31, 2020 ($ in millions):

		March 31, 2021				December 31, 2020
Leasehold improvements	$		67.5		$		63.6
Furniture and fixtures			5.1				4.9
Computer equipment			20.6				17.8
Internal use software			7.7				6.1
Office equipment			9.9				9.7
Construction in process			4.0				4.2
Total, at cost			114.8				106.3
Less accumulated depreciation			(30.7	)			(27.5	)
Property and equipment, net	$		84.1		$		78.8

The Company recorded depreciation expense of $3.2 million and $2.4 million for the three-months ended March 31, 2021 and 2020, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets	3 Months Ended
Goodwill And Intangible Assets	Mar. 31, 2021
OAK Street Health Inc and Affiliates [Member]
Goodwill and Intangible Assets [Line Items]
Goodwill And Intangible Assets	NOTE 6. GOODWILL AND INTANGIBLE ASSETS On January 22, 2021, Oak Street Health entered into an agreement to purchase the assets of a medical practice for $1.8 million base purchase price which was accounted for under the acquisition method of accounting pursuant to ASC 805. Goodwill, which represents the excess of cost over the fair value of net assets acquired, amounted to $11.4 million and $9.6 million at March 31, 2021 and December 31, 2020, respectively. Intangible assets with a finite useful life continue to be amortized over its useful lives. Net intangible assets amounted to $2.9 million and $3.0 million at March 31, 2021 and December 31, 2020, respectively. The Company recorded amortization expense of $0.1 million for the three-months ended March 31, 2021 and 2020.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Leases

NOTE 7. LEASES

ASC 842 Disclosures

		March 31, 2021
Operating lease cost	$		4.5
Variable lease cost			4.9
Total lease cost	$		9.4

The Company entered into operating leases that resulted in $7.6 million of right-of-use assets in exchange for operating lease obligations for the three-months ended March 31, 2021.

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	March 31, 2021
Weighted-average remaining lease term (in years)		10.6
Weighted-average discount rate		4.07	%

The table below presents the future minimum lease payments under the noncancelable operating leases as of March 31, 2021 ($ in millions):

2021	$	13.7
2022		17.7
2023		16.3
2024		14.7
2025		13.9
2026		13.7
Thereafter		75.4
Total lease payments	$	165.4
Less: imputed interest		(34.0	)
Total operating lease liabilities	$	131.4
Reported as:
Operating lease liabilities, current (1)		13.1
Operating lease liabilities, noncurrent		118.3
Total operating lease liabilities	$	131.4

(1) Included in other liabilities on the consolidated balance sheet

ASC 840 Disclosures

XML 26 R15.htm IDEA: XBRL DOCUMENT

Other Current And Long-Term Liabilities

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Other Liabilities [Line Items]

Other Current And Long Term Liabilities Disclosure

NOTE 8. OTHER CURRENT AND LONG-TERM LIABILITIES

Accrued compensation and benefits consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Accrued paid time off	$		6.1	$		5.0
Accrued bonus and commission			20.9			19.1
Employee stock purchase plan contributions			1.4			-
Accrued payroll and taxes			5.7			1.8
CARES Act deferred payroll taxes			3.5			3.5
Other			1.6			2.6
	$		39.2	$		32.0

Other current liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee	$		2.7	$		0.6
Operating lease liabilities			13.1			-
Contract liabilities, current			4.4			4.3
Accrual for goods or services received, not invoiced			4.5			3.6
CARES Act Medicare advances & Provider Relief Funds			3.1			2.3
Other current liabilities			2.5			1.8
	$		30.3	$		12.6

Other long-term liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee, net of current	$		8.4	$		7.3
Contract liabilities, net of current			14.1			12.8
Lease incentive obligation, net of current			-			5.1
CARES Act deferred payroll taxes			3.5			3.5
Other long-term liabilities			0.0			0.1
	$		26.0	$		28.8

XML 27 R16.htm IDEA: XBRL DOCUMENT

Liability For Unpaid Claims

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Disclosure Of Liability For Unpaid Claims

NOTE 9. LIABILITY FOR UNPAID CLAIMS

Activity within liabilities for unpaid claims was as follows for the three-months ended March 31, 2021 and 2020 ($ in millions):

		March 31, 2021				March 31, 2020
Balance, beginning of period	$		262.1		$		170.6
Incurred health care costs:
Current year			192.3				131.4
Prior years			6.6				-
Total claims incurred	$		198.9		$		131.4
Claims paid:
Current year			(20.6	)			(59.7	)
Prior years			(165.5	)			(30.5	)
Total claims paid	$		(186.1	)	$		(90.2	)
Adjustments to other claims-related liabilities			(0.3	)			(0.2	)
Balance, end of period	$		274.6		$		211.6

XML 28 R17.htm IDEA: XBRL DOCUMENT

Long- Term Debt

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Long- Term Debt

NOTE 10. LONG-TERM DEBT

Convertible Senior Notes

•

upon the occurrence of specified corporate events as set forth in the Indenture.

The Indenture includes customary covenants and events of default after which the Convertible Senior Notes may be declared immediately due and payable.

Capped Call Transactions

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the Consolidated Balance Sheet as of March 31, 2021 ($ in millions):

	March 31, 2021
Liability component:
Principal		920.0
Less: debt issuance costs, net of amortization		21.9
Net carrying amount		898.1

Equity component recorded at issuance:
Capped call transactions		123.6

	March 31, 2021
Debt issuance costs		22.1
Amortization of debt issuance costs		0.2
Debt issuance costs, net of amortization		21.9

Effective interest rate of the liability component		0.49	%

XML 29 R18.htm IDEA: XBRL DOCUMENT

Income Tax

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Income Tax

NOTE 11. INCOME TAX

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Mar. 31, 2021
OAK Street Health Inc and Affiliates [Member]
Stockholders Equity [Line Items]
Stockholders' Equity	NOTE 12. STOCKHOLDERS’ EQUITY Common Stock In connection with the IPO, we increased our authorized shares from 1,000 to 500,000,000 shares of our common stock, par value of $0.001. Additionally, upon completion of our IPO in August 2020, we sold 17,968,750 shares of common stock at an offering price of $21.00 per share, including 2,343,750 shares of common stock issued pursuant to the exercise in full of the underwriters’ option to purchase additional shares. Redeemable Investor Units, Profits Interests and Incentive Units All shares of redeemable investor units outstanding at the time of the IPO, totaling 12,472,242 units and undeclared and deemed dividends of $103.6 million, were converted into 184,787,783 shares of common stock and their carrying value, totaling $545.0 million was reclassified into stockholders’ equity on our condensed consolidated balance sheets in conjunction with the completed IPO. No shares of redeemable convertible preferred stock were issued or outstanding as of March 31, 2021 or December 31, 2020. Additionally, all shares of profits interests then outstanding, totaling 3,456,634 units were converted into 38,111,001 shares of common stock, 22,612,472 of which were considered RSAs at the time of conversion. The carrying value of $7.0 million was reclassified into common stock and additional paid in capital on our consolidated balance sheet. No profits interests or incentive units were issued or outstanding as of March 31, 2021 or December 31, 2020. Preferred Stock Also, in connection with our IPO, we authorized the issuance of 50,000,000 shares of our preferred stock, par value $0.001. There was no preferred stock outstanding as of March 31, 2021.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Stock and Unit-Based Compensation

NOTE 13. STOCK AND UNIT-BASED COMPENSATION

2020 Omnibus Incentive Plan

Stock Options Activity

Stock options granted by the Company generally vest over four years with 25% of the option shares vesting each year. Options generally expire ten years from the date of the grant.

The following is a summary of stock option activity transactions as of and for the three-months ended March 31, 2021 ($ in millions):

	Number of Options				Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)			Aggregate Intrinsic Value

Outstanding, December 31, 2020		14,958,969		$		21.01		9.60	$		600.6
Granted		305,505				59.63
Exercised		(53,307	)			21.00
Cancelled		(25,582	)			21.07
Outstanding, March 31, 2021		15,185,585		$		21.79		9.36	$		494.9

Options exercisable as of March 31, 2021		2,375,304		$		21.00		9.35	$		79.0

RSA Activity

The RSAs were granted as part of the pre-IPO conversion (see Note 12). The following is a summary of RSA transactions as of and for the three-months ended March 31, 2021:

	Unvested Shares				Grant Date Fair Value

Unvested, December 31, 2020		21,599,118		$		11.77
Granted		-				-
Vested		(1,701,267	)			1.50
Canceled and forfeited		(43,447	)			14.05
Unvested, March 31, 2021		19,854,404		$		12.65

RSU Activity

	Unvested Shares				Grant Date Fair Value
Unvested, December 31, 2020		216,804		$		32.21
Granted		182,272		$		59.63
Vested		(17,864	)			50.46
Canceled and forfeited		(6,130	)			21.52
Unvested, March 31, 2021		375,082		$		44.84

Employee Stock Purchase Plan

As of March 31, 2021, no shares of common stock have been purchased under our ESPP.

Stock and Unit-Based Compensation Expense

Valuation of Stock Options

The grant date fair value of stock options that were granted post-IPO was estimated using a Black-Scholes option-pricing model with the following assumptions:

		March 31, 2021

Risk-free interest rate			0.79	%
Volatility			50.00	%
Expected term to expiration (years)			6.25
Expected dividend yield			0.00	%
Estimated fair value	$	28.69

Fair Value of Common Stock

The fair value of the Company’s common stock is determined by the closing price, on the date before the grant, of its common stock, which is traded on the NYSE.

Expected Term

Expected Volatility

Risk-Free Interest Rate

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with maturities similar to the expected term of the award.

Expected Dividend Yield

We have not paid and do not anticipate paying any dividends in the foreseeable future. Accordingly, we estimate the dividend yield to be zero.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Commitments - Litigation And Contingencies

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Commitments Litigation And Contingencies

NOTE 14. COMMITMENTS – LITIGATION AND CONTINGENCIES

Contingencies

Uncertainties

XML 33 R22.htm IDEA: XBRL DOCUMENT

Variable Interest Entities

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Variable Interest Entities

NOTE 15. VARIABLE INTEREST ENTITIES

The table below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

March 31,

2021

December 31,

2020

Total assets

394.2

286.1

Total liabilities

337.7

332.1

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Total revenues	$		294.3	$		198.5
Medical claims expense			198.9			131.4
Cost of care			32.9			15.3
Total operating expenses	$		231.7	$		146.7

There are no restrictions on the Physician Groups’ assets or on the settlement of its liabilities. The assets of the Physician Groups can be used to settle obligations of the Company. The Physician Groups are included in the Company’s obligated group; thus, creditors of the Company have recourse to the assets owned by the Physician Groups. There are no liabilities for which creditors of the Physician Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physician Groups with respect to potential dividend payments.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Related Parties

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Related Parties

NOTE 16. RELATED PARTIES

Humana

Revenues

Expenses

Blue Cross Blue Shield of Rhode Island

Zing Health

One of our Board members is an employee of Newlight Partners LP, which is one of our Lead Sponsors, and has a direct interest in Zing Health. The Company entered into a capitated contract with Zing Health during the year ended December 31, 2020. Total capitated revenue associated with the Zing Health payor contract was $1.2 million and $0.6 million for the three-months ended March 31, 2021 and 2020, respectively. Capitated receivables from Zing Health represented $0.8 million and $0.2 million of the capitated accounts receivable balance at March 31, 2021 and December 31, 2020, respectively.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Segment Financial Information

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Segment Financial Information

NOTE 17. SEGMENT FINANCIAL INFORMATION

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

NOTE 18. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per common share for the three-months ended March 31, 2021:

		Three-months ended March 31, 2021
Numerator:
Net loss	$		(64.0	)
Less: Net loss attributable to non-controlling interests			(0.6	)
Net loss attributable to OSH Inc. stockholders			(63.4	)
Denominator:
Weighted average common stock outstanding - basic and diluted			220,736,845
Net loss per share – basic and diluted	$		(0.29	)

		Three-months ended March 31, 2021

Stock options			15,185,585
RSUs			375,082
RSAs			19,854,404
Convertible Senior Notes	*		11,622,176
			47,037,247

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - (Policies) - OAK Street Health Inc and Affiliates [Member]	3 Months Ended
	Mar. 31, 2021
Significant Accounting Policies [Line Items]
Initial Public Offering and Reorganization Transactions	Initial Public Offering and Reorganization Transactions On August 10, 2020, we completed our IPO in which we issued and sold 17,968,750 shares of common stock, par value $0.001 per share, at an offering price of $21.00 per share. The share amount included the exercise in full of the underwriters’ options to purchase 2,343,750 additional shares of common stock. We received net proceeds of $351.2 million, after deducting underwriting discounts and commissions of $22.6 million and deferred offering costs of $3.5 million. Deferred, direct offering costs were capitalized and recorded against proceeds from the offering and consisted of fees and expenses incurred in connection with the sale of our common stock in the IPO, including the legal, accounting, printing and other offering related costs. In conjunction with the IPO, OSH LLC completed a series of transactions that resulted in Oak Street Health, Inc. becoming the ultimate parent company of OSH LLC and subsidiaries. Additionally, immediately prior to the closing of the IPO, unitholders of OSH LLC exchanged their membership interests for common stock in Oak Street Health, Inc. as part of the related IPO reorganization transactions. All 15,928,876 units of our then outstanding redeemable investor units (preferred stock including their respective undeclared and deemed dividends) and members’ capital (former founders’ units and incentive units/profits interests) plus 1,924 of options to purchase incentive units were converted into 200,286,312 shares of common stock of the Company and 22,612,472 shares of restricted common stock subject to service-based vesting (“RSA”) of the Company.
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2020 in the Company’s Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-months ended March 31, 2021, including the impact of COVID-19, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation. The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“variable interest entities” or “VIEs”). These evaluations are complex, involve judgment and the use of estimates and assumptions based on available historical information, among other factors. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. Upon completion of our IPO, OSH’s sole material asset is its interest in OSH LLC and its affiliates. In accordance with the master structuring agreement dated August 10, 2020, by and among OSH and the other signatories party thereto (the “Master Structuring Agreement”), we have all management powers over the business and affairs of OSH LLC and to conduct, direct and exercise full control over the activities of OSH LLC. Due to our power to control the activities most directly affecting the results of OSH LLC, we are considered the primary beneficiary of the VIE. Accordingly, following the effective date of the IPO, we consolidate the financial results of OSH LLC and its affiliates and the financial statements for the periods prior to the IPO have been adjusted to combine the previously separate entities for presentation purposes. Oak Street Health MSO LLC (“MSO”), a wholly owned subsidiary of OSH LLC, was formed in 2013 to provide a wide range of management services to the Physician Groups (as defined below). Activities include but are not limited to operational support of the centers, marketing, information technology infrastructure and the sourcing and managing of health plan contracts. Oak Street Health Physicians Group PC, OSH-IN Physicians Group PC, OSH-MI Physicians Group PC, OSH-OH Physicians Group LLC, OSH-PA Physicians Group PC, OSH-RI Physicians Group PC, Oak Street Health of Texas, PLLC, Griffin Myers Medical PC, Oak Street Health Physicians Group of South Carolina LLC, Oak Street Health Physicians Group of Louisiana LLC and Oak Street Health Physicians Group of Mississippi LLC (collectively, the “Physician Groups”) employ healthcare providers to deliver primary care services to the Medicare covered population of Illinois, Indiana, Louisiana, Michigan, Mississippi, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas and New York. These entities are consolidated as each are considered variable interest entities where the Company has a controlling financial interest (see Note 15). In addition, Oak Street Health is the majority interest owner in three joint ventures: OSH-PCJ Joliet, LLC, OSH-RI, LLC and OSH-ESC Joint Venture, LLC, which are consolidated in the Company’s financial statements. In March 2021, distributions were made from OSH-PCJ Joliet, LLC to Oak Street Health MSO, LLC (50.1% ownership) and Primary Care Physicians of Joliet (49.9% ownership) totaling $1.1 million to each owner.
Emerging Growth Company Status	Emerging Growth Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have elected to avail ourselves of this extended transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.
Leases	Leases The Company leases offices, operating facilities, vehicles and IT equipment, which are accounted for as operating leases. These leases have remaining lease terms of up to 30 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company determines if an arrangement is a lease at inception and evaluates the lease classification (i.e., operating lease or financing lease) at that time. Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the term of the lease. Operating leases are included in operating lease right-of-use assets, operating lease liabilities, current portion (recorded within other current liabilities) and long-term operating lease liabilities on the Company’s consolidated balance sheets. Operating lease right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company has no financing leases. The Company uses its incremental borrowing rate on the commencement date for determining the present value of lease payments. The Company considers the likelihood of exercising options to extend or terminate the lease when determining the lease term. The Company has lease agreements with lease and non-lease components. The Company has elected the practical expedient to account for the lease and non-lease components as a single lease component for all leases.
Convertible Debt	Convertible Debt The Company evaluates all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. In accounting for the issuance of the 0% Convertible Senior Notes due 2026 issued in March 2021 (the “Convertible Senior Notes”), the Company recorded a long-term debt liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the debt issuance and offering costs on the Company’s consolidated balance sheets. The conversion feature is not required to be accounted for separately as an embedded derivative. The Company will amortize debt issuance and offering costs over the term of the Convertible Senior Notes as interest expense utilizing the effective interest method on the Company’s consolidated statements of operations.
Capped Call Transactions	Capped Call Transactions In connection with the issuance of the Convertible Senior Notes, the Company entered into capped call transactions. The capped call transactions are expected generally to reduce the potential dilution to the holders of the Company’s common stock upon any conversion of the Convertible Senior Notes. The capped call transactions are purchased call options on the issuer’s stock that settle by reference to the Company’s stock with no forced cash payment. The terms of the capped call transactions allow the purchased call options to be classified as an equity instrument and will not be subsequently remeasured as long as the conditions for equity classification continue to be met. The Company recorded the cash used to purchase the capped call transactions as a reduction to additional paid-in capital within the Company’s consolidated statements of changes in redeemable investor units and stockholders’ equity/members’ (deficit).
Net Income (Loss) Per Share	Net Income (Loss) Per Share The diluted net income (loss) per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the if-converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, restricted stock awards and contingently issuable shares under our Convertible Senior Notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In 2016, the FASB issued guidance on leases, Accounting Standards Updates 2016-02, Leases (“ASU 2016-02), with amendments issued in 2018 and 2019 (collectively, “ASC 842”). ASC 842 requires lessees to recognize assets and liabilities related to lease arrangements on the balance sheet; leases are to be recorded as a lease liability (on a discounted basis) with a corresponding right-of-use (“ROU”) asset. Leases will be classified as finance or operating, with the classification affecting the pattern and classification of expense recognition over the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. This guidance also expands the required quantitative and qualitative disclosures for leasing arrangements and gives rise to other changes impacting certain aspects of lessee and lessor accounting. The two permitted transition methods under the guidance are the modified retrospective transition approach, which requires application of the guidance for all comparative periods, and the cumulative effect adjustment approach, which requires prospective application the adoption date. We adopted ASC 842 as of January 1, 2021 on a prospective basis, did not adjust the comparative reporting periods and applied the lessee package of practical expedients. The package of practical expedients included that the Company was not required to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Also, as part of the adoption, the Company elected to not recognize short-term leases (those with lease terms less than a year) on the consolidated balance sheets, not separate lease and non-lease components and did not use hindsight to determine lease term. The most significant impact was the recognition of ROU assets and lease liabilities for our operating leases. The ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease at lease commencement date. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its consolidated balance sheets, however it did not have a material impact on the consolidated statements of operations or cash flows for the three- months ended March 31, 2021. The Company recognized ROU assets and lease liabilities for operating leases of $108.1 million and $126.8 million, respectively, upon adoption as of January 1, 2021. The difference between the lease liability and right-of-use asset mainly related to the reversal of existing deferred rent balances. The Company utilized a comprehensive approach to assess the impact of this guidance on the consolidated financial statements and related disclosures, including the increase in assets and liabilities on the consolidated balance sheets and the impact on the current lease portfolio. See Note 7 in this Quarterly Report for our lease accounting policy and the quarterly impact of our adoption of ASC 842. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share and updates the disclosure requirements in ASC 470-20, making them easier to understand for financial statement preparers and improving the decision-usefulness and relevance of the information for financial statement users. This ASU was early adopted on January 1, 2021 and applied to the Company’s 0% Convertible Senior Notes due 2026 issued in March 2021 (Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s Convertible Senior Notes). The Company had no other debt arrangements to apply this guidance to. In December 2019, the FASB issued ASU 2019-12, “Income Taxes Topic 740-Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of ASC 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures. In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the new guidance on January 1, 2021, noting no impact on its consolidated financial statements and related disclosures.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In October 2018, the FASB issued ASU 2018-17, Consolidation – Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810) (“ASU 2018-17”). ASU 2018-17 eliminates the requirement that entities consider indirect interests held through related parties under common control in their entirety when assessing whether a decision-making fee is a variable interest. Instead, the reporting entity will consider such indirect interests on a proportionate basis. ASU 2018-17 is effective for a private company for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. All entities are required to apply the adjustments in ASU 2018-17 retrospectively with a cumulative-effect adjustment to retained earnings at the beginning of the earliest period presented. Early adoption is permitted. The Company is currently evaluating the impact ASU 2018-17 will have on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for us beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements. We do not expect that any other recently issued accounting guidance will have a significant effect on our consolidated financial statements.

XML 38 R27.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Capitated Revenue [Member]

Revenue Recognition [Line Items]

Summary of Sources of Revenue in Percentage Terms

The Company had agreements in place with the payors listed below and payor sources of capitated revenue for each period presented were as follows:

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Humana		42	%		49	%
Wellcare/Meridian		18	%		14	%
Cigna-HealthSpring		10	%		11	%
Other		30	%		26	%

Other Patient Service Revenue [Member]

Revenue Recognition [Line Items]

Summary of Sources of Revenue in Percentage Terms

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Care coordination and care management	$		3.9	$		4.1
Fee for service			1.6			1.1
Total other patient service revenue	$		5.5	$		5.2

Fee-For-Service [Member]

Revenue Recognition [Line Items]

Summary of Sources of Revenue in Percentage Terms

The fee-for-service revenue by payor source for each period presented were as follows:

	For the Three-Months Ended
	March 31, 2021			March 31, 2020
Medicare		38	%		46	%
Humana		11	%		8	%
Other		51	%		46	%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Property And Equipment (Tables)

3 Months Ended

Mar. 31, 2021

OAK Street Health Inc and Affiliates [Member]

Property, Plant and Equipment [Line Items]

Summary of Property Plant and Equipment

Property and equipment consisted of the following as of March 31, 2021 and December 31, 2020 ($ in millions):

		March 31, 2021				December 31, 2020
Leasehold improvements	$		67.5		$		63.6
Furniture and fixtures			5.1				4.9
Computer equipment			20.6				17.8
Internal use software			7.7				6.1
Office equipment			9.9				9.7
Construction in process			4.0				4.2
Total, at cost			114.8				106.3
Less accumulated depreciation			(30.7	)			(27.5	)
Property and equipment, net	$		84.1		$		78.8

XML 40 R29.htm IDEA: XBRL DOCUMENT

Leases (Tables) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Schedule of Components of Lease Expense

The components of lease expense for the Company’s operating leases were as follows for the three-months ended March 31, 2021 ($ in millions):

		March 31, 2021
Operating lease cost	$		4.5
Variable lease cost			4.9
Total lease cost	$		9.4

Schedule of Minimum Lease Payments for Operating Leases

The table below presents the future minimum lease payments under the noncancelable operating leases as of March 31, 2021 ($ in millions):

2021	$	13.7
2022		17.7
2023		16.3
2024		14.7
2025		13.9
2026		13.7
Thereafter		75.4
Total lease payments	$	165.4
Less: imputed interest		(34.0	)
Total operating lease liabilities	$	131.4
Reported as:
Operating lease liabilities, current (1)		13.1
Operating lease liabilities, noncurrent		118.3
Total operating lease liabilities	$	131.4

(1) Included in other liabilities on the consolidated balance sheet

Schedule Of Lessee Operating Lease Weighted Average Remaining Lease Term And Weighted Average Discount Rate

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	March 31, 2021
Weighted-average remaining lease term (in years)		10.6
Weighted-average discount rate		4.07	%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Other Current And Long-Term Liabilities (Tables) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Other Liabilities [Line Items]

Summary of Accrued Liabilities

Accrued compensation and benefits consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Accrued paid time off	$		6.1	$		5.0
Accrued bonus and commission			20.9			19.1
Employee stock purchase plan contributions			1.4			-
Accrued payroll and taxes			5.7			1.8
CARES Act deferred payroll taxes			3.5			3.5
Other			1.6			2.6
	$		39.2	$		32.0

Summary of Other Current Liabilities

Other current liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee	$		2.7	$		0.6
Operating lease liabilities			13.1			-
Contract liabilities, current			4.4			4.3
Accrual for goods or services received, not invoiced			4.5			3.6
CARES Act Medicare advances & Provider Relief Funds			3.1			2.3
Other current liabilities			2.5			1.8
	$		30.3	$		12.6

Summary of Other Noncurrent Liabilities

Other long-term liabilities consisted of the following as of ($ in millions):

		March 31, 2021			December 31, 2020
Humana license fee, net of current	$		8.4	$		7.3
Contract liabilities, net of current			14.1			12.8
Lease incentive obligation, net of current			-			5.1
CARES Act deferred payroll taxes			3.5			3.5
Other long-term liabilities			0.0			0.1
	$		26.0	$		28.8

XML 42 R31.htm IDEA: XBRL DOCUMENT

Liability For Unpaid Claims (Tables)

3 Months Ended

Mar. 31, 2021

Roll Forward In Liability For Unpaid Claims And Claims Adjustment Expense [Abstract]

Summary of Liability for Unpaid Claims and Claims Adjustment Expense

Activity within liabilities for unpaid claims was as follows for the three-months ended March 31, 2021 and 2020 ($ in millions):

		March 31, 2021				March 31, 2020
Balance, beginning of period	$		262.1		$		170.6
Incurred health care costs:
Current year			192.3				131.4
Prior years			6.6				-
Total claims incurred	$		198.9		$		131.4
Claims paid:
Current year			(20.6	)			(59.7	)
Prior years			(165.5	)			(30.5	)
Total claims paid	$		(186.1	)	$		(90.2	)
Adjustments to other claims-related liabilities			(0.3	)			(0.2	)
Balance, end of period	$		274.6		$		211.6

XML 43 R32.htm IDEA: XBRL DOCUMENT

Long- Term Debt (Tables) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Summary of Long-term Debt Instruments

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the Consolidated Balance Sheet as of March 31, 2021 ($ in millions):

	March 31, 2021
Liability component:
Principal		920.0
Less: debt issuance costs, net of amortization		21.9
Net carrying amount		898.1

Equity component recorded at issuance:
Capped call transactions		123.6

Summary of Debt Issuance Costs

	March 31, 2021
Debt issuance costs		22.1
Amortization of debt issuance costs		0.2
Debt issuance costs, net of amortization		21.9

Effective interest rate of the liability component		0.49	%

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation (Tables) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Summary of Stock Option Activity

The following is a summary of stock option activity transactions as of and for the three-months ended March 31, 2021 ($ in millions):

	Number of Options				Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)			Aggregate Intrinsic Value

Outstanding, December 31, 2020		14,958,969		$		21.01		9.60	$		600.6
Granted		305,505				59.63
Exercised		(53,307	)			21.00
Cancelled		(25,582	)			21.07
Outstanding, March 31, 2021		15,185,585		$		21.79		9.36	$		494.9

Options exercisable as of March 31, 2021		2,375,304		$		21.00		9.35	$		79.0

Schedule of Valuation Of Stock Options

The grant date fair value of stock options that were granted post-IPO was estimated using a Black-Scholes option-pricing model with the following assumptions:

		March 31, 2021

Risk-free interest rate			0.79	%
Volatility			50.00	%
Expected term to expiration (years)			6.25
Expected dividend yield			0.00	%
Estimated fair value	$	28.69

Restricted Stock Awards R S A

Summary of Restricted Stock Awards (RSA) Activity

The RSAs were granted as part of the pre-IPO conversion (see Note 12). The following is a summary of RSA transactions as of and for the three-months ended March 31, 2021:

	Unvested Shares				Grant Date Fair Value

Unvested, December 31, 2020		21,599,118		$		11.77
Granted		-				-
Vested		(1,701,267	)			1.50
Canceled and forfeited		(43,447	)			14.05
Unvested, March 31, 2021		19,854,404		$		12.65

Restricted Stock Units (RSUs)

Summary of Restricted Stock Awards (RSA) Activity

	Unvested Shares				Grant Date Fair Value
Unvested, December 31, 2020		216,804		$		32.21
Granted		182,272		$		59.63
Vested		(17,864	)			50.46
Canceled and forfeited		(6,130	)			21.52
Unvested, March 31, 2021		375,082		$		44.84

XML 45 R34.htm IDEA: XBRL DOCUMENT

Variable Interest Entities (Tables)

3 Months Ended

Mar. 31, 2021

Summary of VIE Assets and Liabilities and Performance for the Physician Groups

March 31,

2021

December 31,

2020

Total assets

394.2

286.1

Total liabilities

337.7

332.1

		For the Three-Months Ended
		March 31, 2021			March 31, 2020
Total revenues	$		294.3	$		198.5
Medical claims expense			198.9			131.4
Cost of care			32.9			15.3
Total operating expenses	$		231.7	$		146.7

OAK Street Health Inc and Affiliates [Member]

Summary of VIE Assets and Liabilities and Performance for the Physician Groups

The table below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 46 R35.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Basic and Diluted Net Loss Per Common Unit

The following table sets forth the computation of basic and diluted net loss per common share for the three-months ended March 31, 2021:

		Three-months ended March 31, 2021
Numerator:
Net loss	$		(64.0	)
Less: Net loss attributable to non-controlling interests			(0.6	)
Net loss attributable to OSH Inc. stockholders			(63.4	)
Denominator:
Weighted average common stock outstanding - basic and diluted			220,736,845
Net loss per share – basic and diluted	$		(0.29	)

OAK Street Health Inc and Affiliates [Member]

Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:

		Three-months ended March 31, 2021

Stock options			15,185,585
RSUs			375,082
RSAs			19,854,404
Convertible Senior Notes	*		11,622,176
			47,037,247

XML 47 R36.htm IDEA: XBRL DOCUMENT

Organization and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended			3 Months Ended		12 Months Ended
	Aug. 10, 2020	Jun. 30, 2021	Aug. 31, 2020	Mar. 31, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Organization And Nature Of Business [Line Items]
Organisation incorporated date					Oct. 22, 2019
Common stock, par value			$ 0.001
Number of shares issued upon conversion				38,111,001	12,472,242
Other Current Liabilities [Member]
Organization And Nature Of Business [Line Items]
Deferred payroll taxes					$ 7.0
Other Noncurrent Liabilities [Member]
Organization And Nature Of Business [Line Items]
Deferred payroll taxes					$ 3.5
Oak Street Health MSO, LLC [Member]
Organization And Nature Of Business [Line Items]
Equity method investment ownership percentage					50.10%
Primary Care Physicians of Joliet [Member]
Organization And Nature Of Business [Line Items]
Equity method investment ownership percentage					49.90%
Common Stock Subject To Service-Based Vesting [Member]
Organization And Nature Of Business [Line Items]
Number of shares issued upon conversion				22,612,472
OAK Street Health Inc and Affiliates [Member]
Organization And Nature Of Business [Line Items]
Common stock, par value					$ 0.001		$ 0.001
Proceeds from issuance of initial public offering	$ 351.2
Payments for underwriting expense	22.6
Deferred offering costs	$ 3.5
Number of units converted	15,928,876
Number of shares issued upon conversion	200,286,312
Total distribution from joint venture					$ 1.1
OAK Street Health Inc and Affiliates [Member] \| CARES Act [Member] \| Medicare Accelerated Advanced Payment Scheme [Member]
Organization And Nature Of Business [Line Items]
Percentage of interest free loans received					100.00%
Period after mediclaim issue when advance payments will begin					1 year
Period after mediclaim issue when advance payments are due					11 months
Proceeds from short term debt							$ 1.5
OAK Street Health Inc and Affiliates [Member] \| CARES Act [Member] \| Medicare Accelerated Advanced Payment Scheme [Member] \| Repayment Period One [Member]
Organization And Nature Of Business [Line Items]
Recoupment percentage of medicare payments					25.00%
OAK Street Health Inc and Affiliates [Member] \| CARES Act [Member] \| Medicare Accelerated Advanced Payment Scheme [Member] \| Repayment Period Two [Member]
Organization And Nature Of Business [Line Items]
Recoupment percentage of medicare payments					50.00%
OAK Street Health Inc and Affiliates [Member] \| Grant [Member]
Organization And Nature Of Business [Line Items]
Grants received					$ 2.6	$ 0.0
OAK Street Health Inc and Affiliates [Member] \| Cost of Care [Member] \| Grant [Member] \| CARES Act [Member]
Organization And Nature Of Business [Line Items]
Grants received					$ 1.9	$ 0.0
OAK Street Health Inc and Affiliates [Member] \| Other Current Liabilities [Member] \| Grant [Member]
Organization And Nature Of Business [Line Items]
Grants received		$ 1.6
OAK Street Health Inc and Affiliates [Member] \| Revenue Benchmark [Member]
Organization And Nature Of Business [Line Items]
Concentration risk percentage					98.00%
OAK Street Health Inc and Affiliates [Member] \| Common Stock Option To Purchase [Member]
Organization And Nature Of Business [Line Items]
Number of units converted	1,924
OAK Street Health Inc and Affiliates [Member] \| Common Stock Subject To Service-Based Vesting [Member]
Organization And Nature Of Business [Line Items]
Number of shares issued upon conversion	22,612,472
IPO [Member]
Organization And Nature Of Business [Line Items]
Stock issued during period shares			17,968,750
Shares offering, price per share			$ 21.00
IPO [Member] \| OAK Street Health Inc and Affiliates [Member]
Organization And Nature Of Business [Line Items]
Stock issued during period shares	17,968,750
Common stock, par value	$ 0.001
Shares offering, price per share	$ 21.00
Over-Allotment Option [Member]
Organization And Nature Of Business [Line Items]
Stock issued during period shares			2,343,750
Over-Allotment Option [Member] \| OAK Street Health Inc and Affiliates [Member]
Organization And Nature Of Business [Line Items]
Stock issued during period shares	2,343,750

XML 48 R37.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 31, 2021
Significant Accounting Policies [Line Items]
Operating lease, Remaining lease term	30 years
ASU 2018-09 [Member]
Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2021
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
ASU 2018-13 [Member]
Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2021
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

- Definition

Date accounting standards update was adopted, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

XML 49 R38.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue From Contract With Customerline Items [Line Items]
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	$ 293.6		$ 248.9
Cost of care	3.5	$ 2.5
Financial Support, Waived Fees [Member] \| Cost of Care [Member]
Revenue From Contract With Customerline Items [Line Items]
Revenue offset against cost of care regarding goods and services waived	1.2	$ 1.5
Humana [Member]
Revenue From Contract With Customerline Items [Line Items]
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	87.2		65.7
Contract With Customer Liability	$ 18.2		$ 16.6
Medicare Part D [Member] \| Medical Claims Expenditure [Member]
Revenue From Contract With Customerline Items [Line Items]
Concentration risk percentage	3.00%	4.00%
Medicare Part D [Member] \| Capitated Revenue [Member]
Revenue From Contract With Customerline Items [Line Items]
Concentration risk percentage	2.00%	2.00%
Accounting Standards Update 2014-09 [Member] \| Acuity Adjustment [Member]
Revenue From Contract With Customerline Items [Line Items]
Capitated accounts receivable (Humana comprised $87.2 and $65.7 as of March 31, 2021 and December 31, 2020, respectively)	$ 32.2	$ 23.5

XML 50 R39.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Sources of Capitated Revenue (Detail) - Capitated Revenue [Member] - OAK Street Health Inc and Affiliates [Member]	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Humana [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	42.00%	49.00%
Wellcare Meridian [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	18.00%	14.00%
Cigna-HealthSpring [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	10.00%	11.00%
Other [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	30.00%	26.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Composition Of Revenues (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Performance obligations revenue recognised	$ 296.7	$ 201.8
Other Patient Service Revenue [Member]
Disaggregation Of Revenue [Line Items]
Performance obligations revenue recognised	5.5	5.2
Other Patient Service Revenue [Member] \| Care Coordination And Care Management [Member]
Disaggregation Of Revenue [Line Items]
Performance obligations revenue recognised	3.9	4.1
Other Patient Service Revenue [Member] \| Fee-For-Service [Member]
Disaggregation Of Revenue [Line Items]
Performance obligations revenue recognised	$ 1.6	$ 1.1

- Definition

+ References

+ Details

XML 52 R41.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Summary of Sources of Fee for Service Revenue (Detail) - OAK Street Health Inc and Affiliates [Member] - Fee-For-Service [Member] - Other Patient Service Revenue [Member]	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Medicare [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	38.00%	46.00%
Humana [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	11.00%	8.00%
Other [Member]
Disclosure Of Sources Of Revenue In Percentage Terms [Line Items]
Concentration risk percentage	51.00%	46.00%

XML 53 R42.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Measurement - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - Fair Value, Inputs, Level 2 [Member] $ in Millions	Mar. 31, 2021 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of convertible notes	$ 918.3
Carrying value of convertible notes	$ 898.1

XML 54 R43.htm IDEA: XBRL DOCUMENT

Property And Equipment - Summary of Property Plant and Equipment (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 114.8	$ 106.3
Less accumulated depreciation	(30.7)	(27.5)
Property, plant and equipment, net	84.1	78.8
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	67.5	63.6
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5.1	4.9
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20.6	17.8
Internal Use Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7.7	6.1
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	9.9	9.7
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4.0	$ 4.2

XML 55 R44.htm IDEA: XBRL DOCUMENT

Property And Equipment - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 3.2	$ 2.4
Capitalized development costs expensed	$ 0.3	$ 0.1

XML 56 R45.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jan. 22, 2021	Dec. 31, 2020
Goodwill and Intangible Assets [Line Items]
Goodwill	$ 11.4			$ 9.6
Net intangible assets	2.9			$ 3.0
Amortization of intangible assets	$ 0.1	$ 0.1
Medical Practice Related Assets [Member]
Goodwill and Intangible Assets [Line Items]
Goodwill			$ 1.8

XML 57 R46.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Operating lease, Remaining lease term	30 years
Operating Lease, Right-of-Use Asset	$ 7.6
Operating lease right-of-use assets (Humana comprised $40.6 and $0.0 as of March 31, 2021 and December 31, 2020, respectively)		$ 0.0
Lease and rent expense		4.6
Deferred rent expense (Humana comprised $0.0 and $0.8 as of March 31, 2021 and December 31, 2020, respectively)			$ 13.5
Humana License Fee [Member]
Lease and rent expense		$ 0.9

XML 58 R47.htm IDEA: XBRL DOCUMENT

Leases - Summary of Components of Lease Expense (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Leases [Abstract]
Operating lease cost	$ 4.5
Variable lease cost	4.9
Total lease cost	$ 9.4

XML 59 R48.htm IDEA: XBRL DOCUMENT

Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)	Mar. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	10 years 7 months 6 days
Weighted-average discount rate	4.07%

XML 60 R49.htm IDEA: XBRL DOCUMENT

Leases - Summary of Future Minimum Lease Payments Under Non Cancelable Operating Leases (Details)
$ in Millions

Mar. 31, 2021

USD ($)

Leases [Abstract]

$ 13.7

17.7

16.3

14.7

13.9

13.7

75.4

165.4

Less: imputed interest

(34.0)

Total operating lease liabilities

131.4

Operating lease liabilities, current

13.1

^[1]

Operating lease liabilities, noncurrent

118.3

Total operating lease liabilities

$ 131.4

[1]	Included in other liabilities on the consolidated balance sheet

XML 61 R50.htm IDEA: XBRL DOCUMENT

Other Current And Long -Term Liabilities - Summary of Accrued Liabilities (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Other Liabilities [Line Items]
Accrued paid time off	$ 6.1	$ 5.0
Accrued bonus and commission	20.9	19.1
Employee stock purchase plan contributions	1.4
Accrued payroll and taxes	5.7	1.8
CARES Act deferred payroll taxes	3.5	3.5
Other	1.6	2.6
Total	$ 39.2	$ 32.0

XML 62 R51.htm IDEA: XBRL DOCUMENT

Other Current And Long -Term Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Other Liabilities [Line Items]
Total operating lease liabilities	$ 131.4
OAK Street Health Inc and Affiliates [Member]
Other Liabilities [Line Items]
Humana license fee	2.7	$ 0.6
Total operating lease liabilities	13.1
Contract liabilities, current	4.4	4.3
Accrual for goods or services received, not invoiced	4.5	3.6
CARES Act Medicare advances & Provider Relief Funds	3.1	2.3
Other current liabilities	2.5	1.8
Total	$ 30.3	$ 12.6

XML 63 R52.htm IDEA: XBRL DOCUMENT

Other Current And Long -Term Liabilities - Summary of Other Noncurrent Liabilities (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Humana license fee, net of current	$ 8.4	$ 7.3
Contract liabilities, net of current	14.1	12.8
Lease incentive obligation, net of current		5.1
CARES Act deferred payroll taxes	3.5	3.5
Other long-term liabilities	0.0	0.1
Total	$ 26.0	$ 28.8

XML 64 R53.htm IDEA: XBRL DOCUMENT

Liability For Unpaid Claims- Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Liability For Claims And Claims Adjustment Expense [Line Items]
Mediclaim expenses	$ 186.1	$ 90.2
Earning per share basic and diluted	$ (0.29)
Provider Excess Insurance Scheme [Member]
Liability For Claims And Claims Adjustment Expense [Line Items]
Insurance premium expenditure incurred	$ 0.9	0.8
Insurance premium expenditure reimbursed	0.4	$ 0.3
Providers excess insurance deductible per member	0.3
Provider Excess Insurance Scheme [Member] \| Maximum [Member]
Liability For Claims And Claims Adjustment Expense [Line Items]
Providers excess insurance deductible per member	$ 5.0

XML 65 R54.htm IDEA: XBRL DOCUMENT

Liability For Unpaid Claims - Summary of Liability for Unpaid Claims and Claims Adjustment Expense (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Balance, beginning of period	$ 262.1	$ 170.6
Incurred health care costs:
Cost of providing patient care in relation to revenue waived	186.1	90.2
Total claims incurred	198.9	131.4
Claims paid:
Current year	20.6	59.7
Prior years	165.5	30.5
Adjustments to other claims-related liabilities	(0.3)	(0.2)
Balance, end of period	274.6	211.6
Current year [Member]
Incurred health care costs:
Cost of providing patient care in relation to revenue waived	192.3	$ 131.4
Prior years [Member]
Incurred health care costs:
Cost of providing patient care in relation to revenue waived	$ 6.6

XML 66 R55.htm IDEA: XBRL DOCUMENT

Long- Term Debt - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended
	Mar. 16, 2021 USD ($)	Jun. 30, 2021	Mar. 31, 2021 USD ($) Day $ / shares shares
Debt Instrument [Line Items]
Capped call transactions expiry date			Mar. 12, 2026
Number of share subject to anti-dilution adjustments \| shares			11,622,176
Common stock, par value \| $ / shares			$ 0.001
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Conversion price per share \| $ / shares			$ 79.16
Closing stock price			130.00%
Consecutive trading days \| Day			10
Redemption price equal to principal amount			100.00%
Aggregate principal amount			$ 150.0
Capped call transactions			$ 123.6
Conversion price cap initially equal \| $ / shares			$ 138.8750
Notes Payable, Other Payables [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Closing stock price			130.00%
Notes Payable, Other Payables [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Closing stock price			98.00%
Conversion price trading days \| Day			20
Consecutive trading days \| Day			30
OAK Street Health Inc and Affiliates [Member]
Debt Instrument [Line Items]
Debt issuance cost			$ 22.1
Net proceeds to pay capped call transaction			$ 898.1
Convertible notes special interest			0.49%
OAK Street Health Inc and Affiliates [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument face value	$ 920.0
Long term debt variable interest rate percentage	0.00%
Option to purchase additional convertible senior notes	$ 120.0
Debt issuance cost	22.1
Total proceeds received	897.9
Net proceeds to pay capped call transaction	$ 123.6
Convertible notes unsecured obligation mature date		Mar. 15, 2026
Convertible notes special interest		0.50%
Debt instrument frequency of periodic payment		365 days
OAK Street Health Inc and Affiliates [Member] \| Notes Payable, Other Payables [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument frequency of periodic payment			40 trading-day
Conversion rate			12.6328
Debt conversion principal amount			$ 1,000.0
Conversion price per share \| $ / shares			$ 79.16
OAK Street Health Inc and Affiliates [Member] \| Notes Payable, Other Payables [Member] \| Maximum [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Number of shares issuable subject to increase in conversion rate \| shares			16,561,656

XML 67 R56.htm IDEA: XBRL DOCUMENT

Long- Term Debt - Summary of Long-term Debt Instruments (Detail) - OAK Street Health Inc and Affiliates [Member] $ in Millions	Mar. 31, 2021 USD ($)
Principal	$ 920.0
Less: debt issuance costs, net of amortization	21.9
Net carrying amount	898.1
Capped Call Transactions [Member]
Capped call transactions	$ 123.6

XML 68 R57.htm IDEA: XBRL DOCUMENT

Long- Term Debt - Summary of Debt Issuance Costs (Detail) - OAK Street Health Inc and Affiliates [Member] $ in Millions	Mar. 31, 2021 USD ($)
Schedule Of Debt Issuance Costs [Line Items]
Debt issuance cost	$ 22.1
Amortization of debt issuance costs	0.2
Debt issuance costs, net of amortization	$ 21.9
Effective interest rate of the liability component	0.49%

XML 69 R58.htm IDEA: XBRL DOCUMENT

Income Tax - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net deferred tax assets	$ 0
Effective income tax rate	0.00%	0.00%

XML 70 R59.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended
	Aug. 31, 2020	Mar. 31, 2018	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stockholders Equity [Line Items]
OSH Inc stockholders' equity par value or stated value per unit	$ 0.001
OSH Inc stockholders' equity, shares authorized	500,000,000				1,000
Number of shares issued upon conversion		38,111,001	12,472,242
Undeclared and deemed dividends			$ 103.6
Conversion of redeemable preferred stock into common stock upon closing of initial public offering			184,787,783
Total carrying value			$ 545.0
Redeemable preferred stock issued			0	0
Redeemable preferred stock outstanding			0	0
Number of units converted		3,456,634
Reclassification of members capital		$ 7.0
Number of units issued			0	0
Number of units outstanding			0	0
Common Stock Subject To Service-Based Vesting [Member]
Stockholders Equity [Line Items]
Number of shares issued upon conversion		22,612,472
IPO [Member]
Stockholders Equity [Line Items]
Issuance of common units	17,968,750
Shares offering, price per share	$ 21.00
Preferred stock authorized			50,000,000
Preferred stock, par value			$ 0.001
Preferred stock, shares outstanding			0
Over-Allotment Option [Member]
Stockholders Equity [Line Items]
Issuance of common units	2,343,750

XML 71 R60.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation- Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended
	Aug. 05, 2020	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, expiration period		10 years
Percentage of option vest per year		25.00%
Aggregate intrinsic value of options exercised		$ 1.8	$ 0.0
Fair value of options		8.8	0.0
Non-vested Awards (RSAs, Options and RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense		$ 251.1
Unrecognized compensation expense, period of recognition		1 year 5 months 26 days
OAK Street Health Inc and Affiliates [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		$ 42.4	1.8
OAK Street Health Inc and Affiliates [Member] \| General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		41.2
OAK Street Health Inc and Affiliates [Member] \| Selling and Marketing Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		0.8
OAK Street Health Inc and Affiliates [Member] \| Cost of Care [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		0.3
OAK Street Health Inc and Affiliates [Member] \| Profits Interest Award [Member] \| General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		0.0	1.8
OAK Street Health Inc and Affiliates [Member] \| Restricted Stock Units (RSUs) \| RSAs and Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		42.3	$ 0.0
OAK Street Health Inc and Affiliates [Member] \| Sponsors Exit Service-based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and Unit-based compensation expense		$ 29.3
Twenty Twenty Omnibus Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance	48,138,967
Share-based compensation arrangement by share-based payment award, effective date	Aug. 05, 2020
Twenty Twenty Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance	2,386,875
Percentage increase in stock that can potentially occur related to ESPP	1.00%
Sharebased compensation arrangement by sharebased payment award payroll deduction percentage on employee subscription	15.00%
Sharebased compensation arrangement by sharebased payment award purchase price percentage applied on lower market price	85.00%
Twenty Twenty Employee Stock Purchase Plan [Member] \| Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase of common stock shares		0
Twenty Twenty Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance	30,000,000

XML 72 R61.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 21.01
Weighted Average Exercise Price, Granted	59.63
Weighted Average Exercise Price, Exercised	21.00
Weighted Average Exercise Price, Cancelled	21.07
Weighted Average Exercise Price, Outstanding Ending Balance	21.79	$ 21.01
Weighted Average Exercise Price, March 31, 2021	$ 21.00
OAK Street Health Inc and Affiliates [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding Beginning Balance	14,958,969
Granted	305,505
Exercised	(53,307)
Cancelled	(25,582)
Options, Outstanding Ending Balance	15,185,585	14,958,969
Options, Exercisable as of March 31,2021	2,375,304
Weighted Average Contractual Term Remaining (in years)	9 years 4 months 9 days	9 years 7 months 6 days
Weighted Average Contractual Term Remaining (in years) Exercisable as of March 31, 2021	9 years 4 months 6 days
Aggregate Intrinsic Value	$ 600.6
Aggregate Intrinsic Value	494.9	$ 600.6
Aggregate Intrinsic Value, Option Exercisable as of March 31, 2021	$ 79.0

XML 73 R62.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation - Summary of Restricted Stock Awards (RSA) (Detail) - Restricted Stock Awards R S A	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	21,599,118
Vested \| shares	(1,701,267)
Canceled and forfeited \| shares	(43,447)
Ending balance \| shares	19,854,404
Beginning balance \| $ / shares	$ 11.77
Vested \| $ / shares	1.50
Canceled and forfeited \| $ / shares	14.05
Ending balance \| $ / shares	$ 12.65

XML 74 R63.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation - Summary of Restricted Stock Unit (RSU) (Detail) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	216,804
Granted \| shares	182,272
Vested \| shares	(17,864)
Canceled and forfeited \| shares	(6,130)
Ending balance \| shares	375,082
Beginning balance \| $ / shares	$ 32.21
Granted \| $ / shares	59.63
Vested \| $ / shares	50.46
Canceled and forfeited \| $ / shares	21.52
Ending balance \| $ / shares	$ 44.84

XML 75 R64.htm IDEA: XBRL DOCUMENT

Stock And Unit-Based Compensation - Summary of Valuation Of Stock Options (Detail) - OAK Street Health Inc and Affiliates [Member] - Black Sholes [Member]	3 Months Ended
	Mar. 31, 2021 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.79%
Volatility	50.00%
Expected term to expiration (years)	6 years 3 months
Expected dividend yield	0.00%
Estimated fair value	$ 28.69

XML 76 R65.htm IDEA: XBRL DOCUMENT

Variable Interest Entities - Summary of VIE Assets and Liabilities and Performance for the Physician Groups (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Variable Interest Entity [Line Items]
Total assets	$ 1,676.0		$ 781.0
Total liabilities	1,398.0		357.8
Total revenues	296.7	$ 201.8
Cost of providing patient care in relation to revenue waived	186.1	90.2
Total operating expenses	360.5	214.8
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Total assets	394.2		286.1
Total liabilities	337.7		$ 332.1
Total revenues	294.3	198.5
Total operating expenses	231.7	146.7
Variable Interest Entity, Primary Beneficiary [Member] \| Medical Claims Expense [Member]
Variable Interest Entity [Line Items]
Cost of providing patient care in relation to revenue waived	198.9	131.4
Variable Interest Entity, Primary Beneficiary [Member] \| Cost of Care, Excluding Depreciation and Amortization [Member]
Variable Interest Entity [Line Items]
Cost of providing patient care in relation to revenue waived	$ 32.9	$ 15.3

XML 77 R66.htm IDEA: XBRL DOCUMENT

Related Parties - Additional Information (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Liability for unpaid claims	$ 274.6	$ 211.6	$ 262.1	$ 170.6
Humana [Member]
Related Party Transaction [Line Items]
Percentage of common stock hold by related parties	5.00%
Revenue from related parties	$ 121.4	96.5
Due from related parties	87.2		65.7
Due to related parties current	4.1		2.6
Due to related parties noncurrent	14.1		5.0
Related party transactions, medical claims expenses	73.0	59.8
Liability for unpaid claims	78.8		78.5
Payments for license fees	0.7	0.7
Operating lease payments	1.3	0.5
Deferred rent liability	0.0		0.8
Assets related to human leases	40.6
Liabilities related to human leases	41.8
Corporate Joint Venture [Member] \| Blue Cross Blue Shield of Rhode Island [Member]
Related Party Transaction [Line Items]
Revenue from related parties		2.3
Due from related parties			10.0
Related party transactions, medical claims expenses		1.6
Liability for unpaid claims			$ 11.1
Equity method investment ownership percentage			49.90%
Corporate Joint Venture [Member] \| Zing Health [Member]
Related Party Transaction [Line Items]
Revenue from related parties	1.2	0.6
Due from related parties	0.8		$ 0.2
Related party transactions, medical claims expenses	1.0	0.4
Liability for unpaid claims	1.2		0.7
Fee For Service Revenue [Member] \| Humana [Member]
Related Party Transaction [Line Items]
Due from related parties	0.1		0.0
Related party transaction other patient service revenue	0.1	0.1
Care Coordination Revenue [Member] \| Humana [Member]
Related Party Transaction [Line Items]
Related party transaction other patient service revenue	1.1	$ 0.7
License Fee [Member] \| Humana [Member]
Related Party Transaction [Line Items]
Due to related parties current	2.7		0.6
Due to related parties noncurrent	$ 8.4		$ 7.3

XML 78 R67.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Common Unit (Detail) - OAK Street Health Inc and Affiliates [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net loss	$ (64.0)
Less: Net loss attributable to non-controlling interests	(0.6)	$ (0.4)
Net loss attributable to the Oak Street Health, Inc.	$ (63.4)	$ (15.0)
Denominator:
Weighted average common stock outstanding - basic and diluted	220,736,845
Net loss per share – basic and diluted	$ (0.29)

- Definition

Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 79 R68.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Detail) - OAK Street Health Inc and Affiliates [Member]

3 Months Ended

Mar. 31, 2021

Total

47,037,247

Stock Options [Member]

Stock options

15,185,585

Convertible Senior Notes [Member]

Senior Convertible Notes

11,622,176

^[1]

Restricted Stock Units (RSUs)

RSUs

375,082

Restricted Stock Awards R S A

RSAs

19,854,404

[1]

The Company entered into capped call transactions to mitigate the impact of potential economic dilution to our common stock upon any conversion of our Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of the Convertible Senior Notes up to a cap price of $138.8750 per share. See Note 10 for further details on the capped call transactions.

XML 80 R69.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2021 $ / shares
Earnings Per Share [Abstract]
Conversion price cap initially equa	$ 138.8750

EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 203 409 1 true 86 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance sheets Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance sheets (Parenthetical) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Operations - (Parenthetical) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical Consolidated Statements of Operations - (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Changes in Redeemable Investor Units and Stockholders' Equity/Members' (Deficit) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableInvestorUnitsAndStockholdersEquityMembersDeficit Consolidated Statements of Changes in Redeemable Investor Units and Stockholders' Equity/Members' (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Nature of Business Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Revenue Recognition Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognition Revenue Recognition Notes 10 false false R11.htm 100100 - Disclosure - Fair value of Financial Instruments Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureFairValueOfFinancialInstruments Fair value of Financial Instruments Notes 11 false false R12.htm 100110 - Disclosure - Property And Equipment Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment Property And Equipment Notes 12 false false R13.htm 100120 - Disclosure - Goodwill And Intangible Assets Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureGoodwillAndIntangibleAssets Goodwill And Intangible Assets Notes 13 false false R14.htm 100130 - Disclosure - Leases Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeases Leases Notes 14 false false R15.htm 100140 - Disclosure - Other Current And Long-Term Liabilities Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilities Other Current And Long-Term Liabilities Notes 15 false false R16.htm 100150 - Disclosure - Liability For Unpaid Claims Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLiabilityForUnpaidClaims Liability For Unpaid Claims Notes 16 false false R17.htm 100160 - Disclosure - Long- Term Debt Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebt Long- Term Debt Notes 17 false false R18.htm 100170 - Disclosure - Income Tax Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureIncomeTax Income Tax Notes 18 false false R19.htm 100180 - Disclosure - Stockholders' Equity Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 100190 - Disclosure - Stock And Unit-Based Compensation Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensation Stock And Unit-Based Compensation Notes 20 false false R21.htm 100200 - Disclosure - Commitments - Litigation And Contingencies Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureCommitmentsLitigationAndContingencies Commitments - Litigation And Contingencies Notes 21 false false R22.htm 100210 - Disclosure - Variable Interest Entities Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureVariableInterestEntities Variable Interest Entities Notes 22 false false R23.htm 100220 - Disclosure - Related Parties Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRelatedParties Related Parties Notes 23 false false R24.htm 100230 - Disclosure - Segment Financial Information Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureSegmentFinancialInformation Segment Financial Information Notes 24 false false R25.htm 100240 - Disclosure - Net Loss Per Share Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 25 false false R26.htm 100250 - Disclosure - Summary of Significant Accounting Policies - (Policies) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies - (Policies) Policies http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 26 false false R27.htm 100260 - Disclosure - Revenue Recognition (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognition 27 false false R28.htm 100270 - Disclosure - Property And Equipment (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentTables Property And Equipment (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosurePropertyAndEquipment 28 false false R29.htm 100280 - Disclosure - Leases (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeases 29 false false R30.htm 100290 - Disclosure - Other Current And Long-Term Liabilities (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilitiesTables Other Current And Long-Term Liabilities (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilities 30 false false R31.htm 100300 - Disclosure - Liability For Unpaid Claims (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLiabilityForUnpaidClaimsTables Liability For Unpaid Claims (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLiabilityForUnpaidClaims 31 false false R32.htm 100310 - Disclosure - Long- Term Debt (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebtTables Long- Term Debt (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebt 32 false false R33.htm 100320 - Disclosure - Stock And Unit-Based Compensation (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationTables Stock And Unit-Based Compensation (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensation 33 false false R34.htm 100330 - Disclosure - Variable Interest Entities (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureVariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureVariableInterestEntities 34 false false R35.htm 100340 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShare 35 false false R36.htm 100350 - Disclosure - Organization and Nature of Business - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail Organization and Nature of Business - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Revenue Recognition - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetail Revenue Recognition - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Revenue Recognition - Summary of Sources of Capitated Revenue (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSourcesOfCapitatedRevenueDetail Revenue Recognition - Summary of Sources of Capitated Revenue (Detail) Details 39 false false R40.htm 100390 - Disclosure - Revenue Recognition - Summary of Composition Of Revenues (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognitionSummaryOfCompositionOfRevenuesDetail Revenue Recognition - Summary of Composition Of Revenues (Detail) Details 40 false false R41.htm 100400 - Disclosure - Revenue Recognition - Summary of Sources of Fee for Service Revenue (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRevenueRecognitionSummaryOfSourcesOfFeeForServiceRevenueDetail Revenue Recognition - Summary of Sources of Fee for Service Revenue (Detail) Details 41 false false R42.htm 100410 - Disclosure - Fair Value of Financial Measurement - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureFairValueOfFinancialMeasurementAdditionalInformationDetail Fair Value of Financial Measurement - Additional Information (Detail) Details 42 false false R43.htm 100420 - Disclosure - Property And Equipment - Summary of Property Plant and Equipment (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail Property And Equipment - Summary of Property Plant and Equipment (Detail) Details 43 false false R44.htm 100430 - Disclosure - Property And Equipment - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail Property And Equipment - Additional Information (Detail) Details 44 false false R45.htm 100440 - Disclosure - Goodwill And Intangible Assets - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail Goodwill And Intangible Assets - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 46 false false R47.htm 100460 - Disclosure - Leases - Summary of Components of Lease Expense (Details) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails Leases - Summary of Components of Lease Expense (Details) Details 47 false false R48.htm 100470 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details) Details 48 false false R49.htm 100480 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Non Cancelable Operating Leases (Details) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails Leases - Summary of Future Minimum Lease Payments Under Non Cancelable Operating Leases (Details) Details 49 false false R50.htm 100500 - Disclosure - Other Current And Long -Term Liabilities - Summary of Accrued Liabilities (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilitiesSummaryOfAccruedLiabilitiesDetail Other Current And Long -Term Liabilities - Summary of Accrued Liabilities (Detail) Details 50 false false R51.htm 100510 - Disclosure - Other Current And Long -Term Liabilities - Summary of Other Current Liabilities (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilitiesSummaryOfOtherCurrentLiabilitiesDetail Other Current And Long -Term Liabilities - Summary of Other Current Liabilities (Detail) Details 51 false false R52.htm 100520 - Disclosure - Other Current And Long -Term Liabilities - Summary of Other Noncurrent Liabilities (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureOtherCurrentAndLongTermLiabilitiesSummaryOfOtherNoncurrentLiabilitiesDetail Other Current And Long -Term Liabilities - Summary of Other Noncurrent Liabilities (Detail) Details 52 false false R53.htm 100530 - Disclosure - Liability For Unpaid Claims- Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLiabilityForUnpaidClaimsAdditionalInformationDetail Liability For Unpaid Claims- Additional Information (Detail) Details 53 false false R54.htm 100540 - Disclosure - Liability For Unpaid Claims - Summary of Liability for Unpaid Claims and Claims Adjustment Expense (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLiabilityForUnpaidClaimsSummaryOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDetail Liability For Unpaid Claims - Summary of Liability for Unpaid Claims and Claims Adjustment Expense (Detail) Details 54 false false R55.htm 100550 - Disclosure - Long- Term Debt - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail Long- Term Debt - Additional Information (Detail) Details 55 false false R56.htm 100560 - Disclosure - Long- Term Debt - Summary of Long-term Debt Instruments (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebtInstrumentsDetail Long- Term Debt - Summary of Long-term Debt Instruments (Detail) Details 56 false false R57.htm 100570 - Disclosure - Long- Term Debt - Summary of Debt Issuance Costs (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureLongTermDebtSummaryOfDebtIssuanceCostsDetail Long- Term Debt - Summary of Debt Issuance Costs (Detail) Details 57 false false R58.htm 100580 - Disclosure - Income Tax - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetail Income Tax - Additional Information (Detail) Details 58 false false R59.htm 100590 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 59 false false R60.htm 100600 - Disclosure - Stock And Unit-Based Compensation- Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationAdditionalInformationDetail Stock And Unit-Based Compensation- Additional Information (Detail) Details 60 false false R61.htm 100610 - Disclosure - Stock And Unit-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationSummaryOfStockOptionActivityDetail Stock And Unit-Based Compensation - Summary of Stock Option Activity (Detail) Details 61 false false R62.htm 100620 - Disclosure - Stock And Unit-Based Compensation - Summary of Restricted Stock Awards (RSA) (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationSummaryOfRestrictedStockAwardsRSADetail Stock And Unit-Based Compensation - Summary of Restricted Stock Awards (RSA) (Detail) Details 62 false false R63.htm 100630 - Disclosure - Stock And Unit-Based Compensation - Summary of Restricted Stock Unit (RSU) (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationSummaryOfRestrictedStockUnitRSUDetail Stock And Unit-Based Compensation - Summary of Restricted Stock Unit (RSU) (Detail) Details 63 false false R64.htm 100640 - Disclosure - Stock And Unit-Based Compensation - Summary of Valuation Of Stock Options (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureStockAndUnitBasedCompensationSummaryOfValuationOfStockOptionsDetail Stock And Unit-Based Compensation - Summary of Valuation Of Stock Options (Detail) Details 64 false false R65.htm 100650 - Disclosure - Variable Interest Entities - Summary of VIE Assets and Liabilities and Performance for the Physician Groups (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureVariableInterestEntitiesSummaryOfVIEAssetsAndLiabilitiesAndPerformanceForPhysicianGroupsDetail Variable Interest Entities - Summary of VIE Assets and Liabilities and Performance for the Physician Groups (Detail) Details 65 false false R66.htm 100660 - Disclosure - Related Parties - Additional Information (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail Related Parties - Additional Information (Detail) Details 66 false false R67.htm 100670 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Common Unit (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerCommonUnitDetail Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Common Unit (Detail) Details 67 false false R68.htm 100680 - Disclosure - Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentialCommonSharesOutstandingFromComputationOfDilutedNetLossPerShareUnitDetail Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Detail) Details 68 false false R69.htm 100690 - Disclosure - Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Parenthetical) (Detail) Sheet http://www.oakstreethealth.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentialCommonSharesOutstandingFromComputationOfDilutedNetLossPerShareUnitParentheticalDetail Net Loss Per Share - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share/Unit (Parenthetical) (Detail) Details 69 false false All Reports Book All Reports osh-20210331.xml osh-20210331.xsd osh-20210331_cal.xml osh-20210331_def.xml osh-20210331_lab.xml osh-20210331_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 87 0001564590-21-026086-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-026086-xbrl.zip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

'9<$GAK,H0U M<\X<"+A%U 1%_=6R90HTV@B!HE)MIK9EOLEG3&TS+WQKEA0%0D:G(H!K,'L< MEV0.30LSIP"C]:&8L/^;I7]8A"2K[OI!<>76"(#J&7[C8 9/-L,8.@62@UA; MTH!M+RC[6N8YNSD[[0\_&(CU)4W"U$Z,-N\CG/LT2F-_,;(7!0E4JG%'N-W< MC<$-3JWZVA!$)$>X[@/#S&\M_]8.OH;B9@=?]S->NAM-6_0ATX*0S9\135-@ M4.V2M 6O!-G^5PM#E>4:;XS+!X8M_D*N@C!D[%49$_NK8\V)\N]MFZ)M4U3< MIKAKUZ)[%4L_5X_WM4S78B4(+:V+3031!J:_D";&.GFUG8RVDW&@G8P-8EUO M-HA.'MWUY/63<$'&4PVU)4.MM0]A!75NMB-X8!-:ZRU["O&?1!.6[IGE7= + M]F5SLC]H;LGM\C8NF]C]47<;6=?3K3^:VT,M.=WZH[DMTI+3K3]JOBJZ.E35 M\6-!JNZ!S)' M9XIG4F?$TRM9+2W92OH%CW30,RX=L17"17M\?2;-(V9OLINLQ" MD*];87='/LR'.8'$XXRB&!%[+!;^Y 1_U*W".B58HHA+<$)W/*;'K=^MU1,D MZS8].R$94F29D_Q)MS?;$\G@.EC!"?-'?0 Y@:]I%DP8E?JK*4$7%(]*S4$Z M" 3IHU!W]4T@6V)/CT>AZ-IV\PAVZ'9<>KS=&SNZ!!>&YL]@S-N:]CW!@*%Y M- @&-'5IYDPX&94>A#?DY@P8P(!)H.D#;K<6M(_,X@'WQ@L.C,H"@@] $ P8 M\?FO'7*1<^#-:!2 ]% 3P8N7H1"@64[_^Q'3CQUB)Y@R"O<2,<@PI_S#**[2[:\BITX*+HSB$H6-%15$ MC^*&E)CZFG-@'-FSQN&\@EZPZZ1U$K1X<;GP0\&$J.U0:!Q\0^=# XG0.C7/ M"<,U,\$R%W8Z?W@BG_^1,+ECTKJB 6DS!@.YC!T+5;^#AXFG&X+]T M$S;87FH8/-M;;7NK[1.P$&P/#7H,QM>:^ZCM$[#V"5C;.'U0SS;6QNGF)V!A MYH&);\'6-6"@C"@$-TH:-$YTYVM #1K],F18[^4B/0A:Y\\-Z=%GQJ?CTZ=$M;Q!DE'OHU(]2>4KVIP$ZEN+,@>P-D MT\/K5>C;%R5L"+J _\1UDV62OL):?.2Z#"<,32BP+_6M!1LZ?*&APU)QN'>? MR"SQ28GJ!L<&87"Z10X5"H3#4AH81)-(H;P>>= 0);@VA&A#B&:%$!MFUF!5 M J(A]OC$7+^S#>DHPT\P0_=Y5R<'NU&6$W.;@MH1+M4HBHBO*8\^,%U&E^3! M^2G:_*^".0V7&_G&1QTP$ V*-H#05N#1Y9*4(\3EB]U5L1CB$B'&,J@6,_5>JZVZ,46O=BB%UOT8CW6 7NL+%G5$-53E[%XDL1/3 /\4XBJ[&85 M(2GI[?*6'N/CM><\LALM*_EP@O7U]7F.W3=V.B7%40:Z052G-6^H+44"EG"M M[XCK.U'DS3TW55/3>6:"1.?.RHL=_R(A#U0TAD.=;#18"=0KF#-Q75YWQ/D2 MY;,-H'CC8*J0K0>R7-'0"=?9W=)*G3?#TD81_FS4@M% 1WIW?/[I^@EGI; ! M;AV/&;T;N6]!(!"^DNY,4>Q7=NEDF_!M10.4P5(U&YUIGI2R M(-K QY'G%2$B2$&R/Y ,(UP54)S^&D+*44*[T](K:%!I1BEB:VP$8[JGNS[= M<%//G()8T&%'V\5@II1WU9NO ="^T.$$E,6K#!7'6/](*0 M.8B< ^]T3]7I6/@ETDB"%^:.EI'@A5PN43!C5"9 ;>8XI]G@!R"ZHGDG]2$ M'XT>Q%5SY PP^)4#) /093@Y#PQ^)EI"^I%U5.)E^%%91C+EJ Q?_)=_#OO MC[^A\7^3F-WW=!%P%98YO9*??_(_HFJYH!"U%W;E.Y=>GDGH/C%<;WT'U_$OO81,*0 '^GB@\\+0"19I M4OML+7YE\XQX*G'YTKOO(TY6*]\CLVEP37^0\*L3_D7B]%? A07J$%+*+F?- M+AW_@LR2-!]9>'PUR+,RV8+"EI^2K M\]-;)DMT]6AO>"CCI(Q@9"GPZ'MZN5P%F\O8\;*W\% 60G\X&"V+&^P__V2R MX$4DVA*0WM%70N2YF_=#%<@D"A$I;@C\^E:?./83_^;..#2X08@1A^9 M]%%09Z-%&6.5G)'#157>9WG[>O84:L^7U=YJ1I_^W8?H)\_,3^29-.;.?&'? MHH8D]8>#A*C<9"=RZW#@&@,J/I:1V!6?I!$R;>;%&PKR[OX;7LX: ,G8AR&=,R#;&L3T"L =XCH(1A@#4=5- MG/Y?6G4:S'B4AA37O'"J*O"!Q+7U<,/)J+K[/\KDSRX2PL%LB7*TV7@/2;,1.-1 M/#Y-O16V=="4S%R3-M5T&%E=8*<@V_V*NC\F6]^(?'@;-"DO_O01X\N:M\==4IT_>O#7[$NOOR1O= M4PC,N!GV,J2B.UMW2RKH)BA/#._/H>D\YSV$YGTE50>TN;)"\$JWNB#N7X;KMRO0#NP5%'PP'Q=#.9! M5\.::7T&^N4:KU%X?%FR+"2GF'VT5)@:PR%ZPS7R77@7;*EHF MQ+@5\P]23RG/WKIBQ' /W<$TU;SMLCM+<%%W.$:KA';3TYI[#ES!U M+'!@S*V8'2@X#A9GL\9VWB?+I1.N-\\;95;EA#O=C(;.IW?"%QO*$$\ 128/ M&-KUUGC0:M=%4SJ5JPX+H_M--O@77 5]P[AJD#!ZU-6A#/Q.O,435]+/)&2& MZQWA5PHCZYPRNAPW3AS_@81+72(*1V\(?"^(#9"P4Y5\ET)O"#JC6J"V$33P MD%/E*!G!W\J$V(8:9K'-B1"FE6OF4H6MP/K[, ZQ0/K[+ :.ZP&E_^Q MPVK("QQ6 ^RFU5X$J[:;UN 1+_UVTPY@THMAA6?55I\8,*+[\ R5J:4.B#E3 M+HPL>:IP=\6@@!?+M3YB)V(,@65K9X&\(3RM;C93P7'F437:]ZSE$_?^+9K7J,J6<[>]TSU<:*MNEJO)$Y?:+ M9GL_I:8Y'H.Y:VC3P=[4JZP?X^Y^TE_G 6S%P;4?-)!E M<@(L&V-Z%3 "DM2$G#+^A ]/3G!H,^ZI]]1=XL,A\L9G)4FTCC$V.CW92.MN M!_I -@B-]+#WJ#:L8.H>H9$>]A[E38D#V1X,OL/>F8TV%_K"C TH06O8?-Y5 MRF8P>1^G87-X5Z6:P>%]G(;-X5PK*JP5Q2,E44-:Y6#@BD>;H!BQ^?;-;:UO M;MN:55NS:FM6;/3"[&+5>LVL[M&+,23$.QBMW&3>V-)8A4:N>'KQ M10\75>*TV?)D=2$(4;-L$]<*8FJ"W2]ZZKCV&+(QC[2-64KC?THIQ=HDR.[]F2G$'O MCBW),7^/;$F.^7MD2W),W1E;DF-+*Q53RVB@=6Q0.T<&PACRWD&06S;2&/+>09(Z]M(8\M MY'F!^V +>0S:#%O(8]!FO-1"'DY0^I.=)VJC_BIY0 L.KI2GGBI\.ZV\H$>Q MM^2SVE&YY\Z7-#JPF>,YB:)DN9VGM2+YO6:]+K8 MFO(BI7KUFR6A',:+IW )9KJ>DZ?"9! M@MM \8T*# L' (/DSF=*.O?2$XMJV=M\(9&CR<3KG%U)I3*U)TJXE(T<; DB MOI*9YSK^N>]XRVBC#'"HUD%0L>=7 5/XY#YF%@ W":XYHOQ(HQ.0#8 TTH)- M1-:"L=E(FXU4G(TL-;;6MZ''3:TS$C#CCRFV<(WOL\="5G.(>:7_)O1<9#R3 M\QO*CF8; >Q@$FUPPB'M"*[UIS[ MAQ)8FMAOV* 7E[:'G0':P=DV,6]?EZALJR?;\:PDU7FL.Q\&2G6:P+9A5$UT M9Y90>=MSR%468-T%+"@RJ()"14&1P74$_184Z2XL4'--UT1;S,G^ Z^4Y@!4 M,^D'\O]&=^D0Y&J A!%I<\Q3$&WNH9,QS-=V$BPJR9.+R0?@2TUY M:C!&"LJ]58)TKRI15F_(\N9*D/0@2 MHK#]^)*&U^Q*8WK[DL!EH.IKE84V:[9XYEVP&W?SA]F?27:D-W>13"4.#*Z: MHJ=<'Z\?0B>(')?KX.T]>\EN[L*/H]^]^*GX":Y6JN522HY]0A[H[B7%(Y() M.\P!3@/4 ])$RWDGA)RKI*)";-*Y65L?08&8(M=3M+\YV1U9):'[Q.RP MR8(Y6MPX.*<)=YM77,O@'@1! NROA&YW/5SY7-FW$ELN#$K)KPLJ^'B+6JDK4*HR.:.>66&.KTC!092KOG9"<4QK.O" -W&RN M8V2)?3T0";38Z63NU2:.*H53'02-TM!.H$L C8<6S>>THX-I.P-L9X#F"F'8 ME=&B7ABU@,8C?2U3/MP,2TO],)C$T@)BU(Z]N')BF0-C)WX-KW;53OSJ1O!! M)I")!:IUE?,0L["9]L$.^^J2_&&4Z^*\&]KL5AI3JMLUT0W^O:!;L^HW1@.6 M1F=$_?*@%6)=/*N",R5*\73(2E&:!44&#$LQEBN&W9"VH&UD^N\P99"3^F%X M71FMO)VRY,V6&5RS&7RH&S-7%)U@$Y2;*_%R24A:EB,5Y)KKX\&4%R@/G9.K M_;+J:7F-^&HK)3,:?\TVH-15^ZZ)?]4>T!;Z0&!US;G#!IN MT*N60;C*=\$-\SO^T*9$15]#3K/V%O5^)*"JL22G>P#=G5*:L:05**?YG;F^ MGZQ\-_1NY:3#^S:'1'IC2YV@?UA^,%3<$>V/.2L^F#L=_H;$US2*&-KIU/M\ M+OF9$WD\IWOA^0ECD?BUS#ODCW3+M/9VMIQ!+;_M:5+1"NR$ ;N;Q\JQW42QZ'WF,0\0?! LUEO,=,7;-7% M=AZ$-#TPX.H&B'.V*MA(MD3K6I&5PKT!I ;QD=K#N_L&8+'GY)#1LTVH)J<LQ\XLI MP=AC%^<]"=@IOF&;$2D@%+=P7^3?,=,@]/B[X&F-9_JXM0KJ4>LJ(IZ?'PVT MUR[;%^GIRM/L97A5=(/7E)G$6R9/=_<37&"Y"8J:$0V'TG%W_PT_.JX!D)1D ME:DL["O#=3 DD"I*%0Z5LB^51(-!@BA[RR(,G6!!-@]%B=_9%(^E MLIC^WP,CBS\)[SL!;BA>O^NKX)Q8'SF#:.]#F\"R"2R;P+()K*8$UKC'^K1. M8.F.D=EY/79>#TRB*^P $T?OU$Q9*#=_:-^6W9!FU/1J6]-JOV%((VU4\*C> MS3-F$(X!W *ZZX)EYM91J!2PIE"-.0-TVB8QNX^O#2G+V1%O,#%7P1[=%5JZ MV%,?CA]2%K@C_N"2-1+IX:$SJ)D5X%J2JDSYYN?\_Q[9O?'O_Q]02P,$% M @ ZH.J4EYZFBSTB0 WS\( !0 !OW/DN+4G^/]&['? ]FPX[%A55U4_W'9[[IW(DE1MS54IM9*J/7<[;C@H$BFQ M&TFD2::JTI]^\2()9O*!)PF69R:N6R5EGM_!^9V#QP%P\-__Q^OP,7[JQNPBLOT!5ZD18QPL<_A[^\__ '\KW=WU^ ZS7Y[C H(+G"\ MW\*L!*_ 0XC^@=P$940 ML/_W(_CFS3=O7[WY_M7;-P]OO_WQ^Q]^_/[[KW_XX9NWW_WIV__GS9L?W[R1 M!/S,FP6D___/#-G^"?OY$UQ;M#GCX]E^#W\1^8BJ2]6081@@?P M/LVB+$XC!.ZKEIZ!JRS^&JP0 G?T:P6X@P7,7V#RM9"*B-U^1)7Q"$=9P?[Y M;U])UOO\F*.O?__0M^_3;/__YSZ_97^N/%FG7 M!XG8MZ__UX?K^_@9;J-7A"KB!3$%*-(?"_;+:QPSCA3T KV?H/]Z57WL%?W5 MJ[??O/KV[=>?B^0K8@T N#URC. =W #ZWX]W5[V8?WY-/_$Z@T_$<9+KZ!$B MHC,3\9S#3??W4)ZWOD;U^#/5X^T?J1[_K4M:>=B1>"C2[0X1J[RV5O4&EFZU M/1;H6N%;F*L(FZAX9#!D2'Z*HAV'0E3HZ^AS6ES 3;1'9:>:3,43 624 M>O,:HK*@OZ'2BE?T5Z_>O!4][W_KD-NO.%.%CO;BDU3BP*# U>=#D"09?BYA MED#1Z]>R<7S2KJ)J6 'CKY_PR^L$IKQ-Y(?CEI!?_?TR*]/R<$ZF('F$K@C( MY_^ AS8ZHH,9SJM?LB;]VU<#7W[=5I-^GHZHY"X+9JX_WJL+^CAZ/W".' M!=[G;+A5MFC9A.^_DW.=X.6E/ XE$KO1[T#EP\4_[?OOE6L$]^\?=K6!00KG?5?S"2*R^QQC N/&E1,S8V?SN MJW_G.@!<*0$0U0*@2@VP$WJ 9 _!@6@"BO3SU_-ZFPWUV,+V'CUTM2%![LE- MV[+]^JJ,%8##1E2=);IMIS]H^NXI%\,.;#0 G^,7F*\>"]*?QZ7JP'OT);,! MMR7$C:]QTOZ=20:_5++_:_ZQM=O*N-<0'HBN4CT/I)&J/+>_8T:S+,/]=*I. M8%'Q\_/<:63<9XA0#(JT;.G"&5<$)Z%8[U'TI.J-1U\RLUY+B'M_K,4#*G]^ MA^PV-.ZU13!&17KV=-E#UGDNFN'6[2J/OFP7XBUA'CM/C@,($,OJS^^VPU3@ M42L%9_;C+E;9XBX=^WU:Q!&B,\KWY#>%KFN??-W.RD?B/+HW1P(4"C"LAQ M>S4&7#K^_[N/115J0TH6CFYZ??MUR*'\GSF>>HH8)S]5Y6CA,@G=8*D8&3Q(BZ M\=UMCEYEQ!$B?I8K*J/S?9X37?3V2/MDV&R5=LOTMF,JP=$E4P0$X/S^KT03 M5C5=J)0@2S;P\+>,Q" MH5D%2-X_/I7YH]W9=1J9Y?&I9A=7"M4Z:_\VN"AAH/<,#Y(T") M)JQJNE I099LN N(^V>(T#G>[J),\^!F^YLVEI8E>7-Y!@($2BA^WFE]/&R; ML"R-3(SLSGW?IPCFYV3P>,*YIO\>?=7&K"U1WCR8H8 *)A07[F8 CY@G,&LC M(T,[[(6W$4+O]D6:P4)S-G+T5:O>01;EKR.F**"""<6-NQG (^8)S-K(R-#N MW/AR"_,G,G_Y*<>?RF>C646/"!M#=XKTYMX5&N!PH$>L;6]A!@,L'DV(""AQ(A M:CQB3:,&SMGQWI@$*-A2H\I=.*V2A#2D$/^Y)A.XMWI!U"G AH8.@=X"1H"< M53_0@B<0K+-@HF2('JQDM2"I0%TLM$AX.Z'SGY,?U_D#_I09N;[\=0?6;L3Y M=WN*10<(BA:8RW>0TN7PQ]8*D(!N9V>F7X^9WKFOLU%FG=_F^"7-8LT)4Y\, M!T8_DNG?]>O)4049F/_W$=45!)W&"Y64[G#@=*Q5Z' >$[>X*"/T_Z4[_25$ MMP0'IF])]!\-' X0O* 6"8,$=45"A]G")*,["I1I<'(TAS8PAY&.U[>_8WC\ M0Y+AX=@-LR<1'X@C=UH9]UDB%(LB/6.Z<$=:BQ#=/N,,WNRWCS!7=]=D"(!! (XQOWOV6AT/624D"R-]X[IPUWL8[W,2'F^_>7Q(2Z3<@YY^ MS\R8QW+?,!R?Z.@S-0P%#/ ,<%$O#\D:!!(-8S9]ADH5Z> MM&AR>^!6;R5X^CW;PY^^5H+2\<]@5H*]5C\Y86N_$O1C8:1O7'?N^A!]ODH@ M^7&3\C<53'RW5XB-F7N$>O-J@@?:@('Y^!A56-EZP=*";!GI"(P?E6K1T]\< M1XGX]=_9)@\MD+#>U,^JW&)^A$RGM*R>/'V2=.2[G;%6@&"]D5Z>J3"#*55K M1"@V,>QX@5N';OD0/:HE\OJ^Z<#5F"0/"\_:LWYA"*$Y4-OT7:XB&28L,Y_$ M[JB%5;RXR$O)@\F_CKV7_.KOYYB^OY4F]!D5UM>GL%A]3I4N]@Q_7]_$0_(\ M;/-)2*""FM>GE0C!*H8*T?AHP.YD7"(XA:]AQ9*3R[GRY_E$SNQ<]710'+PB25=/Q-^R-AZT1EFV1;%:E#)M'UQ4%FLP]^$2 K;&/!/JKDQV5[6?S^O.H>-9Q\ N8O:0Q! MWH"?@8PLWG__U_TVRB(0X^TN3PO"W?_]YNNW+%%!?GA#YBGT3/P'XN;/X-NW M9X!F\MA?+X@DNKBO?OOFC @O=I 5/T>'/X01@-7Y"9=Y)),NX0 "-%,@ MKN*85OAG_\_NL? MEAZ'2LZ =<@)F?AJV5$QW2#-&(^W.=Q%:7+Y>0>S AH$8H\ #K02#]BSPZ-N68 M.)Z!==@H/*NW9ESM!-. ?S\G!+3%.NLN3R'_MT1S>:R<)!;[(^),=FXM@OU\?4G:.QE2ZLH%CF*HP0 M4:(+ZY@O9&K0$2L,B1WZJ;'H G?BD+F .WJ9HCCN*G3"I5^&.1]],CW>LT\$ M9!C!,4H,5C56J"2(@*A P,E ,O5RE\1E1%^ZNH91 >_2I^=RO?E80*:7ULIW M6)#%O]N0??++5E7S][LW7?_QR]D"4G )K<12T M Z!C[AD48%CTJB%!XY$Z<73^A''R*45*Q8A.OV-N\DJ&^_"J)(?AZ"?VQ7TV M",662-6,7OSQ?9JE);PF?55RE96DZ>DC@F*@U!LNQB29VWM8LGN/;D#$\!#0 M8D.1+ZQGO;"Y$1'"H0## A)'U81K\KY<2BN;K3AZ!#A)=/M<:_"$-SK*6(41 M(,.D=&\SN%MJ>"2@:[-AMD4&Q]?/SMJG 7UM+83DPT?6/4FQNDFH>DB?3NR% MUVGTF")^[3M+6.FN9XP2TE/17%1Y,-E%4)=I;G]5# ^[# TR6[T6$O;OHATN M_L)2K'/7O#4F&)L:>2EDHE,>:>Y5A@4<=[[]"TDYB]L]0U*- M843#"",=1U*[[!2F]=&1X07&3,<\+K<[A \0WD%$ST&?AK].&"@(,^=D5+B7 MX,CW]+82WM+CDKQJ(9VD/<(,;H+9T5/G$&N;,WB^1#A5:$# @8X19J9)U^$] MSL]1E&[I;%3\D/RZ+TJZ,R\.XII,P]3DVD\%5'#\K8L.8(-SL,_8L>68H7?M M#?[PIZ__Q/<&R4_?+WUST,AU.N:'ZM0MR4W0L8>\I^]+<]>@2Z_JQQJ].NX^ M1S;:;D3M%6&9$)UB]!0Y::D?[HC;MV^JN/V.;NXO.VS'"#_.=;L?=+V2V\IW MAS.^FD66VZ#R%D^]!^ZEN K#^=7\WKW+>_;VH/S<[CC^B" G%$Q[,#_H/)[: M$7T%VP5-3$>8A'!BOWV@K9XJ&IX*&!?FZNA=AW"? 82/3F*.S-:^_:&:K7UQ M)S"'7*3W%&8O6\&[0S67.SJ-V:RI9CO(< $WD. F=P3ZG/PW+4TO#PS)L3F[ MWB_7?:A6:(!UI^*R?'=]F#=59/YIZ9&IY )8AY*0Z49'3%,DP*%FO+-PM)"T M.$[7(\7=(G?*@W4C ^0WW]#D(PW#;UC!IF7'H8(3#*0T')_A\TAX;V)CMO [ MQ]D+S$MZFI9.UAZ(Z]W@$E8;DCHQ."K*HAKCL&B?$]<$/@9R_EN5*JQIM\!I M$3$C80$*!B@:8'#5SO9\Z1+#Y(BC%;>O#&#(F;^1#(?#?(:O[,7D'?UVF[)- M*K9MAC.Z&(-9K.F]@V)L>I)>L3[>%:K!V!PIEN' [^\A%/W*#^!WT7;W%_#V MNT#F22HD8@VK!DP8.N6*;;G*2),_+.+BE+F?<^53GB2_[SLY'DAJ7.^PN+_C MX1,=" _J /AM+K(+3*N?([376D-T?MVJSN&Q."\%)D5"A:&<@5V4@Q>*Q9)E M;][^!7S_YNS-&_9_H.#ORT?[\AGGZ3]I15CEM?M?0(8K 6E1T!.#]'.X>:M> M0U@8L3KD+UB!R !] W6Z!6 (,TSZ<&86BJ??M9LMR++\S.EPQB\U=4>@JQ#\ MYKLW9S_\Z;NS[[[E.U3LW]__\>R'M]\YB\UVDBZ,2.WU)3S&H=LH3:XR7B1J^! #US^RK-0,RQNA+>W]?[ M3M]_ 5O"8]1C13X"I1F=,$Q!P%4&!,SD+^&449K!Y#+*,](3%ZLXWF_W[/S^ M!=RD<:KY+,ZX-)N76L:D>[E_4F& A(.$$2<:Q&%]$X9/D@BD"@Y4>$!F[&*, ML8FR(799$+;PPBJ >8&\R+N\R&^\R 3A\2' M-,.T$.=51CI76&@-*J??-3?TL2SW \8-SE[1M#GY Z)+FU0@!;)1U$L$'C-2 M:$87OET)!Y7TV3M[TIVA/5W6WN*H7$/DWAPA>BR MNS+18/*!*(P(=.PP@^.2.2U?AG,,[ /42@&A%9#5 @\8M!6;JW\9JZ1C>,"B M1Y:_BC\3',7X$HHWC9S>&#!MZ-2=GO/H*])D%V%%7DK11?YU'%GD5W__$/V* M\_,]<98MP5U]3I6.>O1]4]_TW9)\5%OBXN=U_A&+XV%[A&7=:MI)Q8-:/OB% M(EAN*2MY[DVTA>M-JW47>!NEF:H##P@PLW2OP"_9G<=IP$K6"=+DPL MPV*UB;[Z=[%!PQ'F==1>.^,^6X1B4SGHA4%_X?('W&XV;9&FHKY/--Q&^3J_ M9Z\JL]W;6YC?T_UWPT,._>*<[%_WB9_L*$08*P,=_KH/%@P;<@%<=1T_((A@ MG0..R0\C ((*&.Q\(<;@BU5]4,8PM$[%.*'I6*SO4#HY-Q1<2/7RU1U*W08, MF)NNT.%(8*7 RC3A1_P,A89LM$"Y& B) MJQ$6I@F'=7,"TBHF6G(%TA]41/<&DF5OY'X<;A2FH2KX4@R M62]U[I.RBE@W.*O+A%YE,=Y"44[_K>K6Z:@8LYV_$;%>-EAYC;!, @4I0P6_ M%\49__!VYOL$.L1A#4N^GJ [YKAL_;$UK'+=*\(\I'M$.@UEC@%J$*5:$5/V MM&/48$5[&<9Z]!N_N,/O[1"$59:L-IL4I02E<+FA_@+S1]P4@%S]1_O*$#V\ MRPY[-NB.=MV5CF#=YCC9Q^4ZOX?Y2QI#G>.#W=\U.P74)[PX"2YP'!TPY/?I2UHV^@5F>ZAWU+#OVV9#9[/9O;6KV&M_ZU*+/)B!S[967L+?$/XF7BB WBLEQ.1:+V &Y'E>Q M K4>[P.,667VL(XU0V;JM/C\&$W6T3U-PY";-DV1=KBFO0"]*ZJXME(2XRS] M((MU[W,G>8@*+L@L1"=3_9F(4],%S$I?8JA"H*3(W=$8(]:S1>^M0;8-44K0X*)<;\ZC7#8SQ^O<5&8'$(8 M%./@<=A3L1ZR3_4)%W&R)90WME4XZGJRM\]H ?.!CJD0RQJ*--]K(GQL^@GC M1-JBN_PL:II=P%T.XY0O[. .0986R9+5EM8Z^R>?FVC$D@LTFXM/MNC^9AR[ M'+^DK(S<3N138SJ@IQD9A!!?[):X&I# IRA]">7$LT,/PNZY6KZW',WSF$+R M/C>H=0*R4J#6BGU8UFOJRJ:0%3XD6GR(\M\@[?O$"E"GZQB28E%DLE>JAT>] M(B1J"VXKK# B6($@K&ZR<,D0D21@6%C40%528N+8^ EF9#J :,>1;-,LI9, M^HR&08",BC(G9D2TCU$QWV&" <_ $\=F<1.UT.NY;!A1I$HEUK1KX+2)H!)8 M?*QITS1/9'4.W\4]1HD\2KJ>RXX#.)Z0C &ZC\W6)(-%I=+48O8IJ3+W8[-0 M-9,ODN>QN68!J!KM>>;,L\MZ/5WM*ACE=IHO.\@@5,)\E:K&)]F<,,*NGXJN M%$[;2L&9_21=SC)BU+4J3\=9:![>0<9PFM)#>M)_ M6G)B5^^]M6B2ME<09L[&J'!?!TCKFZFOQ5W50/+XZM1A;2L&3Y,((1FMBB*! M-U]^OWIMQ""A[^GW2ERU ;R9W_0 ?S=NI9Z6#CM2:H(Y(LIDR# MDKTMSKK'Z8"Z(T7NL)XEP^9)-8XF+UF$-VFINZ:3OV53W*:2XCX4;F )T. " M8DJ'[[ R[K=#.!853LO%SK(@@Z5T&L;Q\Y,&PBU6 KI@/J:H552 2'XAL,2T M!E'(;[V:NP&V9F YE!\M!@G7\@&O,!^%;-G(.'B=L>1O(#H).3(1"/L)\6YJ M^@+*:;#X#(2)'?QCEM"-:,H\3"ZC/"/!5K .H7I+_@'?1GF9QNF.S0?O8;S/ MV:N2[Z(BC75BPA[+G#];;!_#'=$)QBBB)0WI-G$"X9;\F*0O:0*S))"QS9F# M8-=D+-89VO'?4@94VHA!L=*'CH@MC4"C$F ZS3KS?8E2Q&<.TML)XJU9[6Y" M6[2K*= HU(3#;RR]VO%ZGZ6ET".,3L&4_=[IKJ+I%\9TWU2W@J=1+;\!4KW. M/$= _PVF3\^DIUF]P#QZ@C=[>D]NO6%5=J4:NTRU599J4'B+@BK>B6ZTR#5^"1*L/G UR=,"+>TCVP&U*6Z0KHR N$#H K0<^1 M,37D4M:\"V!'QR[&W,!+=U#-0ZJG6"SB?E24.:LCHMU'[PAQK$X\^-U_ M^],W;]_^)=3 5242:UHU<-)$S-73Z?IE'XO(TJRYIUDA14&0ZUIN/JNE#-8^ M*P(HS*!.W&B]/0=U4R8B*:B*>SXJJ0R[G:."*@]P2V_?Y(?+?^S3\B _'G-! M%N79T\,S?<,LQ0G_DVH7H"_7S-ET<;QT$+42 #(MVH\5@80IPM+0.Z;*&?][ M #V',?W8QOS#3U)T^NDMH>@Y*B"MK;+;P>0\0DC9&7N^;.9QG<*\N%6%1.^, MQPR+_(> !> WPW3@44L9>, -SLY/-_*NLCB'!.,!W^\?BS1):U^D7AAEL=(! M)3OY9GYDBN?%U6YZ=J7IB2:F#TWD%;5&53^7"IT"\$AK]\ N:)GBL9VZ-B)9 M\TNI-JZ.R?%Y18$6E[U5 -S>^Z[K1]*4A)R0Y*#!/=.C1RHVLNVDSLD5.,=D M?I"1?Q:Z19E'!#EPQB[![IP18)+6Z!/H/C##B8I@.K&2E($V/NJWNJ*SR':1'/NA&X%7V0N9+./^8 MI:5FVG!$B-DT>U"HE[ET@P@J2, P%1-14\R6U?C"RB8,EANYQ[$E)HP6(?O& M>!G(.*IFV ]\V;P7/1'FHUPWE5O\+MKAXB^ /X*$ HGO<4+PJ*V",SZ2[3ZO MHTOG;/0=O>/+-M5CCH3YJ,[5G.D)S+_[><"C)@K.YLC(W%[\>Y4D*9W)1.@V M2I.K3/1N^KX^(LB<@T'![F.@@0,4[]55%FB/K\8JN27 M9%'5G,C6#YX^"3;UWKLD>@B7F"R']HB=];Z FS1.R\#B9(0=K&:S,)FHEP<< MHCF%/U,D=-^_TX^'83E6=6-ZY7HX='>TSU87V @K0)1(PSI&#)D@5'-C2(V7 MP#DZ6O%SA/9-2?*>L54GH,SDF_-H@N>&7W[HYKZ,\K(_$W0&WL&G-*-])7B, M$-W2#2,6K?P N[#_$CD7,=VF7+38@CX5-9G+P>^)R'/X/870X_:S@ M48,%QT"U[N/CE1G3]8QU<^'5?=T)(7TP?*9 M5'X@E8T$=Y#>5X[)4I5]:O4IRI,;6*XW[W&^@6FY5SSR[ [+YA"%';:'-Y;% MV3CFN_(]P?V._$CG7;0C)'_,:_6J#] $?R#=H2OWP:ZI6KJKU$=R*.-<&\#5 M 5P?,5MK-!*)<:83H!?82,\BJ15&Q\+'FHEZ%ATPY_ZB#AYLAV=_6.U8\__(SS..TT+O7;"##@B72WK?),SKF$SWXG^W3 MJ/,4(.AS^/LNAS\Z'ZZ\X1!LZWMYY[U[FWBB0;OW#VEF9]2OJTKT-(!/U'>+ M65M G;0FDZI3,&<=\92L*4^U5+I:?W%W!W=B$ZK#)-HQ-R+-DKE!Z3YN0U5P M15WX;<>>GRA">Y1 @\KCH%,P:OBTM8)-PNN,N#G"[*<\(A[3D=ZA&CU25>F% M4Y@5[(JD2*(:I#",<2PY-L3U46E=RD O(FQM7>,XH*VH6*0;='4"0I/NA&:M M#9#5 ;4^G=LG55.FO#$2C&\.S0?N8T.]%=LTT7D9R2/O\IX2[7/B;F& MMSSGY%8=W]W,*W K.ICJ0*+&(G+24VN>O.SXW)L/^KXDC^HX>P?>G79(DHK@ MW0'(GQ-JBLW7*E$K.R7Q/Z[KU+D6'8!J/*N[&37)_6HQ68&7@:-(G:;5UMZH]C5T\#SUD-L';GEG4\Q M]%S?PILKZ"5*@/.N.T^5'O19CT:3*L]:Z>+DBH3SMTD[:MP[473N"TR7634Y MZ[R^=,E?6U"ZN[38VRN-#7PTU^2ODP1>S?0W)D'1+KRWUX(ORY; M*4!7RK4*@.D )"6"]-!QHGN=$X6KF>]ZTZKOI^I_2J(, MGR48%^WGD0*!"RB?=4%XNH'?/F<5@)_I$(DUK6K@5Q^S'5DJK#<;2'/XY[@H MBZML%<=X3]:>9 U*Y]2D2R6_R?CM+ #,?- 8T(MG5S!AURG+QB<"+7W^,% M% HPK)#?+.@GK/NI@AX#3N%F-["DZ*1GIX^3)^\.'PN82/.&55RF+\SU39S/ M1+K54\"::!XJA%('W3 '95, 7,\UHQK]QS BI/M4M_W1! MU5I+NN>25WJ"K'JCEN[$D)]9PF]//8],XP+N:+RZ(9Z"WB_1Y="IMSU@4*L( MCA^WIT_:+Z3;V]+MF'^RA<]Z\S[-R#JUFN:SYX@+/M'7ZLJ495KXBB*&ARY' M0J;)BD1 ?+/!#Z6;$V80U[%MLYJL"5D(%V,+N78U.Q+H1=U,$M+-E2P@.&* MY[(%\L1Q>@%W9'!+F6[D9P39'BI9=DLZZ\2HFCQS E7DNX]-&97G9B2X,*)/ MBTAL8M ED(8Z^*H16:"ME)F;.);*X?7(\'U*5F?9Q[WW6<>S]A*ADPY-BJUA";-YPW3-GH*VL]!YDG. M(D\<(!^S'$8H_2=,?HK2C"XVUJ2KSM,7HLR+WL7$45'F?(R(]G'MX/R9G@BG MJ_M-E.;@A5UH(;'RF&Z(8#893VH-PH@:52ZQIF%#Y:T=4 T6H&!\X;RFTX : M;^+8&C@2( YEFB3V=*2:,Z>.XB&/7X>>E%AC)WC8:";MB]8C6+K=$57H3U'\ MCWU:L!.PH>3@#/P FS.Q',Y%X(Z<$ZK?3YHKI75JEFJW^@[&D/0MCTCKEHV: M/):)*58H --6"UG&$PA-4I M6!CQ"F%>N4&E1I6480DRI@E8*;A!N&?G.YW_?N24_"OIE/Q2&ZY ?FV&2A&) M=:H+H,J,\C_Q#$N3 .QXR\)$*'HK/"!@)Z3RN:#1)0L#H4[S1-T@[@.T$GZ@>U9@S^]5 MQ"A*M\&&YABKPZF^(<,NAL'!1!]?=HB.5RD.KZALDE-+BL=#<\"\2Z)R/$ ;\!ECE*G2<=>A MNA)9WY+4"5 -H>:4*H-X"LTP@E"?/VQLPL5PA>0>M/-N3'V/&=30$P>>^BU* MG!=&;!I0;'2Q=[H+O?->Y TC0GFY%5]7\P>E M.Z=X ,W_U?RT @_OQJP%]>,1/&KTY=&L$M&U$D'<4:VJZC[@%3TLFL-W^R+- M8%' XJ<<%UJ#[K@L=&%'W05<&'&IS!K6M6"P#+4CK"X&_8"! M@ ,-'F" )>'6V*[]*#[CK*"!MA/(;*L9 M5K"!AMTXQ4,!.&+D!= Y'I05,F#0[)C5Y3BI,\]C_5IJ#TIU3/(#F?Z6YJ8MN+&6EJ4+]> 2/&GUY M-*M$=%-C)8B5IE2T]QR3SB8OTT<$+^"CWH1X2(S%E*E?K(>G;%K5F1]QGN-/ MA*:"ECF*&W!0P"S%.NHY0BB02:T%WQVK3UU++XC; MGM4HP9<*'X!&@\X!TOI$XF0E__M'%+G>?]Z\2M4N_;^?+^WU(,TQOE;%R-N*!+K-<7[2L:(2@5)6O"WR-A3H0-/]P76 MV8ZPV9G6Z[=MH,SUI^\J,""CS;A@8/6[Q(.SEY]A'J>%WD/U"L+<3$,[A?ON M\*$ HAT^YMB!A),RAST+A@%S!L]7Y[C%*]%5;R?7B,%FVOQDV*9)N7C,A>^J M?,OCH3.M%D;X&=!LE$V;+HLV;_9LXBBENM'_HSMF+Q&"K!(.G4_%9*)%_[#* MDO8OI$_R=]B/#WS73^.2'UAIL3LR:;O<;*!>+GUJS< M\1X(-FJ*LNA5(]C?P^B 9O)@/"___UK>BJ3-)O8_DDJ@49;_C1X ./Z=_'G> M!G!Z7:1N!JC: 6A# &_)DCKFR?K9V1S1Y0O=]V64E])^IEKO=P8>X5.:9=1? MZ*$B)NH+Z!*=]W"S=ECA]3].7JP/P";'K]OK1 ZD%<'&8\9/C?K];H?8-:0( M59>BKK(-SK>L_HS1PY.J(BU*I*M!>"AK+P&SQW(0+@*J7*]))C:TZ$*(0QV< M-??O)-@YR_OR9/QME"9DX:$39B=?M;FDW!+EZ5P4*Y=#*^=4.Q!A!$T?!7C$ M/H&96SA[)1M0X?0I-^M=QYE?LY;=2#QES1XF,W_/>ND602UC5&J(9[TZB@#R M%XAT:AQY6L*Q#4I6]37A[[U<\3H$R;M]>8/+_X0L(O16:ZHR;2;<:A@^W@-- MTGH;E_1D]!A%S,8KXNT[NLE1%&"SSV@>M7S.\?[I^20(PNACM;G'IO9?"L_U M&HKOVLNHH((%!!<08$"067\^=8F._"G*Q*MEY\3],$J32+RB=DL4I3.JUIN& M$:J+&A@=&'<$:%$NPH4";DM)2!J!EDJL6Y>5DEYY)![5Z*4TNYVR-W#K5]@+ M?:\'XXO, FC0O'WSK0@9.BV0T0G@342C>;VI;DE>D_^](EA*Z4@]>?H.KR/? MC3\G.&9G /EC:FV_II[,X:D/5PI\/:^W&E&*34R[!/I:58C&N0._4'S %!CI M=8)K:E?/:]7*\ ;GBSIS13Y]GSYEZ2:-Z4U5/GLDRXE;(B\FBX0'^+E\1UKP MVV3CN)%N,PWY!KIZ#L>H<53<..H7,.[;N*RK*8(QW?]J[NEP\MJT@7U':@5H MF@&J=H!?:$L :\K4/?*I54W60$-2+)Z@[Y7J]M'Y+D8"6WTHT(35#6>P3A@, M1.U5@JHTLTFFFG0O*X312%>>84ZQ4M D%>N;U[6G/:B^;:0JR8.'/;A[-D?3 MNQAR "M0#0I5?.K!YJ&C*>EJ;;J/COD4UWZ9.57;4$#-\I@F<->!!]9(5?[F M2PZX7]+[7XC/M7R^WV^W47Z@R^411L.8OYJO?:=9LL:#PG;J*U:NS]NBOW\+<^['0-E0GY M/%[1N1( %,BS,F/[S]V(@>'+G_X>5W%V?60(K1EB9+XEFE!'%%)CH_G? MTO+Y?%^4> MSHT6:NDSK">$HQB2>&-2,3YW*T]F>HCF70MM1R%5%_!@LH+B@ M IYS;?8^2O.?([2'S1ZCT9;=L!QSSH;D.N6) @&&)&VWAK=SI\07UK&?P92X M%BKMN#<5[O3W[]3EF>B5>%S; M\QA<4T^[0&N2^;UOAH3W#Q0G42L;<_A&:%G)]2:/.I(\^"&CH?@ M%Y@_8KG8)D,]$_X8M?TQF!FC :,J+FD]6YR:/:5>9+Z94Z\9FE'):"*E)]<# MC1TX7BK?/D4XH0T>TJ*XDI MZ5L?JZ* K4L,!G,T3<'F[&H!.:6W0F;$-MB @[<(#FPB9\8ZMC*Z0M;U*3PUI%H[47Y@ ##VDQ] OW4TCKQGK!6W./\8"6S!^N8H3>X_Q3E"=76:7>X3U]:IB6GCY'4;HMB,.)'Y)?]T5) MAR56S+8PN];J"M+BI+P;%=P>I"VA:5P+E"K >H?JR5 T*[ MX":3KGT,>R)RDG2"I./[/:WAQVZP'][!#&[2DNHJJVXY%KI LU@*6Z.['TFE M7G>]&8JQ,$+'H;M@]\0LWS6J3$K+#[A"O+3$ 50JL4ZWW0V',81?P,?2+L_2 M)\&I@-,]T"++J'+H$>\M@$YA5? M15&D,/QFF VL9*0@+8\:HS[WG-0C,T+4KUB';\F17$ M 0JY-U7A"FL8;XI^M4,)H^YU6(Y3#_/8V39^%JQ'#7:WX]8*F8GA8)^O#[XO M">@S1@GQ%'I@N3SL)X53>H? MGXB]UBZO/23"L(1NOT@_I8YEOX'<;Q#=T4DI9 @UCA5HPHJV<^(E>J6Q^[[N MRCL\%L'N\(PRE,+7(ZST.H1]B6N?#+0JSW9TZ,Z*/OMLQ," Y$]_QYWD*!'7 M+JM3^V[-$"-*#9EP F>YXM$0ZGI:-\E:2(;^7;3#Q5\$DR%/[A3729IF70Q_ M8S/T,-93C1;KS3G>TEU.-A&X@R@J8<(>D+Y_CG+X&!4PN8T.Q@^YVB)9;"Y8 M(;O=A&AM)\K* *&->+.[T0=4"@6WIG/D.]@M4U-DZI3U?"?K:32T64--$#?= MT)Z&078O\6.6EJ\8;"N(%A87(]YA$AA#5"S<$XRZ4/#NJ ^=;Z@EJF[3DO=8 M64)+GZ;9$\QBZVL/FH+-W4 +R"GI$C(_S"9CA[P/948ZMK+Y%".@DEI& YZN M9,_N['$XDYWZ.BW3I^89U)8R"_+DP4',Q-[+8E>[MYIO-/HYRE.:EKO*B$O" MHKPD*I8'R]C5$&I.K#*(^XBMH$&%#1AX,#&J3RHVMNMB"$2#W!T"B4LK\85U;3C&=Z]/$ M)R<9$V0?#68@,.%3P3$]# :3M80Q(-S#)SJ#O(,[G-/9H]$9 MIUX9%MLH/3+=[IIP$%"C!-??C]*#54TV1?]^K('M?JN*.'JW Y^ZM3,=;;/X31:5]&>4:T*6YASM+/)IUVOPQS?OID.B6E M @$$163?0^NU1_G!JC:;HM<^UL"HKQX0XLZ?//;+-[ $U[B0O"I,5QKL@D?L M%2P1 Y%MTLEVGK6]HN\V1NAV_XC2>+W9P+QZ'/Z@Y?#JLLS.@*K(]G(D5P"# M'4,&6$ '<"!7BSJL:\;0:6K?5N(<<5A0X;+#"G>0?"_*TG_R_1UYK6E]BG2Z MUJ+AAHK;[S/.O=Y%15JL-[>D<57LK++D/GW*TDT:T_<5XACOV4X,4S8UK,MI MAV/>U=O@NG=XI@U]8TW6A[G[.?%K@I\$M'!RXAK8)15+=@,D>\#ZR /H?J>D M#&BT 94Z#N<.EUN8/Q'9/^7X4_E,#P-%V>&>J+(O#&<0.A+-!BAU!"^SB0H> M/#%\$',%0,$T #NF0@!S"P-JL9F!ET&CW/G6'')P(- !A[>>5$S=-*32J@!F M&+R ,J^:;-"]*(FQK23=*?9?H:3W,"TG];P'[!0P!:BR/JOD+>IWVP1&YZA* M9G O,"_I8PNTYHKA2#HFQ:S;'9;J9<24($%":]#P,1*4U-Z/%';^T5*1,JQN MQ'#I:9^A;+@9K\D42 -0M^X> CG:[6!R'B$D)QU,XUE-F*'?J CW$]T,&<0$ M&I02=@!38#WZL+8E@Z>J%>F<)XKK-H4V87O0<%,"F.(>[R=83'-'1;G;]?#N M?'032M1"^CW=C/I#Z+M1"O-@)2,&SE'__M3\H70#/TFIN!QGY,<8LEL!7#F+ MV-*7;4ZD+I:/(Y8Q04,'L$KPCA[:DY.*+87""$9CYK&MU9?&,JJZUT_]G%:A M/']$7\ BSM,=':O7FP&#W>#R/V$IG%4GK T!;.HN&P#Z"O !%R#X@"A0=0!A MA+F=.V G+"R2>A'UD@9T&VFX$U#V $]5BZ*2*?)N7Z09+ IQ +%8?4Z5Z@8J M"K*I;C,@V-MIV4 &7#5ZL):U@J9"1%"-!"HH4&&!7RC:3)<6+O V2C.MN&A_ MT?HD,A?TQ?M]I[E/CW[+U@C*M*AE5? +EVV9]7P/X7NEA.:B!*ZK%SZ?P6P56A./;:RO$%M]1$DK4+K:K*\^**_$NQ*[L=K:H?O M>9T5VM5-&SIU[2PFYXW"@@H74&!P?L2;]5QQNA:BX!KG:Q30Y!+5-=3=%H:? MJ?7J/&LWW,LRXC;'.YB7AUM$[SQD":VMO:.]J-$:0D6:^:1S7+K7U4,%#Q@^ MNZ13:Q#&FD*QOUO")$\%W1-1*)LKA.F$=_79?YA"6?X41*I^OK\\)TFJS M25$:E;#02YDI"C,;R)6$>YF$K5?_ 0H X9-B#@+'2B&A[\LN49E "F87J< M8FWS!L_?"\P?<=W[4?HX,N#0]/@6HV\ET>8<,9VY,B_F K@\C.M M61[(R<$QKK"B 0/E1<0+-SP%<9YUJ]A>;_BUG#49PB-ZA(%A_@VF3\\E3%:D M?XJ>X!VD&US5'VG6ED3LT6=H*2-Z"N*.A+#J*.Q9"<-7TWPJY>?U.RER$;]D MA2NER2^H#WT2*H&(ZP3R2G'Q@9*^54U'FI-/)D)]0 0&\9[>))Z+)W.&+]9+ M.P>7-1U.F(O6&HOQI=('"(5 K;7X 'M.G4X53CY9Z0ZH\O9OW(5O6A205?T< MR:DY>+\O]SG\0%3>[K=WM--#U;LH[W'>YJ8PG[DY K0XI^)" ;^S0J&2<)SZ M=9H-SH_=+I!-7;=>A+V0]45X3$=_Q'6J?89KU3C-^PZGL9GDNNYV5G&<[V%R MG4:/9%E*:V2[Z%O&I;IPAS$4KVE; 0XD]- Z V5N.R->S;K+X;$C=CLXG#\V MU^4SS,_W>4[Z#R=AJ2C0G$DE *_!R#0 0H7P0E*/4FQDV4705^5'^^@*)/IN M"*6N U!)IB6)"A@3A&&C1:"1J$/O<3 JFW@I5+9"LINZ^:-22E4(M0YD8OTQ MVT5ID>,_)+_N"_:\FTCDF\U@37!+$;SIGQZ8\+=E'NK)QM7^\/_&/E9E_>.Y :"VGJZPH\[WYL]\J MTEP0W2?=;\CC[.D5VR9A9:\D_-!B>I3*SL@=-FKXM'5$X3%17O9/6:N*8A\1 MAM@;WOH38DV!MCM&(P!^]RAK6H0"_-WSD+8550D]V2)4LNLBR.OI K6)"Z]E MO;U$JU7SS^Q7GZ(\>2#-U*W5M$=0QD7' M=IVIF (M9/8N*F!"#Y&1*2TO]I_GQ":\*LJ[0_,9L1_$E&YLDB7T*/%-M(4& M-1F\X%M,?SSH\^5'HU8_ M:O_'+"U)\S^J]P"*@FP>$1\0/(&[,4#P>P)9_"&,45^-,ZQEPJ#YZ0L@3@V- MGX]SQ4^S+N^>CS!%UZP.8K&*R_0E+0\NCDB9H[E(49JB^ZVCPWR"XX,*/XR( M=>@EG4EI.SZ6[Q$=Z:K>V;?L)D7M)_.GLL9LV=7/\N6,]VY%&]J?1VFJXK7# MZ9O0D;G"Z@\+ZX%,O4NC.S*B[@OS))V.JF>Z(S(#0?=;IVF* M8K_EOW/;;=D@N_4UDFVHG*=L3 MJL:])!U#ZJ5^CO*4:G.5D0@A7>QE5O+3D79=D()8%SXR"N-UQO/SU26E%9;\ M^)Y\R)/^^Q;F&YQOV08Q/?!7/D-P^WPHTCB-,OKRZWX77">C[@Z=/8@B'PNB MOB/V*V1008,*.XR0/GZ.BKY>'J^RY")%>S)]P9\@LP@4V MH&^FT;?2V*-<9-:Z)?T]G9Z&%MUFGM$9Z09T+-0+.GJ CD?8N%.L)*?P5WR% M(:0O\![&^YQU/)>?8[1/8,(K*6YW^U+4?#ZVE_4Q0W?0UF?:7*GB_^BBT!0T MJH)*UZKZ9*UMCW\%L.7JTP%/CT6Z9?<+<[:^ZI>X)!Z81J@:A)@"!5CORZ(D M Q:]-<]*+=.IJ.QS>-,]EK'OOQX?RI9LRZ[#G0X"=OXUWOZQ2).4N,9]Q-;3 M;$=?]Q&O?B$6PWF?4 _!$?$T#X,(9#HVR@M6-E6P'%1!5:, QD2=8YOGE&G3 M4GIL;+V17J0V.#.J(,V"GU'I_QK!HDX9UC=>^/0@B9DZ>-B91_(O"5/_"*2; MD+JZ7>L?CI*^9,Y +<1]'!#1@;PMUF]FW&N)8$PJ?/<*W (5>_JI0/$"\Q5" MF%V7Y4EY?7\=$&)1F*!/J'M_IE"O:JSJ3%!8'CY.%%:V7;"DH(8/8,"'EPBA M5??+0Y7*IC?:8++.V=1P5XV*ZILL7QD M_ &#"GG^K0=UXK"6'8,F2>[N1AAR][[+1&U#KIJE&?;W^\=?85P^X)]);Y-F M3\9AWR?(VJ.Z!?L/>X%+S2^0@PK[$>).PW[(CD&3U!OV$D/B7?-7_ "B4,)+ M)^"SI5V=P*D;.EH8%WDISB!\E (\9)S1CHQX[.UED*CGT'=R)L73UE$-69.&XN>HK2TV! M9FPH _Q+Q(,^?]C(C(O@2H13@PIJ6- 18TZ6C$?O'7XH\#6*K9X-;8MP\MBD M+-+/$Z'1;T=/A'ZX7[-G0L-]%[23JN[70$_M%R@MK5V=DW&F[;6:)J7S9ESZIE9F?-[ MTFGQV[O#.YC%ST1;[?.4X[+,$_ACLGU,F"5$0"%!C1C&QHLR=UC7CJ'SA/HI M.C0LS;/=>6J!2A_];!B*J":=YCF'2\Z'% M'7R!V1[>Z,QH1P38'9 ]$>BC/AU#D!D(ZEC;,#%8R5Y!DB""@2& BH6;^29I M/>^N&1SV'!;D_&4X;^F!WF?APHH0->+&G_%S= #4/TG(GA\O$?13'F4&(T?K M:^:&E\2XCP4F/#"_[S(W'K!'0*9%>E952=!=$HOA;1HW%RY55]9#WS9+['1+ M\Y)YJZ! 46,%D&L;(0./FRD\P[?.CE96;X"LLV4^=4>]:NLNWQ5C3WT5/OQ] M5V[@PRK6W),Z_I;A^;:6%#\G M#E=WE_>T6F< ,=9C:MQOC'#,VDH95C9U>/[/@\I5]HP5)%'35K4JDOHYO>-O MF)>%\74FC\N>/SHZ[(J[6Q^ %L/B?3(BY*;RK4_HZ-9;S5> C*O[IG-:<6 M",621U[F9,C_ ),T)KWB*HXA@GE4PF25O-"JH57A6PZG-R70E6IF83T4+U.* M2@40-3J 2"@!=J(V;R$8"^>TFB'MV-SPRZ%8[K!J?B4%0*5!77NYBDA7,Z Y M6HV\-%CMY3L1)[ MG6U;VL'[=)ZT1MT*.YE('BFM-Z/L^;(3TCVFU<*/L>ZIYX"%@C/YE)'FYQK' M4:PY>L6UI?@ZTYPX]W_?B0/4\B8).T#@P@N]4TZZH^_(5B':?R@&J?'=S4C] MMJ,O)M6:8!"7#Y^P55Q*WW?B%[6\:>*2P(47EZ><=,?ED:U"M/]@7!(L;W'I MN!U]<:G6!"_GA-Y%B"Y%[Y\A+*]IN-('F#2O0?3+,#_FTB?3O4,)),"@0(45 MQK&B47:PJL5"90(-D3#/?8:N!NO?9!B2XI8,7ZN0I05&_XV%,:N%R\=(>,QS M/X$==KTA)+DZH#THR_+X[X!L7\>T&\C03VJKD'A\6'O4H*$3AIQPU1%9115: M!8R_?L(OKQ.8\J@B/QP'$_G5W]E+K+,;Y#O,K2!=1"=>;UJ]4PDE'FCX_ MZM(]A%3^%&6I>#8XK;%@ A+RO_/&D@&'6-^:X?,E(HI#@A8 H*#TUG?KMU;K MM/H^%"TQQDN,7NSS-'OBJRG^2M(-_,3^Y&B:^@+S1]PW31AV&#' MEW(%0Y_ZPB #Y::XS=,85B\LZ8S$ T(L[JSU"?5P%H:_CH4W&T@).0,[BD=Y MX:2$,>R.4X65K1S&\HB-*V<-W%2X0P( C@_4HGWZ"E*=%B_?=S KM :S M,4D6M U*]A"# H\].KZ7$ 'DD('$G!IU6,^08=.$CA@B6$ & Y=C#'F)H@M( M@C>'217$Y[@HM?+Y/0+,R>@4Z#Y4*IAZ. (Q!0HC0(99P4K&"I(!=&3\"@*< M#QO?TPB2EQEQB?-HEY816L4QK21*G[PMSG%&5G$E3/3&$15Y-MW4N'SW@7*S MI\DM.H_;4R02)@(JC%#1(A&;&',)A-6C"P<$ A$(2, PP?DX=7Y2#D/)%ZY4 MP1Y]9FIJY2$T)5NL@K60?"22FD#D>:,JI[3?X4Q$91',GILAY=C.X,NBM\I\ ML 2A2'QP\.JLATB*-/@T.N9)@9Z\-; M_MM4S77EAK!$"H,"/X\UQ.-S@Q]@^8R3*]*K%/R]TT]TUO"<[DB_0RL<1D]: M"10-H;:/U"F >'MQ<,NP05J# URATYT# 1_&^*O/\\F[@\JF7@RGJ$4GAP4- M+JB!P:T"G=/4QVTT>:L3DL-R'-9;E>3ZKHF;TX*KH06:$F%#!7%/#!@R.:B+ M%U8(5X*:.&166[K$76_NX-,>T9 XK(J"#+ITK^(.QC!]@8E6["@*-.=)"-_G$%[C M*"LJ#-6EH*(PP\1RE1N:[V.*AX@T!!XBBUZ$4P#I1CU"L;=O71CY& M;VIOB%Q6V0!%*=N\AG][AIDH:U#MA_TM1>@=?%*_'6THW-@']<%\^21-#$54 M%;(@$;KP5"#X1+2I"J!4]4\*\(DH!!ZI1F&XJ85/8&LZ/+OQ*H<7>^44FHED M_P[,D4+Q7EH.)=F'D(FS\ ,#OY59,'!:TGGC_4Y<3JS[^*K 3 6BZJBJTDSO M@ZI(]W0[MX*6%I9TM-]6I7@J1PS 34YQ?K6#7Z&UCKLI#P]LW\0;;H6HI/& ML?/PHG$4%##4>B'@HG%S36Z.Z#2?V2S9"*C5?J8"J'7@^X* :E%5 @/U&3*J M"'@W>?M=3A L/4#,#A;;?'/NB1;@PD'+IQQ\VZ495$?>1341G;2NW9/7)?YN M1UOG_6K#_3/.RP>8;R_@8_DA*MG1@ZOL@>#!#S@KGXMU?@T+K0,Y9O+='(Q7 MQ?-]]Z&@>@#R]RU(B"9AY%FMB.^Y\J!G\"62C([X9?OW3 5 =0!4"5!I0:9I M@.D!N")@G0.JRM3[(7&<[UFQ4M($]!!]AH5X:VJ5)!%L5D%:8/,[CH1;""1VT:?IW;3 VGC>K-*\(XF _7+T71_WYRL+GG_ M@A$V2 M6,5>(%(BPH !T'5A!S%7*K_&"V@FX#WSSYNV?WOQ9/Q@4!5K--,8! M/(3+_4= $5Z]^7-@19GT*,1&EEP$76BT8^.80<;:VV\=QUHCT!-Y%8#'6'O[ M[9)B[81"U5AK6W(1=*G%FA)_7F*-YEL@7._HXRE$NVL8%? .TL*'U;]HWD8G MV%0EFM.GAN"A6EJ%"! %.0,U*/\%2V&&$7^:M&(SXRZ#0A&"'!(T)#(8B4/^ M[X=!#OW<87@F]H)7F;S63+,XW2'8VU.Q^;#>=7LK&(M#]N:P'BY(,&5 FK77 MUD*?,S#03Y\!H17XIKDI)+_J?IGWI/F!6+'M74Z>L%W%M#1-!P* M-%B!#. *E.!Q8X5G_O9TRLSV,S,%)C-Y: S,_BV%ZG0-G!48I31$DU_ I0I?L_3C=:Q3ZLLWS*KI8[EVUU@ (%4")P9$2 M@&D!N!IAI,N,'0#;&G]I9*,^GA^&>9[GOH6.C?3?T#:1/@W?OC(W_P+AW?], MMRD!RZ/?'[V$Y_BVB9FO?0Y,7O<5GN^#R6/4' G@$."BAJ('-[;1H' M@K+;I*%3UAMP>F0I/L01(UR0V?9Z<\\4+6BQV1>8[>%5UI0.H:=XB^LT@U0A7V7 Y7AOZ8[-T#6Q/BD'902VXA^@1Z3PWHRUY C]F2 'Y,--G<>[;]@03UY5X6!;KK5(D M#>7K#1!:\%+@G/*K3"XG]2!3[N)!G%D,@'RV7:7/^AM$B*:T]9+-Q]\R\[JV M%"_]2 41R/1RP.*XWR;A6%>.U]JT'V">)FFD,>EF&EY!C %%6:>A<9\Q0C%J^UU9'9O.HBZ2 M]%3-D@6>K["?];-D!=-HV9:PFOXK&<%+DIOH&ST]Y?")=4RUM5:/19E'>O?" M1D69YTM'1+MF4,*2J?NEP@LDLZW*'=8TI&6^[!QO=[A(6P#F.;(A:?89DG[I M$^3"X@9%FOQ2H+4CX35FX/ I[!_B)&2IF_"3R?+=RL[AR[B!2NMMLG0_ MQSA/THQ%QRI+Z*\^1!D9&/7O#"B+,UP,JHGWLSZG28Y8 @=1E@"6^MC6^&#+ M% B@T] E%AM8> $DME;XE"L9F55W9K]MP!TN^J=L)W+;Q"EGN=#\RU[ M!P@_HI0WIZ@WA',8XZ[HJ\[?/P>6[VO7&1;G>T&FZ\D); M^H;A,JR6X&>Y3,2S]!H!"&$Y?&IAW&T'H^>1V91IO=D4L*2%:%9/49H5)1?] M$\9)099A]S!_26-8\'._JD2;R39].ED?RXOS/#Q#$&UI51_YB")F>M$7.NG5 ME/*9IF.(D[%^@T['Z:+W"3Q1-5ENIA"*@EV.7]($)N#Q(+ZVW479 7QB+?@Z M />T\B!LRUX8'4A[RMOT'O:)&,>*(DE'FI]UH>-\H==^1K45:1'7@8>98&,X MTGA$+=@:J&V(1@,@5 5[4P+EEZK]! W.J:^(!6E^<\1VL-WAW<1HLOY^V<( MRY]RO-\1O96W_/3D6=RZ49#OX;(4004,%KP[ $,&#*HH-6VC":[,:7#*S:Q M[Q(X1"[I\QU_]8]_36%.J'X^7)-^!&F7%5"4Z(2_ 02O45C#L0'D9O5S<%&G MPF9WW(W:=!G,=<9>)X4,>*8R )45/L"([ICSURE/3&-0 4!/L -*58#^I6-2 MB^*NT%2W\*+H/ U4&;L[9.>ZSE\9XBK;[9+9,=UNZAB44F.&[3=*N]<=9T"J[5!I!BK5 CS!X_-L0MW7$Z9LS=2U4' M'N/K[,4+S,N4K*,OX&-96[4YD:K5E2B)L]KD'Q/OJ4-X8>2RT^.U"B##)2S" M"'$='K&!01? 67,\HR:( LJS80ESOCB[H5YS&QUT\[2](IQP(XOTW.9X1S0ZW!(#E:LLN?S' M/MW145)[.T-=ICE'JACN ZE"IAM2%39@X&QGJH8/:VM#FV=L:NNE<(I[P0)JNN\^A),Z<007Q[@/R&F=/KZY98;\'HB'K4E=% 6=^$\>$06Q@ MR@6P)4)M,+S>'0 %G6='H[^_(2KI[V,HB?/ 6R/^?T?9 (,J479LR@6PI1)E M/,3FV8>XAE$!GS%*KK;T="#?*='?AQ@48T[3@%@/P52! 1DML"T(%;ZPA@$# MY@99TN)G V*?9^P=#Q+"[]//]">3 MP#4BQRO[U2/63_*BRV15ZA!18L"F1A M=?.%2PPZYF2EQXFGU-YVMRIAS?EIRB'%W0#'1M&Q( 0BQ1/GU#W47&5D7]E$0(?"P@JW, " M8YPHK&R[8$FI$FT5!1+,7 &RWFS2&%H,%ST"S#GH%.@^*#A,L /%,"]8R5Q! M]K+[0H\WU,#S]<9;NEV$.-1A]EJ/ ""PXE MTK".$4,F"'5P8FD51SOMWM$7[V[@+L*#"2;6VWJ;?0$>M+W$9(;6!+AO: M#/53WE'B0:E TG^RP;1)?-'Z'D7EU"/5.Z;SZAY6 M\)C%0F.@]O#&X$SZ] \IIR5DAV:NLE*J8,FZC3(L$(5*! H%9QX[AVL/_&H0G;I=#O.G,Z M5;";$/"JX->DQ\D*^!YJENWO^[;9>-(MS Q1FP+H$> MSN%5, !1')8.#F.@&J8$*UDJ2/.C8\LS"' YMJ_DQ?%_CO*47B=G.M#4M([3 M=WS9W.(GPMP[>P41G*_WLX!'#129<^/9?KS<>"+W;6CV649C2/E#2#J@.,YF?Y#?CZ6(W^#M DP6;V0WS[!.TAW+ZH_/L!\^]9\I:(B MV]4L>AS+?>!7F*\B#@KR"E6,H>3#6_#[- ,'&.7%'\+H!8SY[UT6J=I^:5SW M+*8J>"#P0:V ^ !3(:2HIO4HZ:-G=U$);R&Q@MZ!SA&[.M&L.]EEX:LZHQ7"D J 9 J##YFI+,(&#/O.4V.K!"+1=[> ,_EP^? M('J!'W!6/FOMB9ECV"RMS##=QS;=5PDC@JVYQJ[LNU1>ZQ4V5:)_=@TJ10#1 M!%!5 -<%<&4"C?'_)#/&AT_81VC7HOTS+Z"\!/(WRPKD8T(-XK=ES8619Q2M M5 ,2K3CD&"7 6IMY!L(GHIJ">8G4;Q<8J2U:36.UL>CB*+2(5ZI$P!'[GMC" M5\!RV=.03;&\A.MWRPO7%J>&T=K8;4-%1K>RZ-/XM0)3I8G[O3:?1]^MF+S_YQF:TP9XZH,%F35QMB;6_L M/3S#'$848L$-,B*2J:% YZQ#IH^A/(07@ MQZS:((3)Y>>8?'2UI?]R%HW] )XH[@/T58SK1Y"RHM()O==$1IAP#A[:T*X: MN,/67A;%FB$M:P&X&H#K,>OI":.3D!Y..4YV@I$/E_CHN@82@&DHCV9JG$WT M=.YPBC.%89X3K+4XW^>YU?FA4TG.^1"2_=]HDD+D#,0<->A8.69O/&1:M@R; MJ;$ NU8SF&]I7-SK(!E]L= MP@<([TL<_W9+5'LF*+2,[#G.RCQ]W--K]DKG!W6DF=UK5Y/NI(XW\/D-CJ0)J"'Z#,LR$ HAMOSB%"T MBLN?\B@KBSL80UK1YCUIT<,S_ F3$2Y3+7'N#LO,1UU@>_%@H1A-=E+-0$E5 MHS.":E8*SE=WE_> J >>F'ZDC^<* NI;H'R&X*G6,8#R&DY="KNF;SA&'+W" M$1WH'>>"%D*GBD>H6#T6):T\I3,;&11C\:I#OUBW3SH('%YW72"!7RJL0)ZM M4>$*:QAO"O\2T5 -#>]@!C=I61@L\, M;M.B".GEE %J3H.CRV)!TG 4"@+"24IKZM67[%&NEEZ!-1$=M8YA@@J4O10# MSM5:Y[,'DV?"YMU8IQ3K(.J0ZG.\Y^LFVJ6QM5-0O=D03:==6J_APJ7DJ',3 M.( !.>OBPEF\M]Y.J=?E"=Q HLO1(OX+:O8@RT2GBFG M&(VX7J!2C% -0-$ M-=#H-O6V:/D,\ZI?%]6?KYN]"I/M446)%IMO2@@>MDLI;A@]J29MV,QXRZ ( M2>PT:ZJJDKF$ZG3#="K_.]Y9M-M!:6K4%B)IHQ'A(P+,QT\P@WF$JC0(WZXKM,Z.*8DQ\Y(1L5Y\16#2 MMU79 "\VD(MZ+_\0@,>HTH8U[&BR8Y:\1$3/ZE#SZ'3,8)_, L%P=\P8T<^> M&%>GO@"PW*TP>U_!;A@*>939Q7Y'M;M C7@,Z!:1&(3@RZ!-'3$%T4$%:3C MPZ&3S;Q.L'DUR-O\8;22D%= M-:^LMP&K>:7"T?B%3%VZ,X+\M;$<@HBK5X#?1=O=7^B+\R]I0KR7K*53N 'O M]UGB(%$XLPVJ]*"8MM7W_12S@O-F!.\)!?G!02*P7Y!ET7SW;#N\: MD1)?QQG 8?,%S4TKW\>AO&7Y&,A"DV*V9AJ6ZF6]S.]A M-&%[FOB;?RFL2!E6-Z)![H:=U;_*:(5@,OP(:FG)F>$R,X6I[6*R?+#&[ MO9!6H'6B6#J '$ >194WK&'(<*-[."U"E@.PI$^)NK@R-E63D-3UU]/"KLQ) M2!F3YD:@LZ2)+-+3$MSU/<;QU(F./P:10>D@5C6)4/K%ASGF7.4G;D-RL&JQ.,4O';H)8-IOUEN.R7"_0?/:/?*&& MWHJGTU9+S'^3F*TBV] M$25^2'XE PM=8XAT[X/JHMQ"N,4-<5TP#R-7/?[2Y^8X-KLU5_U8ZU%ET,$O M3)5 [M"9.P.VYF%QQ"-_G*ND0*ZR8I_3-/U]_ RW,/J<%BOR?ZJIC]ZOFRVG M>\2Y#[$:"#1(\^"=7'Q(WMEI:MQKC6#,BG0M.GLV_SK-X%4)MWJ/EYL!3)/@D+]@ M3&^LI%!K".S\NKGE.\1-'0PY3+>/>_+I0,)AB""L8+D R3C9E6@ )O?^.*H-4JH2K2A107!7W*\(.'".B7&]^HE>!R?SP MGM\$OOPKF&76>E4M:X+ MXZ:L5)1GI%7%+9RA=H M ]@"-B 9FYG:X(J;.!).'SP6TV2]XP7]WS?SKCYY7GRINEG$GGNNU]+A'!X8 M)0>K&"U$(EJWA 0+!\J"LW, ?O5';=4['3NG![WU]7:\6&F'M;'ESB\<=B9OY^Y%'/F MZ^[C;?"=!O_U+?GD-/.3+KPIW>84W\,BG[L'56>Q$Y$!O[#J-_KL_R7X@'7O M(?Y"-5O2Q*.QIY2(\CS_Z,._2@IS'F205O*8_E]^U=/F'HY[EA(0OQ!><]BM22GJ@6PET[[U5 M?;Y_X_U5Q\;[XMJ*3IOY@ $O "4([7@Y;=&["I=9=KF%.:W:&3W!=?8A M*O>YQNN"AL)=>)PBV"2.F I=0$Z4J=UR5ZL#2%^Z%0H%YY>Z+M'IKEIL#'NQ MF\5M6SWMXHZ=7S=?:'2(9@[,G.OI1 M;1Y(DU3K\0Q_WV)IW2'/P\WENH@QQ3D#%"D,?Q_D ZO8*43;H\;LM=69T9T4 M^;%V>O4:BV,2W!G?5[7%Y;C^:=E%%5N%R M'YNIP T#%_9DQJULJQ[_RJ+,N]<1T6&ZW51CGRJ%6-.>@=.%.IC2)TKM@E*5 M%[MEFP4Z9>&[OVMZ*^94EJ=[2140N!W9'IEJY!OD (_9)S1[M_?@M8P]J]ZH M1V4GQ>N/U=:K7M_W;3?4NYS/+R_8NHO8#]DH/*M/&W(>UG\=0>=D^;?:$-,\ M?")R#^^);A]P5CX7]/GQAV=XCG!!ZVM$I>:E7$VAAO49=$#\E&B@&@"N J Z M *X$?[Z=J &$'H J,G]@FW&-C?UZI3VSGB9Y1^RZ"Q*'S,3T,NIM$3MS6GC[# MO)D3#*S7)G7Z>T6XZLVO_=7:/YG<7(=62'^,H-ZQ]=I5,7RO9/1-,I5XF" B MWDJ* P M@./,<+3K01SB:4X2OX-1GF9//Y/_I9N*\JECG6@Q$&YW'$D+S,]9,7XW(J$$ MOPC0HW/KS7GU,*+.W 6PM?471S>2F'ZH3Z8U"@"A :A4 )4.X&XP'3[!D%?= M#KC0#.,A*:XZ6EFJ_X&ONB0"DMFW*#2HZAW]3HT7+BT](V %I+!I%,BEN2'_ MVC7[EOR6W"):U$.-M E[[J,QD]XP:U?35+].MN0V]_#:&IB T$(>RM99'9;6 MS9_GNK7,MKAKK7F->J$-1ZTV/V!0P8,&'_2=RYU\DK*!M(+@^S2C50KHLR?% M3SDN-'-5O4)LQL(>H;Y&D*+8LV=D:$G?4*8E8^1@97L%2T3=07(4(& PP$, M:.*8N,UQ#&'"CD)<":]8;^0UCTYPJ$@S)V=_B""%0YE%61#&=&X011H-$=:2>3@T8(BDG":3698X9\D-\%E@0 MVM=Y^D1&/D1_>[&'="6^WK!_1 =V.&Z5);34F6[NR 3!+H&AC^BAAJDTNV9+ M";#/"ACOZ00#/Z+TB1UXX M,&%@BRL(GL!LFELF_O-)N= "5$CQ93-3@9TK) M2,A_07IBI@LK//B?@S5O)T@3R[F)R\T&DB'A!39I ?/,\:A@5UG+$: I8KW8 MT<,&'HIA/8=GZBY)$-J M!0QNQ[A4.;Y[LZ>']]8;]BAQP1:Q-%^[?_R5= $/N'H3^BIKAGO54Q)6XLU. MA1K">3GHRW6AT<<>7RYX]I/EW[D^=)&:5F]NIYE(T;,)%=VP": TB:US8 >L M&)2J;!V=D"YQDAEJ>=";Z&F),_-91?%>?/3H0(^TK;OC^-)N80#^J$LL-K#P M]$4E+V 1YRG;R5IOJF,U- #H&_$6!YK'Y+H:%(=QO)]"2QIXVMGV'$HKB&]' M@>3/C>COG?NHF'])5/?,@21H.@NJCY^Q%0N#GW6)PC2X9TZVSF3+:+UKHB[3 M%:/]&/Z7*(L+5062>\-TS-!+(;0G/!DLX+CT8$TK/NV?#IETDC0PV S.D);5 MRI.-&G[25ZY(PAL82!)(RD&VU@DIMNAB!X6Z"LD!$%^IVGH5&6(WJL)D;S\Z M:LS%L-;3D\JY=HE,CCSK_JG0#";R951ZIT<[ -5DNMHCZ\?P-,>1,CF[/,WB M=!8B M3"4@= JNCWC(HX05A#Q8[/J,"O;I Q+0!'.YDJ.!A, M)>Z[.-:*\A,3+XI/ MK0@6Z/3\Z+R;.UVF(;^CIYWI,3G)2FX67^,@/DGO ?42T!70(F-YS 6TXGK0 MZHNE6RO>97^08W_>3,L=3."6[3NSV8.+@^(#(ETQW0OA/HP;*#$NPW_0B_;T M"E:PR4\=>GO#>,3&"Z&R)T0E5OFL.;QMP*M-G9[]F19YN\HN/\>P*-:;V\KQ MG S'2C@>NF@%7 ^5\I^>*;9\ ML[G@Y2X#.*NKQ^?I^Y9CI@V>N]9*I_L>NGWUG0G;@^0L#/=!"@D8)I!!>2\Q M\2SA'&^W.&-IOOX-J@O(=PQTI@6:@LU' RV@"=)K<;0#:9:6*?': Y_4AS$% M,*,:6UEZ4;36H4J11>I[:/<45/"60SCKY7G79HKU^14DV/8^8_( M]3-F]W3] #)<5A@AA.%:E3NL8\N0>5(9GV62[,?J29J%6BVB:.VQF>.-E"'5 MOCE:GPY8965ZD:(]!5LEO^Z+DL:"\M.ZFD(=W!(= YGB;JA\LB,B:H!$Z &B M1I$ .@DSRKMN@:I9W>#NIS3:WD8YFXC>PIQAJB\>!T28+CMZ17I:*+*17YR+ MB'*^*FP.OP7@2RI$847K+:8;&#CG==P'O.KJ ]R>[9JFS=TGNN1S7!0>5/A@ MY;"YWN.NO8!J@NZLB;KP&]&U7"!((ME'L#AE$R_H>6W?JRR!GV'R@.D!0&+L MRW_LT_+P0-JJ^UBHFCSS=9Z*?&]5GP4L[3PX\.^B'2[^0J9[#/\,4 W"6+UK M\8I-[+L$#E$G?0\5?15QC+=Y7BX=LX7^.Z:J$OWQY^N-TR\O"OL?0M6Q\3*8 MU(M%W5=3':6WR4*>*ZC^FFK_=RVRF4>RO.5B3C,7:N]I3I:$[B,$CQDK-./7 M&2-BT2X?4J"B/10&0,6Q8^\*D;K78_B#&2PI'F-:(OS,OUG%$[)]3'*1M[Z MJ.T8*#WU:9[.=SX(C%4NHFJ"O]KQK?08\:$XRO,#/04\=@!MX@O70BU^#WR] M>7B&?(9XCK<[G$&;LK2:,#[N](["AG(^9O8CAQJ.H'1M6]'R"R:][J$&KG97 M0<]UH1ECHDVU!JOUL=N\O(^?8;)'HE9^]78+ZR>O=9Z25Y=EMD>A(MO+#E(% M7!?QK]^W8> !;"!I48AUS6FP]3@@_$%U1:,FQ[DO/;@;P[\D/WHX7ANIFS%D MBN21=X0?\ O#'Z46N=E0;"*2=>V1U$) MDY6TM.U:TNDL +3$FL_]-& \W"J2$&EJH"-M$,9J50_Z;"D"K R^@PBAA5&IZE 4D=FM<]L MX1)RG%_E.( 8XTG&/U$B!U!->-IMW'.<[*--NGV=-Z!W/686G-272DFO.E MCN(^H.2>C[%(@RJ.*1XM"XM87A/ MU@52#5KKC-,,GBPW<\2-E]@\=-(R^@XSQP8U.'VUI8$'#'_R._SU-N!M+B;9 MTG##G?_C#DN5AW4FM4;B;2Y^:\-YO=5/(E?J@'>52N*6&%G_8[K*;^Z-\< 6 M)7;)ET4M +#;/Z(T)K\AWR=_"F.^;.,ZV %G"W03)'L(WWNO%1"W@*3BV^1W M5 FI=H"3.>4#W.YP'N4'OK_/9M.7GV.TI]7_5DF2TLE%A&ZCE*SJSZ-=6OHH M>O6 B=CFN-'(O2TO?=^1(63R=?JX03'F3CH@UD]!P;Y>BD&&T>6H,(8U3!@P M.Z*KJ'&JTSBM_B&$@%GO2[+^S6CG81TU+5F.R9%D3QH_N,$-.(BZ6!R+I!.+ MAL[82$RM59A2>@T[W:8E3*ZKK1QZ@B[*#JLXIL?KV#2_KN^GFM+0DVGX+K8& MAI>$!CUUF-6+7I:P$.M'^:VD0DP#+_;P >NM!(W$FKFO)HP7#S[6 M@;KFEFM!J[M1-4"RAX"M_"I- G!-4^:QA>F7TDEUI^2.>B?[EV@G;Y<8#@4P MJ)&!@ 8"FR>FFI*TUDV=)5#;T[71*%UF(U%/^]8;(-"!@ <$GUZX5DDN>%E, M]/C[]?5YG1*A?J>_'M<4;#YIU0+RWQ6%M% W(Q=;V7911([VO=?D_Y]+V4&J MP#RK?D7K&.8!3*1[9]IKKN X;H-+$%@0KA_!#I,(_$8%3"A M># KV)"_RG-B,$B7)N\.S4=NHP-[R/E3E"?UB1Z=2L&NT QOZSA!]W/MBN*^ M8L! 5@Y(VH%'D6P2GQ,: J;B&6B.6%V$4:+8L6MA]R0.)SG<#(#-A1RFUKL! MS0NA^KMCU96O(WH M3@ XTH)OU>R>'G+=X.A5X!WA]8'6[&G=C]MJ@'8O<-A M;YQ^,^J\NJ4B.U=4#Y](!W[@ M_[O>9NGCOKC*Z)5 >CF08*G7@]219K8B4I/N9[>6@0+Q'P$.:G1 X>=?PVB2 MB?7-&CYQK8-W"JPI%OX,K)7(:0-U.XK+[0[A X3\MA+1_9E,!^UZBU&1]IXW M C%!OU%I4%7!%SH$V'NH,MS1A2B9>2%L]GY3;' MF[0LJAH%;$&IUYD,23#SMGZ)7KH* 0P;0(I4@22L9KHP"6F74QYD MPSJR?;<%63;#R]+W)YC!/$*K+%DEVS1+BY+>H'Z!EY]IO@GJUYY7%&B^DE," M<.]] I;=$6P# X$-<>R[N9=".7GFNG!%>+3-#R\(O(MD 7I_[ "BRHFXW[IL0*QC&Y2IBL/P3IKS#'?VL/ M9OUM#=B ZFG;PJ8EDTA)5'P8 14LRE25J_W]JL%.BZ666U5,QD7;6[:Z+"/<4?W^/Z_?/>D MGOQ&"6D0KND<-5.+#"T_UGR[MZDQ.T]UX]2%B6(S_N+$TWQREDWGK3YT_LECI^Q9W:D_79XCF( M8G**\3U*?\"_52H#;0_#"!SKP60I<]I%;"[ LEQ;<"@@ ,V*"W+J4\\ M6LDRT40,D[+N7%EG+-[QVVW%Z>D,E( !1@PHY.$S/H^N ;7Y:RBJ+ZC? I?+.<""/& 3]W=L:OF3I?H!5J";#\V\D4O5WX M"+.D-C"&GLE@A?_S(,VY0W!Y;\0Z#N "/D5)0O\*XAE,OWOI96+>W6VYV5') MV$R[V)P1": %XEZZ[T[XIG M@7VYGY>C,"5#T!8W[\+>DCR (!+63^ 8^<6_#W=V_(8O4\ M!NAV:ADUI=_Z9T)2JRLS/7SW+>2V M5MQKG'DZ"[LF85EDM3F8YE//WL [K;4A"T15";.F+7U&I%0(MSU%-EL7F686 M= OT_L5=160CLEP)Z0C15W(=<3+Q5X^S)D.PAL7/BY_F W'9B?G&XH85=F^B ML3*V$?FNB'6$B"RYOS&9B*S+7),Q6!F%^".('F.Z^ M!>*1Z&SBZM%0'IPA=0U=9Y+:X*R(?^P3WTTL;K>/IVWF>NOZJ!LG0=TMV$R'R1)VR=1 MT:-8:)-9I9^3 -IDPG.A MFN/P>7QA>C;ALSY+\"-\'F/RD=-UC#;J)#()[\=XI(+7QQ@A MC__KVO1X%'>[;"U)A:]T'G&Q^^1*!NTA?0]3V&*S'[L6Y#15"-<2)C!-JB'WT*Y4>F!\ASGK/1(WG+K=3%-CPE=/C;<+0 MLK%#QP@O+#;.NO?@[1N4;YO?^=C)/Y _T(%_AN#BR_A^A"2G^ D(,3_ MAM5PFUSM]C%ZA7!U>,S"-*):DQD"'0-2CP9. 9HASQJ%E,44)7?ZMSV74QZY MT[]MN)WR!O!^@+(CH.H)N$U T1<@=N8OXPZ3XU =C<*8O[J, IB.VX!7A*W@ M+?;[.(+KV^0&_0[3#T'Z*\RE2S\[!N0Z"B@"]#8*\'ZP4KIB".!=(:& =@:P MWK O3CH.Z))]BV$LHU0AX@^N/XA>(EVAYV32;,4CA&F#1*X MS$]P!2>.DC"%Q+VC!&1$*,BW00Y"G-?O48Z_% 5Q_ I0&!Y2D,*8'"T$.0)7 MJ[N[B<^(5:AI8IXK;>HYT]#8G%3,13>U$FP4-."H!TTQ)S@-$-V\P@5"4<=! M??#/JJ_MN8H#JN(]GP"LRPG OE(Z_B]83 RH1OGIG!#M0"T)ELCZGJ4[-8H MN8N\=D_S6H'9 <]K<6,QS6MW+*_=#W[F:((J-T5OO5F$ZTTD,G)<9]D!KB\/ M*1Y+V(X7[556AA#RI=(8V-B94@*K*V) 4J GTD+:69 ;8C/[E"1[#602ASR5KH,Q'ET])6K9>3PG@ M"_G;DSL#]KF&G)EOMKSB4:R*40PF:)VV5H?N&59>I;#V'0(7?S$'&#"H$,\E MUO%2:RCE'Y'O*14T=(W,0_8V(ATA5+X!;"^:9&II!67F$;2;P2[":H?]SXNM M+@-P6741I4#LB8$#%UK'4K(\VI%E=J53A<9%#M@N-0/!WH8HD%PV DWK1K M"C9E"5E?-CL-TPU9LJF+#4LBCN)\@.$VB7X[P,5+I+12T]:"?B!N;M'"#8=" M#EE<2U$0;NE)UE*J'\-XCX60G-[\M$9\;(A2!OA"I/SB..D_[>LE(J^S#?.' MH@V3-F!M?O6)%CMU>H6H.U]MTN493(Z\;S3F71=Q$/ZZ"K=86/8!RI::;ONE M7A9TVI*59(:* 1F3 W94D >I2(<%4+=^_-*V&#Z8JE=,TU^8E ZBCHP\KH$. M95'[=7*L3!H767;8L1/Y]U'VZ_L4DG>?(%9,?H^S2R?'Q^3!C'!X1Q:<>;<@ M4MYNL!CRU!"5 U(LR(_!U!WS3)P.4S/B[%EF[)Q8==L(", !00X(=%!@!_>= MS/4_.%Z][&&(9]N?48R;B:/\==3PV ;'$^HVP[,P\2C;GV%4[*&58Z(E%".\C]6+RGP$+.F$/]R1NP/P91^E MC*K?O,(@S;[U*#3:)9R)I]P>R!?*@T!,HV.2#$R(FP M<(.*"R;W)PO1U6I8(1Q\H>)[-CNIZ(.6.SEK3BE=?T8!Z)%-G% MZQ*/)BB.UB10+)+U1VQQX9,"J>I1'6T1^F;6%&G>BP4@Y.":"(6><#@"4[+! M#W\>2@YDR"(3)4)\RH&+(PXL.C@PSF$D#8VIGU8:(,0I%VR==SJ[L-!^4&J@ M529+A\'!0?4\EJFSB@UIT^M=BF<7Z>L%3. F"B/\I_SA+MV6AYRA4Y%DX[1C M8Q+X^@9P#$ (7F>R=T92"W[HV':GY:MXVXS:UI9YGCE![B.PB!>QD&THPM: M20;5CEEVM:!W +"]12O'+KDX$%)YQ94Y\(4=P/S%@Q.8$D9"POA JF1=PGT*<6"@RX_)>K%# M:1[]0?]3S9WUVM;CE8XL*R& WB0D54S(:B@LL("U (9FV8$ QZ< ,8@0:*@Q MIF;\VML W/($QQM0(@&7QZ9?U$QO*AJ-IX18Z/\MZW];]Q?JW7IDSGCV73[B8'X L1"JA4K^<"IQ;L3?Z/U.FYM?K2>WE#2?9JD64P MMT U=@D_H*T; 7J#%4(.)$;0&MJX$C$LZQ)KJBYIN3-:ZNI'%*\O7N]9*=V[ M("6"9),MI2;UAED%$592*Z$TX'&9N"W&0!8SBS+$>P;#@WQ*Q]1(4]].RGV7 MFY@"@M>'-$BR@%8GS6K87@?LJRL),+$MJR#0[IX[%P>H/"!"(>NT]7_U=!-> MAQV-6_+*1IDD$QJVZXV2P$HL:-&2ZAY]9S/ZUNQHUL)UQS9C^>&7,I9""JKS MV"IQCT'&V=ENZ;;Z[G5/0\8-8VL7>IH.T[Z5+*$^KVW3[S9&:G"\A_ ]2GG- MMGOX#).#XB915PMZ\YKV%JU,8[ X6E"N*%S')7JRURII)"2G.C\-(L:A8=;P MH#/QT'Y(;1,%*5PBE*ZCA+)8RW-[&M%<^^]JU,X.#UG?%D5ZZ,%R]D+2*O36 M-O7'F8<9QH\>Q<,[XS*#/9H2&YK[-;9J/']JD&(YT?4ZN>TR97^FVZK,Z9BM M+P=N6G@9>S(Y; 9I=MKH9*[HGPO)30K-SP2M3__,3/EN<#J:9! GJ&KIXNGO M]+*0XW:L)(5<""!IN#]I8*OJ49=J?%*S& ;4=3P:[%@'L50-T^7%ZOY:L7II M[3>:E32%-NQ4+ T?LS0:WV4:%8S:E."+,NL%2?$D89FB#*C'8J!D,*&O38./%0N\B,-_^-DJJ'RN!TK8P\1 K94B@4W5BL?S-9VE@^GDNM MO5RL?"AU>OV-3[I*KGFPKK(W>HGLX\51E5/2IL(FW2%YC[U0_1"U1"-#W*ZE M41L1DFT3D5BD1CUW<;'/3$A:<]Z:)*Y;@X@9V3LNAWI&2P/Z)FALT+Q'7'KM M#=UF05+:\M($<:5]#]C?DOCZ],X=**;B-$S& M8DMMDY[@JF_3NQ]I'U ]I"X/:8J)K3C6 ML!62UYZ_=A%&XP=T/!:#99])7/D)*3EFQ%7$AHQ:I6K8F<,DI4AO?:;!;MUN M-,G!N]&6L!9V"NJJ"7HAC&ZWN4LKIABV3-_UC_[\"*?G)89I3P#--')!S5 MXO+!!J7@D.R#:,U]8F#E#/:R0(;[59W&BVR2H7UG^J;^VP].F^^$;.19[$!^!)W?#A..( ]WP_O83*PS$0]<# M^O&P"Y(;&&3RWMC3B!XK.ANUXIM8(J]C5";N.(??$JD@IF(]<%(Y@R%I'7:7 MFFGCC%"C:2!Q>EO29D]/R]8H)!27\IM'LD9$:BIU4;SH=@_)ZY+)$Q55!;"_HI;'.+YH>Q4@XC$YZ],$E^3$UZ+(/D].6G%>)C U 9Q2-9SK>!X0:F M*5S?8]E+_/^1VDI;PZ\'+-V3?XJ/CW1. MV@=,P.!LV4%F)_)FT9G23:$WQ;H$N 6? .].L=3P@ "5QV*1D>XX29SJ]\%Z M,Z;)]*MF*[%CR@:S,FA\A/EU$J(=O$%9MLCS-'H\Y*3D'%EY7T.X(W^SYV)R MW!\L_ZFH3+MXS/(T")5&&2/B]*.C ?'FV?X13QA2HK/O_1BZ3%("6=#]#,S/ M@P+& Q@@0! !$1+;CRI @3JJJCKTEP*8^Q?="D62M>\EQA8E!PR-)\,HR? W M6*7X.U(6'B5UA3>K6266V$(PY/$O&X@L1!S,NQBC]"/>6&82;*&!RHQ M2-&MK@HEJ&""$B?@0$\B6DL8,[(UUA'=73G6#X\3V 0E;\7N M1QR(ZZ3O*D@3+#^[@VGQ\G@4+I+U910?<$JJD]A)-ZGO)Y(B;"PT)&A'BG5Y MDZ*I&A!I:G$BQN)1JI )L-#JU?HHI(_3<,$Z"5/+^UKT?A:1DK$W<>":Q>_= M_L"6_V\W] [5[9Y&QT])E&?':EGLT$'N1)QYF;I/,IG#8.F=+G93CR+D#W5A MN]-[(F$%DESJ8[?Y$,,)#@0H@ 6)\+#&&B$O>F&P'NS16.$,1,HQ [,X7CRJ]4Q%IT+7D88WM76B+ECC83!]/@GXJ/J1K8D9LM?@_2]0A^ MUBW7G:-UX?#.TP(*=G:N)L7! ;[6;V-;SH;GT\\03YGQ1'$%DPBE'U$.77B; MFF"+[J8"9&Q_"RNL(*-@\=0^AQT.-Q%_TZ*ABL.I6]F6QSGPK1&\R$]_F?PX M9- ##'-=G)&I%7)K^J4>,T];LD*XE3A;]X Y':I'W8KQ2\VUMPJICKD0^3;XMTI^;B#S["O<6%F5E^+#9P%M&)? MK1HX;S>@3FP*$#2LN/CGBA>M>JE.C0LA9XB,[["^:U.FQ M&(<>]KMI@!\,Y-@$<3_-KXTP;%05!UHJ?ZY]5Z=-:PXR,F]<,>0!Y4$\_2ZI M&U[#OG)K,4V<7P;[.QR&UL[7U;<^,X MEN;[1NQ_R*UYV8G=K+*=]X[IV9!OV9YU6EK;F34]+Q4T"4FLH@@5+[95OWX! M4B0HB1<<$ 0I$!,Q79E.\^#@ W!P[OBW__.Z\MX\HR!TL?_WGTY_/OGI#?)M M[+C^XN\_Q>%;*[1=]Z7Y_^^;6]?]XLD+TYA+;\0KYT9NW;Y91 MM/[;+[^\O+S\[,Q=/\1>')'1PY]MO/KES=NW&>F+ %GT']Y<6A%ZD_S?W]Z< MG9R=OCWY\/;TY/'TW=\^?/K;AP\_?_IT=OK^\[O_=7+RMY.3 H$?Z;3>%/[O M;V\^_'SR\^G/'T\_%'YQ9ME_6 OTYN:R\(N?YT_V!QN]^_#NW;OW<^O$^HCL M3Y_?V];)I[//Z,M9D5.\W@3N8AF]^9_VOR8LDOGZ/O(\M'ES[?J6;[N6]^8A MF^G_?G/CVS^_F7C>FWOZ6?CF'H4H>$;.SUNJ'L'M;UX&'EDC/TS^^O>?"NB] M/@7>SSA8_')V_K+ M?WZ[?;"7:&6])4M%=H%-!PC=OX7)#V^QG:P1!U]O*G^#_NUM]FMOZ8_>GIZ] M?7?Z\VOH_$30>/,FQ2/ 'KI'\S?TO]_O;W;&Q-8?810@%"V1Y47+9"_1A3AY M]^[T%_K!+X]HM?;(3KI-)YY07 9H_O>?<+A\F_TN'?-?RGXUVJS)W@]=\B\$ M@5]DL!59K]C'JTW*7W9"LO].?.?*C]QH<^//<;!*8&[@^Y[0^0U"IWI2ZX#L M2#]*?IO"L/,!>HV0[R G(T/Y[W3:"6,9:QZV=V"@XX9DX&13A8&??W&0 M2T<\H7^@()V\/3G=;JE_(3_Z+1WCT7J]<>(X MY-B%,TR.G?=?[AK"8AV%KAE^(!<7F@:S #^[J<8"9_F 1M=,TS6=!H_XQ1?B MM_AYUZQN_T,4 W0JQ.PN@<[8)6HV#M8X2*[E9$$O<.Q'P0:^D1M(=3:%JU_[$XKC8. Z.CWB!SA MB&I"Y 3'P/6NHM&%3I .=>V&1 'Y)[*"*]^A;A!N_:#R^^X0)N,%EG=##,/7 M_XN N^#@X\[8O$<+E]BFEA]!M/OR;SN\MR(46*E7S8JL[6I"+ZQR&ATPG=GN M[*9)SP@OP]7?=\CL_XNM@"#D;<1X/?B\0U;38YS>WM?D9]QRJX9 Y^Q2J=." MV<+G';*:0@(4KA4?=\#FA SC))AX%K?S9.^C+L\[X01\QI-ONK@R\3,*)D]4 M/MOU147P6WOI>KD6/P_P MJI27[6BX##X<."CX^T^G)R>G)S^?G/ST9DUV(O6B_/VGLY_>Q"%A!J\IVY9' M_PW-$1'^SFTZ[THV$QZ)3 M1\IM#AF-OCS,\/HP3CPJ1Q'#Y,FY<#NZ4')G3 M=P:9/=6 8?-IW-@;(9 V>D7X[@V6DLO6*HU*!@312BK^M(AAH\"\?MOOQS M0PR2/^27N"5Z*PT?76!:]NDZY*_.N>71JL*')2&1YPK5%;CQ4QE >1L'LXVI M,%DFS-P*GY+%C,.W"\M:I^DPR(O"["?[>3';'_]VZUI/KN=&+@HGOI/(J27V MR!8+K_Z,R:[B29?AI]6O+0([[# MOHW]B*P)86611.E0R)4F)'M$%>A\<_U$6HC,\_#;?M:SW=JHX?H>19;K(^?* M"GRRR.'$MN-53$N'G4M$9+H+0IZ'FHI9$3/:3>^6F>4Z-_Z%M78CBZO6L)&$ M"OX+VM@/RXNY4A2KOU7!\2R[P<68+OV\GU,+2<#DH:)JO[@1O:3IC48N:AI/ M1;Y-;CCHUJDDHV(>A9M9\$)7A;=/-./()=?D+?87CRA8W>$(A3-K0Z].&.8- MI%3,9TKTP*" (KWY^2LV>*BHF,7E5H;<4V65_->-Q.913T?)>JP1C3[YBUMD M$5-G"^E&<%F:B2D^VVQH$6';0$CQ7 "5375?]W'*!5BO)*$2]^I>@ZH*)X%J6>CY9S:J"I9)>%X8'[K&%7;;]0)H'3 5NH6(<$ M5/!^[?HN;2CVC(@U'%G^@JJL6U80:!)-E%3,YBO&SHOK@5P"[!OU.F#296\Z M_QZF0(GK?P>$U&CF:QRZQ*ILL?6K::CQ;V "8[29>5;:X8W(MC75"X![OYZ. M.@G93@6OIJ%N!B(*Q.Z'BB6^J+K= ]>S *TMU]GJO *,5Q!0J6?>(QNYSU11 M)$>KA;993D?9WF'#AV+SJ*.B)L) 9(-K$\OCP@J7 A.H(*#$ST<&!#GSDM]7 M+@/%17@O5D@ZM#C3:KG-X]^WKH]NR!]!UD79U_5<'Z0,D!_\-K7^>$CB]?]( MXO4WODUTA\E\3@PO0C_\AGA[0@*("8 ;!E$!6/*W?5#)CWXKYA$D223$:\C##HUF2@Z9DJVWSX MZE0?W4O?.91&7*W.,G3.M$:GP@ X0.; .F&5S2#Y;.!I<9E MP"IWQW"^.'"J\PTQL#X:L)H=@JR^UXBF.AZ3N]A19'SGB)>V$_NYVAI;>>!4.+ MHZ@A!TYS;SH,.%BQ"\-0;YT,AF%E%50.E^;Q";$M5XZ4?&UL2+J'I#NTSL%S MJGG4AZ]PM-(*+RUXS;'3/+@!QJZ^]CF'3?,@!WS+U92^,]#T-CS!H#6V/F#( M&0E7=3,44-(\&-+F*JWM;,( ',UE :0RQ_R1>]; 898:4LC!I7>$@U^.G=; M5F4XG6D>*8'A5-F3C,&EMP2#P<73C2Y'3O, 2EMI7T3*6.Q5N!UVGF2HZ2WP MY>H68GU)]\R%.7?)010M MG7QZV.3SV=7F8"/SB5)'KA7^S(U))1/ \9 MAX6+G.G6:[KUZM"MU_2*+9_4\'K%ZM0GT/3N&E;OKD'T/OI'O+)\"];B:/>; MKGH"T1?DIO-OUN]$%I"CCUF ME56K5E;:QX%;MK(ZT;/5E_165IH&R+MM976B=^RR_O"5J3V[Q^Y,.V0:%$7< MJ+WF )WJ*;?YM']<9HPP:/1.!V[9(.Z=GAN'P[*&]F<:2Y?/6J0XFS-IVLD2 MN*OXNE28'HUPAR_#[H/!KKE.\N3]2)JD LYC;;W:R0L[X/H/,"/B&% \&E1'R-1D]K->C$>U-V5L,*R/:^;/W6"=((^:;,SD9 M6D;"UV?P,J2,@.=(VV8-,XV@YZAE//FB0,;W6W^2_S";9<+ZT6+&B4VTJWA#W(M,&D M5VY&T$7I_B5LLQ= A/.O+(IE *YXDV41)(G:TF>?E-ZCX-FU4?A %(=+1%1PVTV---^9K&C7@[^2OT+F)3B BKE_13[!W*-C M.RO7I\H$&?U91*HVDE*2UHN2^Y,P\$ L65GIR^)W X-^0 M0SMLI/DDV74$XZ.6A!H]CNYOMAJ44WJ(N>M@. GU.!?>ZA@N,J)J_XS0(,2V M@G-[4H'E4HUT1 Y0XKF-:#J& $M57W=5_$3,22>VHZ*&!*O8JB'0,<_38#L@ MI%BK_%M3MV?J]DS='O]%(*( 5I+H/4+7-#F>@KS3D61@B!;D:=KO47I!WIF> M.2G=%N2=2<\@>$;!$^X?-K[C5Z[3[!X]/8OR:C5!W*B@L@VDI_3F4_!QO>7! M0-(SK0D$4K/%R&JK])3DS2*)R^K?E4[OM86)QX/2C-F!P'JG=S(FGP\-KPM.[S0%/M!#+#8*R MPBJ]=R$0VKIH.BL@()HE^5BLM$CO MIUQ$D2KFVS&L%#S8,GBEA".QDE48Z7T9\">L[ACD>ZFU#"UY0NM+BI:/%M3_ M=I1X<:51Y\\]:MZ^4FBG-:7',_",7-LM@\B1Z>#1PN-#1J#:A0$H3ZT=IDP3 M@+ (CWP]]?CV5_OBMQQ/B0\3:K/=>.HI&8#F*A"OPLU1?*>WWLN'8F/)-H-+ M@>]CB(T(Y+R(":!]7"T*E+^1:45GE\VQOJ)CJI9,U=+Q5BU!JT6: M"9FZ)5.W9.J63-U2A]J;J5OJV["74;>D>23&/"1F'A(;;MW2J!\2:ZA:TO@I M,5E52QH_)B:O:DG39\4D52T=RJ13/06Y[+*E1#R9LB5@V=*9WI&V#LJ6)(;( MCQZQFK*E,SVE/)\FU?PDZT?MD)'W).N9GDJXC"=9QY(8(?@DJYX;IW4QX%A* M2&MQD5K8]GY43W]<+"U_@<(;_QXY"*WHV;SQGQ&17\%WWTW-G4).W-6?,8$D ME5WA)9J[MIN[0%MEYTCDXQ@R>61,5T7\X? E(4 (8O_CWSSWQ#M3%3G91X]H MOZD\F-%C3R2 Y(1ZWK*[X6)D.*;CXZ:\K3((MCE MA>/P.5114.(K*-^Z\$DT$%+SVEE>70[GO^1C%3RG8R7N:#C/)1\+7.(5WG%8 MW40#$150II*9^A6P3P0:O-"K@H!2(;[' W<9!20T/M]/YH?HK M4FS#27 X20!<$S>%.*80QQ3BF$*;$X$<-0NDVX3B/CD15$QX6DK.@C>Y-#^@MSQXOM80B; MP22]-./H8*K)3F"/)>C]^A[@C+9*.F&=R$V-E92\)M9)VP JE"R7 VB>1A1, ML4@/\BAJ=T,^ST?E-8P@DNVW&?#6I\51T98F38RE1;3GF%U0Z*3/+09;XV/HQ@\Q;UICC-FJ%IEWA:X[AIS$K--EOE3WV M=O;%7+SMZMDS)-^==N3#NO*/3,+)[9>0XRN_(@ M:@ANF@(9Y=_]-?ET.B=[GIP8VE>*$)_8-HX)>$27I:*(9K?9=D",UEO7>G*] M)#6.-\N\Q0!J6OBG8I4">(> K?OW/E62$QVOR5FC6]ORLIU]X\]QL$H%LDA6 M-"]))75#A 'Z__2"?+8\>H29KYW^ ]DKNS\H_";L5+482&73GN- Y BP2"WO MS#ZZ1.E_E\)WN75[G@(J42\&L<7)+#_$QNSF=TXY/S'M.? MMSPR(M15'QVB?C\C8L42=>X2/8%D9RV980DZ$?U*A'J/LTY/CVSQ7DI5K2B< MV.3#AC%CMT6;F67Y$;F5Z#Z_IKXB)Q6:JOOL.MN0S64I5Q2R3%V-*1L^LS]Q] YDD@*BBMP%WM'D"-V60 M.G6IZX;Z,D&^%#&Z/<[THHMIEA$54$%+J&<;YY;^7<#/!2+9X[*(>?($B/8S MQZO5VL,;A.Z1E\3 94VSCFX_,]WSH;:;W@$Q*8?J 1&91$S&2[3&8=KD/=DN MM]A?/*)@-2$Z!;^Q)TZ_GP6:!8BZOB^W\:1M!D/&(__3Z-C C^.PO-U45L_SN$S8\]R_D?+5^:D* /G>D.&'DX^>DBY[A1&G\]P+DT0F"4.7 M;I@*&LCL^&FJZ2/X>QQ&6QN>R$MB&K@>(D9@^AX>/9*/F-,@%!%NW8ROPP,9 MJIT$$ETCO:]-H2E6GM+1L@E8"9WAY#K531.W6R[60EW5MJXRG1G. M1G#+P+G1TY(#+K%P>9@U9G+T%8A7CF&K]UTHX/^L1;3,C]M%6Z!A[E/9:/)% M !B^NA?TBN';+KJ4H_M9=RG;E2S(HXX,2B-4(4#61:=9ERR]S0?9F%8F-C! M]3879,K2FEP8!J?>5D$G^[,L'RIO'J/IHP:= EJ11\,-D 0T%64J"L-N5[+!TQ6R3;%P-EC84#K"&F/#$Z3%.I M(T1KRDQR;-_)DZC#Q+:[DU]$T4A/#@QKB]@8EJ.4GCSE@[MI!M55D*P1KM[Z MIR0H!>IENVB4.TSQV0YC[K)K!JC>;A*Y6[:JSIZAJ;L+7[XT;6J-K7E;9SF M0MIV,&3EWU;'K$2I;A*3K\,G^4Z6T:Y#$=91O6*C MS]EHVG$B/6@^]NR0DP M=[\VUD5>[PL.VA-O)PJPU\,OQTSS:*D 9BV[.3)D];8'6NQ&_DZ?#$P%KA5E M[6QIJKF'0S+O:;"P_&T&--E/=Q8%8SK/',H9>'7=;,'$!M#,EI]G%5U:"BRP MYKHI/[,"(GG-@.6QOKML)N2W']R%[\Y=F_JL4UF1]+SV7)M(AD<"X#F9P1^0 M(B[UO G4_3:LX>U!,^N&8F!^>B+,\CUJS\DI'S&!LL$PB H[F/QM?_>2'_U6 M; 5]11:47D![#\[63*")@DJN=UZ&%^ Y_5YI>>8CM-?#_I=*.E"UD1\B5:>2 M!NQ=NY$+7-ESQH][J: G(WG*^."AY_HSS?#1T[CCDH@U*&72FN&DYT/TG/<= M!EW,##2]'Z6O/GPP?2O'ZU3/5^F%M%G\U(QU:JQ3;NL4OF^Y#5!>2DIZ=AT, M+M1YJX9*[\H6QQ0Q_Z+H;A\"M[FQ%XV]:.S%X1Q&B#XT!NL1J&EBN/JKN\5W MCYZ1'R/:3X8 DG;4@5AWU=\/RI(K85.!^K4==9M[GR@EO[K1\B(.([Q"@9#= MQD]30 ,^A ELKM62,#::L=':V6B'VPMDF%5^KL(:.QR<-D+<7AG;?Q2QSV!T M>[?8A&# #>LW!L.M:>\;:\U8:\9:Z_D$-NI 8[#+>/1(+*+3ZFZ.75MN\,/R M8E2(6;(24V#DC9/8H RU)IX5J&DY"XPKL1!; R$![;>6=Z1AK0J89C*ZB1P++.0(9=1!JQJ0S)ITQZ42. MI(A=QT&L=[V)?\+&PC,6GK'PC(4WO,,'T8 ZM.^>4?"$AX,70+ODP;!42];= MW/N*L?/B>AX!XH8,Z2]H(]WLN2:(U<=!:%#&7QV_"M2PFN%;6H%0R@(64\T0 M(,..GY8QZXQ99\RZMO)$Q,0#$NY=*1 #PIA^QO0SII\Q_89W^/AU)/T-/[#N MB<758MT-O^1U2:"-M_O-H,RY+6L*-*U;^DH7VGVE4RR5LHF24BT79+C5?6U, M-6.J&5.M5H#0ZH!83_ST!F59<;"MH@LYY:(P9LL@&1;'#!E8Y09H\P89:,RR@8!&N<# M M5ZC^Y6&9_>B('*J^[663;_S35]1IT^M7CA6>X*&M%JH#(H2ZR2615.Z\+8 MUS%]SR+I*[HY1SZ:NU%(1%N1I9;FF8S13/3,&'G&R-/.R","W"-2X<4*G!N_ M2B*2/;O]@_-['$:4Q>2EV%"L%:6L(7O7P62#9VQ*8U,:F]+8E,,[?";,QQWF MDZ!K:V]L;H->E^@)V RE[,MA&95%!E48DH7QQ&S#<@+&W#/FGC'WM#/WZ"EO M%\>KHM#[]=PP-6-;&=O*V%;&MAK>X3.V%;=M5:ZKZFXND:.#5^C1>H792@>? M#'/L>>5127N P"A^69.LG MW,VL3?*.GY"!UGHH$S4SEIWFEMT8HV;<$,A);CM2[\2@)*A.>,^$Y M8U*.RJ0%478D8>9?$Y5!67R5S"K0 MP4K'WK2T[P!$C6EG3#MCVFEGVDV#A>6[?R52E.&6.K)F!0D[G5^[OD5N.\O+ MV12*%TH:L'>E02YPQD0T)J(Q$8V).,3C9TQ$7A,1H$[K;AUN0Z8S*X#;A.7? M#LH2W&-11:MP-N+F,;#\D*@/9+YM(WP@LL8&-#:@L0&ULP&K9(#0\P*-M'J_ MR[FG:XPR8Y09H\P894,\?L8HXS7*0!JN[F;9 UI0P'*7Y(T_Q\%*I"RPF="@ M#+8Z?E4HA.GP]VB- QHW;MN7A8>VLM?VS+]31I9)&_Y=ZT_2, M56:L,F.5&:MLB,?/6&6\5AF7!JN[-7:'HEL@I'1[BU"D(KTVX<@:6[\8E5;GFS^(E0F\Z)_I*1AB\:'RV1%MEU\P=%!2#4 M3)3 1 E:MG:O/;>@+N\S&.BJ]6XX<4\3\BZ)[N "XS4WXP(0/ MM P?# (T^&&$Z$,Y>A_?CQ.]TF #O^++\/M@\#MPPK:S?')L/QEL=_AY M%&NQ"-!BVZ)GRUG"@>@[3#P$Q1>@L!5%=THY"0&6KA&ZQL$#"IY=&\'B)J6? MB@1SR'$.9@1L(ABVU+:SA 9RF@F96).)-;6+-1%CP:59L^A1" ;3T5C4E6#4-[ER66:.G% ,[R?G0*W/?,R@_:1EHF@5X MC8)H0[;@U9^QN\Y+[(&AIF8Z@PHVU;"KP+V3C3[S:,"TR()('(2'F@JG524? MH. )A)J)$I@H@>E;)7(D19S'',1ZUZWX)VQ:6IF65J8F9<">*DU]Q?P-K7@T MH X;7 VL 1A N^3!<$0=K](,?1&CKNS+09EQ.PRJT/[L)7)B#TWGUW%$QO_F M^NXJ7MW3:7LS:Y-$#*]Q,"6;SJ))K 4&Q9H.RQE0I%8['SFM\]@=X5?D+I9$ MY$^(E+ 69+]2B9_]XR,*5N2L[?T.736:VGM/Y!ZO@=4Q$VI:E!!F+G 8B6^" M2A)C[39]>WLASVJO(G84SH7?//?$.SL29HTGQ'A"^O*$I/>BB-MC_\O>->&* MJ1B'AG%H&(>&<6AH %JFU728M300[T8K\*HT5Y;$I+M3J&57^#,]3R2L*WRE M=IPJ(NHBUO>LT$ ME?@VT@)G)!Q@0A5$7KLPLD00[;!@+&OVC\B\:_V"0-"V>'W4HB/D<> M:KVK)P6CN[^23'&>KFV83&9B1^XS.<5R MX6HU]!#P*JYQ]Q#QC*:CMT62[[YD@]T_?.=WRW 2$GJV88=BLNT)R0G,9=1$ M13.6B&!YT Z&5\%Q\:QZ5Q7!K'99WCDM5.S'<5$(_"EU@UB8AX*H@(H2KZMB/U;AE*@LHX3(W# MU#A,C<-T>(>O0H?2_5F:>IT3=ZU.Z_Z:C1)C"/,9?:-Y!*=CK#F-?Y:+J_G6 M;A>#>J_@!?,AH,,9@Q)W]S%$%:0N'CVB8!\S@U=/M;(]O&TB'NSQ(P7H]A K M_&$%+IWRC4_8(5LO4]I%PH1\M 85(6Q@66GXII*7=G$:#K(Z!F2,%]EXD4?N M19X&"\MW_TKD*;Y%&/B&Q._3Q-_7V2)6.W5-'I7S1JG9VQK M8UL;V]K8UEK IN!YE4'L.$EN"4U;/XJZ)8#6B^Y-((4JA^49QTI[1?;QS$4A M1$(VV9T5)1GXYW%(8 [#B>.XZ>QN_#D.5LGO7:+(S9#M;G$V)<<)-482W- FPCY(3T-#\L<1!EK=B^T74@ MQ_G&?R3CH6_8CY;A-*"O"D$F*T9?J!C3QG'R7CJ1/S;=PPNRB[XAQ[6)+,J* M7'B]'+S4!!@E!%U,%!TBLQ)ZM+TA[4U.@"YC[B>H12AW M/(%?7<\[1PL^[TP+XF+3R!\YJ:>AQIE)E-%$HCB7R0642IQ$8PW)OB"V=)BHLTF:,:Y6V_(4(&<&C&O]!LN,CU+M'OT$OR M3_(D>8%B\^S";'HALG]>X.=?'.2F,R-_V)\0^=%OB<]T<^/;.%CC5#^Y)+A2 MK;+P(Y[)0*B)!)7KS?9#UU)37)F;GK(WTDJ?\8 W'FJFI6)&YY9'9>C#$M'< M'3O="^!&/754^IH%M/-.-0TAM\,ZO8)3$?'X@J'=GZJ^;\_,U$>MF"E\WYX9 M_KU6\W%[-G@W2^6G BQD;B.B+2./O@2-G*TG(ZO#H_[V%7"QH%0%&$\)P%9N M]QOA02'K5/Q"8, +>JM/[ @&__Y7 @-?V=0A[MHLM@*#NOI[*IP+5&.L):/$ MQ+4\%-ZC9^3'-/<>OJDK"/3BLS]'OKU<6<$?\"W53*N?&6UR/J!;JYF62&@K M<,GW&RHY9LM-Z-JNY8?3^7]@SX5L'FY2[7/2OX7XUK-;9:+ODNCJF[X\$RT\N^%;HD/J-@XGDX#?HGLD7 ^JDFHD1AGTWA/!<^ M4J6,3^>)!*:DIF%3^%KN,27:_ $50^UA QA6JF%XWI M13/P@H#JJI/J@ZU[T1R_@,0PJ:Y[%9W ?8E++_71-#P7 JI&8S-5[WNJYP'LMM[W;"2]HBJ5!WZOR>Z!?*\M9F#?%#>:12\;:]2LM_H*]F5B M;E2XXMPY@I_&KM(UIRWLBK;/VF+%G0Q2B]Y^&DN.WF>]=QIW M;ZTDEXE!IK>VVWPX:]/5=L[EJ;XP\:3^-6-V>![UU#I@R9^Y\K^?G\I@ MTE/% ,/$F52XL1(@@XB^T*?C]N&KI"@< MMYW:#H:.WK*[^G#55>CL'B_]7*XCDV!P=-4^=N!CQE8K M#6@=2*9/>JH @ 8[<(?0Z2<]Q7D+T&H[*>6X:1XWJ=>?^'MI,;ST%/A"G*4 [A>[,32R 4>3\JA_2#,9K;0)H]*\;P-);T8?B-[VTYAJ&^ M64>RO!'\3PLR5(WP++W&>5^GS('\J. B[^$YUX=X12O"IO,'=^&[4OT(U?8(R(#]LE +(?/1!% MUK$")_R^ICTB;LB\R#9U+>]J/D>P/EQRQE/2Z5B TXF3'GL:*^L:E=VQ!HT( M[)V]5L.HP(%>I@A-US2GD;!RBZR0B%\:N,_^1F]CR)1Y*8H\*5(G? YOPZ;G M1CBI*7GLM6HSG)VX@F;/M5T=C?PD^>-Q)Q<,-)4:.@I]1-O$:H(WZ'H(HOB@KU$%72$ M7F9/3@X-WYKW$0I9?#-1)YM;J9 M5A\S>L0T8Z3PLL(M6A"=+RFLA&\]$>I#FS5TD$I"XBR?\0KR[=@8FSWFZY> M9$S?P?EF_8Z#3'S#GI&L(= 5SSN#@=Z/+/M2Y&9*BGO(WMA>A,#[J>)K 4;2 MG$;O@F:,ADEI&]'J8^B%V43%/&(N9T8#>\2<)<0&T:7(CMG[5"1@7-;9JRDT MO/.-\*"\2[#_A<" $YM6$+% %PSKJJ\%&+DB\B:"H;WSB>B0$*P+'_2= _-> M=@[,>Y,#HWT.C'ED?*R/C(OX8$!)47RT5)S/$G^R[V0= [;_*)(H!:/;>Q:! M$ P8LIAC2*<"'1'@DZ/Z(2;]R5%-$Z2Z?7)4T_0HD>,H);_Q3#LH5>4WRN]X M,BCX9"3JO2_);]3XH0'H =ZSNG5_(KC<*X%+W!UCR.HLL>3[N]NBYZA MRBJ-AQEH\AY5%4DS1OGX)C2&)OGVK^!@KD[5.>.&B. MVWL]!9DH;E4!;8:7D7%%MTQ9%H+NK\8VY&W@QF22'"!-&U[Q)>/@LMP@!HTQ M:O=O0WAZE^[/H;9.JA-$]^ @?]1SMTI(U:Q!^##ME.&IIR._S>D'/-2NGZ,+ MDLTM\%"[IH^\P?+YFQ]JU_2A-U$GF4#I"(-2SPNC7:G.80RDHH"(P:AO?;@4 M&/FZE)]H_*"7+!CK:@QS'+_HF:?1&L?] M/\P9\3/2]>*8")%0LS:,=2&\_: MQN*8"+>0;K)=)YZ<0GGH. .OFN>>SD@*J$M37AF !9RV\-SXC#IM6P.O/1:E M+I+*35]#A69L[WPC4EOF+GPKS4)[6-,FZ\#BLJK/!5CY%7F>#2Z_WO_*E$N. MO5S2E$28DHB>JV?%H9L%V(GMJ*@VPM:[AD#'/$^#[8"0I2[_MFLU %0'(T+9 M5,4<156,R-*.H4:FQ6'"=>=Z#-4RM=(0-PKI,13*-%]RO*D^&A?&M#^#O%5K M^B4=2*]:T[3LI=NJ-8V+7MH?SL:L/ UK8>1EY6E:(B,C*T_3,AD0-/M.00:. MOG*<&YQ*GZWNC?%!*.UZUADTTK7R9Q0\X?[!:7^KM0F7,'SU%.P2 E7PE)&S M+V,++U_@U1J'R<]R:$/)H66.,8XEK%PW%74.3%!'+?:-"AE\C=(TS3Q,LLE'ZJ5!\)4 7F @=U\\>J$XR4XENND#P_H/< MY%2L_P-:K X+UCD6>^]#);QFN=8X%T MAWI")C WL,"<"<>;<'Q%G+94_Q".S=91ZU%9$ G!-I+J/>K*.]D2N[!NG<86 M7.4X :8%H6E!.(!@SD@BK?P'DB?#0<_(JJP,!XV#JMP9#AP6S=CBJ7Q'D--: MU3VD"K/^<:6'0O<(6;U'!P-]3[I'RKC0*G4@=A@H&P0R[815LP]8]T 8V+.. MRWS_'8:XRL*QPPIRY;'#G0/8<1UE\UC'$O3BF9*II]2EGM)$'48:=>BCF+;K M0M+20;-^OV)/ZID*U@%6L*J-ZIM0^9!"Y29::J*EIJK55+6:JM:!I3>;(*P) MPIH@[$ /IU T2+_HK/1HD*8A6@GQC9$$8TUQJRENE0@0=_G=OG_*E+<6P*FJ M_)4NK =2FRBE<%.ZO!X(..KZ]>CWKJ#,;#9- _:=9;-I_#SC .JH-7[G47D= M]3L%+IT>4DRN+3?X87FT?7G^[,\W9-%_HD;1Q''<='8W_AP'J_0]$H'TDO;C M#"JUI,5TU*25$+TD'C"300R/HO!1-*-V$ MTKE#Z=(W>YD@Y8ZVP^@IG5GA&A2)J=?3Z=V[SS5-#%T@W2/E0MO?Q,=-?-S$ MQX=V)*%*UEC"XT UM@Q)/IU\+'%T,1NH#->I;NA<% M%Q,#6$%/3GT!WO5'LM#;J98.^EF UV3B&Z+S7/T9NVN*6%[&F/WCC. <%7]# MQ$4O8Z1!.>E;34B!!5[)PAT"6>#U=%3X$B:V':]BC^KREXBL-#G?:<2#;(-M MVOIDA27#D%G+&U,%0I7#$[D8@IRE391ZG8U0J(*'VE&X?G_SW!/O M[$B8-7YJG?S4=/0HB&TJZFZHL%N0^Q:P;?CHJ)C)E.Q3&^4R #Z%"@)*:DKQ M/'HA^O$E-5VQ(/\U1-3LI!6QOE'08@4J22B):\2![T9$_2,R[]I]I7\2. =U M5%3,XA99(5IBS[E9K0/\G#I3X-.H)=.KIO!(N(>'P[G(]3JO\PUE!1H!YR*G M1(+92^3$'JHQD, Q3WZ:O:Z<2/"3@UCO[AC^"6.1-6/Q KT=L^"3@8''FP'Y M06L@(:*3!\.BZ!]+$!!RK6).=8"YI_5,RF^)79U&.)80GR!TE?; 6()Z@KC5 M6((,.3U31%HB5^$#&$N(4_B:]?= RI49ZWINF';6[S7O3 M]E7:#F#+(C6Z%^YV:KS>EN0.O=>UPEX@],F#X39HR_ ;J>U?BYZ\4'^.\R=Y M&>A?4IQ]VL9^^[M'BW1]*@E#[Y/T78HCRQMBKI6T"FA!XH//J.JYUKE@&U_@ M,(*]QGSPK9(G(@LB#,9M\3N3YF/2?$R:S]C2?/*D:7@0=N]+$VH=3*AU;V7& M4EM:L9=-%:FI(AV -TU^ 'D@C@P5WC3-PWG5DDO(9R8_A#>0K=;.%[%K[S"T MY/L>AK2W1+':MV25QE)Z\-5\Q=AY<3V/0'1#AO07M#1P$H8H"J6Y;-J-,2C/ MC>!45-2.%3RWT_D^=>FS;8]*PQI\VV!!G90 MTCW/]WS#V +WL8.0-=Y#XSTTWD..RZ=$?C.]1L23""3M6W0:_*7LJ1D!1=##R&$I!I67K2 F]R@ @/- M7"M)B-/>C"_)?-[K#OAT' 8+UA*NGHZQO"SF(E /+NWI=(S\$>5HJ""CI MO+1&]!4L?Y'P<.\NEM%T_CU,Y0%D#@V$5,QE;]#I$]G*/KTEKE[M)9%S]%7? M739O7>N)F&K1!C+35L.HV8^$+[2W((CJM]G?Z MIL W*1U&I0Q,4'*K[6L K MGS[$>DML G)2KQ&"N>&KON[*@]W\C&.#"[N&0,<\E[_.R_6:<54C$.\P2'.\_RO?MC(?/Y78S\X]_._51?:6%HS-7N]R_2.L31? MJM'8,%S'9*@I:/X_>-1:&2-C:2C$!V6#!:OTT8G!@U7ALM#=<0T#J=XUQ;!2 MD-W>FZLU?WR#-H3#/AD\G,Z3?]INFM3CF.,'\;M":0_0"37/V[JY?$566D3-Y)N=G46*U$461?HQC/[HGBI.,*[_EF$-6!42GIOPJ MVV.TR-,,!38PD NGK?[R;ER:4VDS+J5MKOQ.KWR>)6"R76\_0$OL2@^L4DVJ M_WOQ.J8=X[^1+;2*5\F_S:Q-TG__.[E$@COL7]"W4CVJ4NV"&>";7+&)A:R$M3( N*E_AD3F[G?R(K>'!?>7.D MQ&AW.(F.^.=D7>T.HTQ=N\^=[#1&>W SQC%7"I\X[:'-^)$,W-DB;XD/;LXO MN+,94])#FN\=T< ?7Y#WC+YA/UJ",F7%QS!."NF>9=&E&$N*D3P,\W,\EA)9 MR="E0G\L1;%RP4N5A+%D94G&+E$IQ_+86S5V0K;'6)YYDP/;KLG984W[D6 ' M]S5TV:CT(#Y^O)A5NZ.Z>,-LF&\:0<-09>G-[\8JU7@]TPRIL(.R1E %'@3"A1S$E$0,*?12)\9+42!8LUU\HDR2 M#>0]6J\HI '^E.(%$6CAQ(Z^!A91-.^1C6B3H&LBTAZ7Z"LFPM5?<4Y%WE@J MEK"$4X%EJZ,BL%39!GB(L/W'+ [L)4W-\"S_ OM1X#[%5+QP-_;FI:80[G/L MDQNL!=+[!!3RGL%YCGPT=Z,6DZBD)-+KF@J.@J2XA;9_KR%@6F^;UMNF]78- MMT3NT\%HL7]RM"U/*+Q62Z9WBX9GDEP]0_1V+[=OHOU%2WRD-]'6-+;8;1-M M^3'%@?E=ZEOMUB@YNH<.^91$S*^DZO["G"A@^Z:)[LTON'&"V*(,-#U+8T4W M5ZF'@8&EI^H VF%R7$_,^ZYGW3IX__$Z)AEPYE;@=56SQN'R;X@C"_44?U5= MO(=KU&,-^M1/3E641$)8I-)2FO9T:]NM+R(PPBOV!X6J9'DHZ=W MI61Y&5K>/#7<.BD!Z#80,*$8$XHQH1@3BC&AF..QT4PHQH1B3"AFP,?/A&+X M_9DUNJF)P.P[*1O+&<8>@X'9DB8*4SB(C3X%$X8IAF%:^(U,\*4L^%+M.#0Q MES*\3*2E.2S :K,4!ULX!C[J>$O=_'H(N0AV&:RATE_@I<5<:FF9DIJJ)F]$ MER;6+/F>$-W:(&QH;A][$YG>0S)B&XN;I #TC_1.R4.W^W8@+_)-5$;S\JR) MA)A(B(F$F$A(621$3\M)7B1$STB1_$B(GO[%CB,ATMT\1Q,)J=-P&#YZ>E\Y M=$/,I\'J'C#B0PILD8RE=5WS!FLT3KOLNG9<4$FNKY#8A.WX\.1W3HVERQ@ MKT:D].R;E4OR:QQ\]]>6ZUQXEKL*)X[CIM.Z\>]R#Q4 M],&R OHL6C@C)WY)SL.Y%;IV\BJA%T<, ZXN6$VDU+A4PV@Z_XJQ0XWP!Q0\ M$P7MZM7V8H?P=HG(RMON%F.R+1)90JR!%0XB]Z_DYS!O:_O15*!"=(F ZA27 M*/WOC?^ O/F-3S8F#8O?D],0P-X(X:6H9G;YJ#:]U(D(ADVEY',5?&]3./+Q M!=Z3KB2AY.6&@DC;"C,_EVJ_$U6?WIQ;CH0<[8(#=.4NWKY,Q^^8+_FH,]ZL M5P'>=C_JBK=[RU\@&&<[GW3*%\3?7_A (-XS"_"S2[3!M/]S?F0?["51,6'1 M'BY2 BSN4>*/X-1\W)X-LDNYPS*UGYL@G0G2*0[20:XPM#R1,^H M2;=!2TTCXE+.9ZU.N'L\S[1#D$>?+L=H+'65S88/!EA=HWDOK^V-63"F=\_@ M>^TP*W/;/.F/9^0W9U2^T3>[PU/1M6LUY-#QV>8^ M4W:5 ;0[YM 1$@DPRAEOF,C-,<#&:R0OO*"FV[>&K.4=680\O> MZ$J1&%%'!';/;N<.S8JK^%R E<*-)L1+]?>*\KWQ"K%5H6Q2<<.=[,5)J,>Y M\*: <9$QB8$F,=!T[S I?4>7TE?=043/7 UY'43T=/N;9#R3C-?CX>-2MG3/ MN(,HKLV8C24+#V:ZX"8K:RQI>""X*@WDT76L$>Q\-!*Y?N@#$LRL*F(GO0O] M&A%2#F$ZB(X7P78^4)82J*3W78$2'E;C(R;M 2!BO5MA_B+#]Q\P*?EA>C+*L7.ZH722!1D>"ZM5X3%='RO,? \D.B MTQ"BU"?A!IM+(@VXX6RDHR:Y*%_4"^P_(V)-T&<1DS^&A"%R%]IY/0(LCPA$ M6&0A&-D['*%_(&>!BE F.Y1_:=S@F8ONVN+0^R0NW&48_$/7+0*KGRDKU#9 _M,6PM0-N2FV2O*_U(1@F7 MV'-HF ?9,>VD3'9CX@FP-K LQQ:## .# D]RY[U#>!AS93N07&')34OWY6/@ M+A9\"3G2AFI[H8F,/E>EW;OQI-S= ^)JIHC M&SF_(QB'DQ6._0@\13Z: UG%>ZJ'RU[%C*C(DW(%DV$6H'7Z2.P,$;LAVL#N M2! Y](E".W 3?60Z+W*3L"D^ MRR:ZZF=Z': _8^3;&Z)3)MX(U]X^;RP^RSJ:ZF=XXT>(7%,1A?EJ/B=7%'T- M0X+.VDA8_54P)4J#2R0$_>EEC*CU.ITG?[$VW[ ?+2>^0_VIXA<#_PA**BNV M0I):BI 7).N_5_*078!MA)R0/B.2:%"^38 L"GW(/'BHJ=F-J??SFFP1P@(- MI89? QP"168E$9$,^T3:/N)9'-A+HI4R;UY! 7A OHN#9!=P)]N#Z0HP7RUP MM@\#%FP'_YL5Q=0OS3L#0>*MI\&TF0MB0/!K1$U4U%\M&2B\WD8>*BK%9J); MYHM\3L0VL<(SM:2X(41D*H!X#VJ/9:/4H&FAYA1HJ)_!K4B%726)UH=Z0O[' M2?ZP"%":'/>"8>5+ (+JX;ZS((WLFVFHGP&TU*WL:Y$V%'-RTA]?"(G--8Z# M1$<,MX^G77@X3/Q^$; N$DA4J(B4F=S4A($]8E#UM01&($\8E']K'C;AYOM ,SSLB)'!%:G#+K]K"=TZFF&C=OUE$E5L7T* :6GGY< M ; $TN08BGIWP!#>F/P@ /":JK-S $_-K0$NXF?@&?,"TMXA MQTWSYLS"FZZVCP=#S^C'I=I+7:,7!IZ1=_Q;+VL$Q- S J]-TZ@8@Q3HPIR8[K3I2Y'\/V8PF0M$:SL;\C0-,&TTE^MZ8^98_?18->T$[D: MJC) 1^^F 33D9:B-7MW)?A78>3E'\-/H%1V^MMP,L-%K,0(=UW/T3$Y&8U-] MAI4"-T+/[S\\Q*N5%6QV0V8,P+#M4Q P^H-]%8)S&KWVRK6"8$.4[-2A,YT_ M+M'5GS'9M62OK[&/VC2_ @YCFD%"VR;>(>#J5)!0W8D%PK1ZI&N>">+@M^QK M)6^#$"4HS:2!M[8Y_%8%Q^F(-T0$OR+G$5-W'[GG4K$@UD:&E^(09@=M,\-' MS[2=,6UG%+>=J7CI&"(J3;,9MY38L9TV)&'"?38J;5X8.I M.&/I-@-2( $H'AS64[V%/M#,P'5F$<-,[[!/\UDM,W,9.GJ*?PX'046_GB(V M>N=)\6%3Z8EB,.D=(>1\BKJVWH(:\@:C5BYG!J4"Q7XH,9L$L6W14W+RI$5K M&B@//TY3-0'S()F)913XG]AVO(H]:@(2Z4+$S5_;]]X/>8+,"41VI$]U/=A+ MY,0>*CFKH' -/RWC4C@8#WK''G2^9=#=GP[:U,:[;KSK MQKL^E*/(K_U2M@;1+6;>7D5$_O3!O80 8. U+/:T'V_MOSGTI/0AY( M+Y9VL EU$NG 9U\&9@_^07)KXA5ZM%Y9SZT;?XZ#U?9!)'2R(__F); M572QBI245+N[*Y?@>.M:3T1+23,?+7]S>WN1<_?==R/![2A"?4"S3@H!0$L* M)"S@R[E'MF>%H3MW[41,3>>I6AE>6&LWLKS+&#UBUAR(UZL#)BO >@4X$]NF MZ;<4ES#OJ\7+-XRFBKWUB%9K'%C!)KU;6HGS9EJ]S0A^-FK)]#"/Y.ZX>K6] MF$+)=("9Y1)U>[OO6TR0D[Z2S@\LY[WLTDD7X?L:^S#!T8J\@ #Y3I1!(J8( M=6)77](7^IQ+]]EUB)(83GW:W!"MJ*F9''M>"0(DJL;?2K!+4;N,Z4->:1/^ M%,W"DQ%S[HF*4E:S.?.666VTJ5HRBN.CZ:\H#K2 BP5#Q<64O 'RB,R+QAT4,.0BKV0XI) MEMZ1+N,TR-J)B[46XJ?9_PS/A1H,\=-4TCZ)7%83S\-))TK1OE8U1)3$*F=3 M.,^%CY3(3LO+VK_3UX"G\T(C5?@IX:&F9%;Q4^@Z+M'6"QQ!#T0-$2ER'U;[ M4?6YL@MV9W!:D2P2=V^B-(!P!-=4<<.JZ!Z"Y]G1F.LHZ1Z,YQ=)&"9'=8_. M"]Q0N/0:'4U$7@BH&AU)]PY!0"'&KR"/I445V SA1K.\497>@@YLMAYVI:^R MNAF$>HI SI/D$$. W,W@R?'2] %)67CMI&\QT,R= <[FR\'3]*5# M('C@%,XLB&&F0*KHJ^".6*G4M%T;H7(H6(+^6&Z7E)KYUJ,,KPR.I')J$A^(PCA M#4(/*'AV;91LZ ,>[Z@J%-)&8R]6X(2/F.A(Q7^GS:+N$UYEGP=I7"0\ADJA'B3X=R+P@L/Q%4JA^OF&_,K,V]$?)CLN' MWH9ZMGWD)NNUYR)GZM_B%Q1\LX(_4)3\"G?JGSJ&E,)E;S/"^I>BUONKU[)7G!#%&832.[H M&S\B(CUT[60J2O8DB!\!H;BSYY.QZ,*1G_X36=S5- U$!GUDB +BI@U94F"5 MG)'#057>9WF+FDNBEW5^6>V--NC3?Q=33_5TOG5T/1,[D<:&B3GSE7P+JQ_H MC(=!(WCHW^D2J]M6U81WJ9S*S#!8!6'%QR+G>$T[NP5$QKO1UFQ,)BI4V,A) M3*CV,HRF\PNR#-!2R_WOE&Q@Y'DTK.X[J=E _KPU->&%;LVT1!JH/$P(06B] M8-67*B#]BGP46![M)>BL7-^EA494K@OCRDE07;-6UN$-I[%+>%UA Z$>YP(M M*JPEHV(>]T1D$6,_VH8#DK#[_<-W^#YK("2B-0=X3HAD&?#)%0 [Q'44!G'! MAU5W;O(_2;V$[U#?%:W@$:B_[61\)2[2?'S@@=K[\"@:J/_FN2?>V9$P:[J] MZ]3MO9 J#A?Y)1^KZW:1/]LLVKSC@(#2[OI[/'!O&4Y"7>WV;T2#7,4K_KU2 M\E%GO*7>8R!ONQ]UQ=L]O7%AG.U\TBE?$'%5^$#@NGI$5MTD_YO99P.=FF! M2+9D>;KRW:>8Z)/4$4M?AVK%;1TU)_ MX8^OR!M4R8-/>6K1=%YD\QXESP$F;[<=>+I#H=>%6X[4>QVX)*AP)WM%]\8V MW9UI7"6BQM(!IU2@EZ RM@8W%=^HTH3&KB>$H6&T)V'MJ<$3MBN)WNN+,9=G M\:#CUH$7E.U)O6_!>B]R>3>5PW.KITSO7%/@?8SSHW;02G^,\[V>6[#;QSCE M]YUY1L$3UA*V+#JM>[,9)D<^[WQI&>JZ-ZF1DF>$6[. MI6(X:RX:.L:9,Y=.]T9"2B1Q;>;ECEP^U1=AGBS69LP.Q.TG/9T[L#SF FZ< M.=@,/[VO*V[\JA+Q&5!ZWS?@C=9<1,&@T]-N%-ICA]4SK-F7WJ),A>;(62W% M(-=47='.N]IO?A[S;>(*&.4O>V9!U4N,I8@<:J7[8N>N?>R%T7F97K M; 7T[%.JX&3(Z960+\3IR#4@\%%H:-3!@#6R7Z'L!_5X86LD_5V1L:Q1)UV- M\G4YT_-5H8&>':Z>7?G::)K:-4#="=ZBCBV2N7Q4+1*X[2);)+W=FQU).='F MH#GL[\WE H>=MP4M0WGD;CXAE#OL?)POC.9!E2-;F(I>WVRU%!RCH37I?XA7 M*RO8;%^W3JV&"74BD?E+[]7//]CQM.SGF-.0VXGNVO+4A;MKP"OMP5O'Q2": M3#5X1 H&77^M=RN9X.N-9)#D86+0+8(/3].OR%TLZ67YC )B,-TC&NDDT[K M?E+:'EO>(PI6?1UV?O:. ??"MN& ,Y.PJTD_R0 MX4$-86L0.&LKK8\#W\+5GN9"]:179(,? V:%#: >LX/!!Z45P"]>E=B5#M_[ M"W@%CUM^4$@$:!^#+ME]R[[&N!0S?,F=<,? V[#DD\#Q^PPAC/BP M'6:T>5@N<#\>Z(9CU&NRMM:_WG9YU='<9 MO4]6_C2K\S;G2G"95)<4L.KE+V;)E"^94/5-OF0?S9+U>GM5-EGZ+#W@8*PL M6767^2)]Z6B1QJ%.R!%Z!_7%V>J(3] M !HF-N34SO1!MQN?3"!.S. IP2=X7%K^]B#EW3?V=(?$T42[C^:=YI0DATKD M]RB* AKG6_!+',D*P3@^[M79;JQP0L&K')BJ#6*XV[SQUVERD;GP5R+'Q.6LM*SXT19:FR-(469HB MRT&5:NW)*-VK*^MENKH7X,>>:BCA4>Z]FL3J,/+%2;.FO M9(TI(;#W6"VKWI;^7*/1/=0G1;#E-#K_D!82G('$ZO8U=[(=V4+"ZTAA"7-JF-)L%^ M("MD$NP'OD FP7[X:V02[ >]/";!?ACPFP1[DV!O$NR'AK!)L#=2>3 9VT>6 M8"\'E1)_17C_\)T_(9^3T"!6V.3DFYQ\DY-O04EN0GTWGQ]=SN\O*Y!CS"Q/SZ M><%;V8D?ES!R5]1& F4J2A]R$ 'Y*H9S/B=A&*^RES+6B+K!+]UGUR';Z)Y, M2$E&!C\SRC!]:I[&$V0:V\>4@&!VQ,71[LP?V"-D/')-#6)O[K-S=+C>N^$? MU^0VN/&)^D44B%Y1+6=FT)@>JGN#2%PKO4[//DJL]A'6#+?M2Q;+D M"L4CLI>^^V8UCD+YADO4D).M5Z9R[ M)_=,6W ;M/9:I Y.[ZG>%TBCC8:K;4B&D?08Q* P.I[,VC,]KYJ!AO7XG6!L M@:1GU)H%DN/[[2(]:*[%44A<2TO"6_2J4[-=Q]9X:".0Y6EF^C M:QS,EIO0M5W+_QK@>"V4*:*&ET$ED70\907.W>D:!00Q?T'%F!\B4""GY&,5 M#FGJ1IW.OV+L4" ?4/#LVNCJU?9BA_!RBSS0:4,,A ,8 +.<$AU&;; M5!E.+7)I&DBJF-\T6%C^5OM@V*>:R:Q@G4[GUZY/+#_7\O+K2"AA1M* O7N1 MY )7FC[3L#W&EQS#=P2Q!-&B>W:,+/'>#NNQY-C(4RBPN,8TOIP<;G$!R933 M+]]&>J:4;!$^X?-BG7>(T;9/=XOM=NVT%<2LV8'1S6=](; MM!P#:N5GMLX#R@#34[H) 2;FW690CB7A$"SQ&L,<#$.]56;>T!$^C&PQB/3. MUA. :"<^V6'/M6/'B06;&4AZ6T\"(,G(-F -QO2^707@+#97F"R@TK0=@@;87UC

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end